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Abstract 
Long noncoding RNAs (lncRNAs) have recently been recognised as multifaceted regulators of 
gene expression across multiple cellular and developmental contexts, yet their contribution to liver 
energy homeostasis remains poorly understood. Using global transcriptome profiling we 
demonstrate that both chronic and acute nutrient challenges elicit global anticorrelative 
transcriptional responses of protein-coding mRNAs and lncRNAs in liver. To address if lncRNAs 
functionally contribute to the control of liver metabolism, we performed in vitro characterisation of 
regulated hepatic lncRNAs and selected metabolically-responsive lncRNAs Gm15441 and lincIRS2 
for further characterisations in vivo. Through CRISPR/Cas9-mediated genome engineering we 
generated deletion alleles of both selected lncRNAs and verified that expression of the respective 
transcripts were successfully abrogated in in vivo mouse models. Finally, we show that lincIRS2 
deficiency causes hyperglycemia and impaired insulin tolerance in in vivo mouse models and 
provide evidence that lncIRS2 is essential for proper glucose homeostasis and insulin-evoked 
suppression of hepatic glucose production by impacting on AKT phosphorylation and 
gluconeogenic, lipolytic and lipogenic gene expression. Collectively, we propose the concept that 
nutrient-sensitive lncRNA lincIRS2 is transcriptionally coupled to alterations of systemic nutrient 
states and functions as molecular relay controlling liver energy homeostasis. 
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Chapter 1 - Introduction 
1.1. The obesity pandemic - worldwide burden of the 21st century 
 
As a consequence of the current obesogenic environment, composed of inexpensive calorically 
dense food and an overall reduction in physical activity due to modern technologies, contemporary 
human societies are facing an unprecedented rise in rates of overweight and obesity. Between 
1975 and 2016 the worldwide prevalence of obesity has nearly tripled, with more than 1.9 billion 
adults, aged 18 years or older, being overweight in 2016, out of which more than 600 million were 
obese [1]. Proportionally, 39 % of worldwide adults aged 18 years and over are considered being 
overweight and 13 % being obese [1]. Overweight and obesity is defined by the World Health 
Organization (WHO) as abnormal or excessive fat accumulation that presents a risk to the 
individual’s health status [2]. As a crude population-level measure of overweight and obesity the 
WHO is utilising the body mass index (BMI), which is defined by a person’s weight in kilograms 
divided by the square of his height in meters (kg/m2). By definition, a person with a BMI equal to or 
more than 25 is generally considered overweight and a person with a BMI greater than or equal to 
30 is considered obese [2]. 
Once perceived as a problem of high-income countries, nowadays every region worldwide, except 
parts of sub-Saharan Africa and Asia, are impacted by the obesity pandemic, resulting in more 
deaths linked to overweight and obesity than to underweight in the affected countries [1]. As 
overweight and obesity are associated with accelerated ageing [3], morbidity [4] and increased risk 
of death [5], a recent study found that a BMI higher than 24.9 globally accounted for 4 million 
deaths and 120 million disability-adjusted years of life in 2015 [6]. The results further illustrate the 
massive global burden on healthcare systems due to overweight and obesity. 
International genome-wide association studies have hitherto identified over 60 genetic risk markers 
implicated to elevated susceptibility to overweight and obesity [7]. Yet, the 32 most common 
genetic variants only account for less than 1.5 % of the overall inter-individual differences in BMI 
and thus, regarding the dramatic rise of global obesity over the last decades, point to other more 
influential risk factors beyond genetics [8]. Known non-genetic obesity risk factors not only include 
individual diet and lifestyle [9] as well as socioeconomic risk factors such as poverty [10] or 
education [11], but also behavioral and environmental risk factors that transfer obesity susceptibility 
to subsequent offspring generations, such as parental smoking [12], parental famine exposure [13] 
or parental obesity [14]. Although largely preventable, the combination of the aforementioned risk 
factors and their compounding interactions with each other signal a devastating trend towards 
prevalent obesity, which is underpinned by the fact that the incidence of overweight and obesity 
among children had dramatically risen from 4 % in 1975 to more than 18 % in 2016 [1]. 
Substantiated by dire projections forecasting the entire US population to be overweight or obese by 
the year 2048 [15], obesity turned from a historically rare disease of the affluent into a global 
pandemic that not only represents an economic burden for todays health care systems, but also an 
inevitable challenge for future generations to come. 
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Figure 1: Worldwide mean 
body mass index (BMI) of 
males aged 18 years or more. 
Global map depicting mean 
B M I s o f t h e a d u l t m a l e 
population (ages 18+) by nation. 
The BMI is defined by an 
individual’s weight in kilograms 
divided by the square of his 
he ight in meters (kg /m2) . 
According to WHO standards, a 
person with a BMI equal or 
higher than 25 is considered 
overweight (orange) and a 
person with a BMI equal or 
higher than 30 is considered 
obese (dark red). The graphic 
was created by the WHO and 
taken from [1]. Authorisation for 
reproducing WHO copyrighted 
material was permitted (license 
ID: 264641). 
1.1.1. Comorbidities of the global obesity pandemic 
Overweight and obesity are closely linked with a plethora of concomitant health consequences 
that, although diverse and oftentimes unrelated, ultimately elevate the risk of total mortality [16, 
17]. Recent studies indicate that overweight and obesity in adulthood result in a decrease in life 
expectancy by an estimated 4-7 years [18] and attribute 15 % of all deaths in the USA in the year 
2000 to excess body weight [19]. The most prominent obesity-associated diseases include a 
clinically vast spectrum of malignancies, ranging from stroke and cardiovascular diseases, certain 
cancer subtypes, impaired immunological responses, and neurodegenerative diseases, to the 
metabolic syndrome and type 2 diabetes mellitus (T2DM). Excess body fat is frequently 
accompanied by hypertension and hyperlipidemia, an elevated amount of triglycerides, cholesterol 
and phospholipids in the bloodstream, both of which constitute the major risk factors for ischemic 
heart disease and stroke, the leading cause of death worldwide [20-22].  
In both men and women, high BMI is significantly associated with higher incidences of certain kind 
of cancers, such as cancers of the esophagus, colon and rectum, kidney, liver, pancreas, 
gallbladder and specific forms of leukaemia [23-26]. Significant correlations were also observed for 
higher rates of death from cancers of the stomach and prostate in men and for death from cancers 
of the cervix, ovary, uterus and postmenopausal breast tissue in women [27-29]. Collectively, 
around 6 % of all cancers diagnosed in 2007 were classified as attributable to obesity [30]. Meta 
studies surveying hospital stays and surgical complications in trauma centres demonstrated that 
obese patients had double the risk of major complications during surgery [31], were more often 
affected by surgical-site infections [32] and ultimately were diagnosed with worse prognoses 
compared to non-obese patients suffering from the same etiology [33]. In concert with impaired 
immunological responses during hospital infections [32], obese patients showed reduced vaccine 
efficacy and serological response to vaccination [34].  
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Despite the tremendous list of obesity-associated diseases already mentioned, the major individual 
and economic burden correlating with excess body weight is provoked by neurodegenerative 
diseases and T2DM (see next chapter). Obesity-related impairment of glucose homeostasis 
regulation has been associated with a higher risk to develop neurodegenerative diseases, such as 
multiple sclerosis and dementia, as well as Alzheimer’s, Parkinson’s and Huntington’s disease [35]. 
Overweight during midlife elevates the risk to suffer from Alzheimer’s disease or any kind of 
dementia by 35 and 26 %, respectively [36].  
Although its comorbidities are variable in severity and disease characteristic, obesity is a 
fundamental contributor to the incidence of noncommunicable diseases and death across the 
globe and burdens global health care systems in myriad modalities. 
1.1.2. Obesity-associated metabolic syndrome and type 2 diabetes mellitus 
The metabolic syndrome is classified by a clustering of interrelated physiological and metabolic 
traits that collectively confer a 2-fold risk to develop cardiovascular diseases and a 5-fold risk to 
develop T2DM [37]. The five hallmarks of the metabolic syndrome are comprised of abdominal 
obesity, hypertension, high levels of blood glucose (hyperglycemia) and triglycerides 
(hypertriglyceridemia) and low levels of high-density lipoprotein (HDL), all of which are diagnosed 
significantly more frequently in overweight and obese people [38]. In fact, a recent study calculated 
that 70 % of obese people exhibit all five hallmarks of the metabolic syndrome [39] and as truncal 
obesity constitutes both a syndrome and a cause for hypertension, hyperglycemia and 
hypertriglyceridemia, obese people are predisposed to develop cardiovascular diseases and T2DM 
[40, 41]. Promoted by the ascending share of population being overweight or obese, the worldwide 
number of adults suffering from T2DM has increased from 30 million patients in 1980 to more than 
422 million patients in 2014 [42]. Compared to normal weight people, the risk of developing type 2 
diabetes is three-fold higher in people being overweight and seven-fold higher in people being 
obese [43]. Yet, not every overweight or obese individual suffers from diabetes; however, more 
than 80 % of all diabetes patients are overweight or obese [44]. 
Diabetes is characterised by permanent hyperglycemia and clinically diagnosed when fasting blood 
glucose levels exceed more than 7.0 mmol/L blood plasma [45]. Causative for the sustained 
elevation of blood glucose levels in diabetic patients are defects in physiological insulin signaling, 
mainly by impaired insulin sensitivity and secretion, which results in diminished clearance of 
glucose and triglycerides from the blood plasma by insulin-mediated uptake into peripheral organs 
[46]. Although a series of pharmacological interventions as well as changes in diet and physical 
activity can improve health outcomes of diabetic patients and facilitate many diabetics to 
participate in normal life, the underlying impairment of glucose homeostasis can seriously impact 
on quality of life. If not well controlled, diabetic hyperglycemia may cause chronic damage, 
dysfunction and failure of various organ systems, especially blood vessels, kidneys, heart, eyes 
and nerves, which can ultimately result in circulatory disorders, kidney failure, ischemic heart 
attack, stroke, leg amputation and blindness [47]. 
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Despite pharmacological interventions that can delay diabetes progression, such as metformin, 
sulphonylureas, GLP-1 analogues and DPP4 inhibitors, T2DM and its concomitant diseases still 
represents the eighth leading cause of death worldwide [45]. In 2012, 1.5 million deaths were 
directly caused by T2DM and additional 2.2 million deaths by cardiovascular and chronic kidney 
diseases resulting from the constantly elevated blood glucose levels [48]. Worrisomely, 43 % of the 
3.7 million deaths elicited by diabetes occur prematurely, before the patients reach the age of 70 
years [48]. 
Nowadays obesity-associated T2DM affects approximately 8.5 % of the global adult population, 
aged 20-79 years, and caused approximately USD 727 billion dollars in health expenditures in 
2017 [45], underpinning the urgent need to counteract the global obesity pandemic and its 
detrimental metabolic consequences.  
1.2. The liver - central regulator of energy homeostasis 
In vertebrates the liver not only represents the largest solid organ and the largest gland in the body, 
but also carries out more than 500 vital functions, encompassing detoxification of endogenous and 
exogenous substrates, synthesis of proteins essential for immune function and  blood coagulation 
as well as storage, metabolism and redistribution of nutrients, vitamins and minerals [49]. Directly 
connected to the gastrointestinal tract via the portal vein, the liver constitutes the first contact site 
of the body with ingested dietary nutrients, potentially toxic chemicals, xenobiotics and all other 
resorbed substances [50]. Whereas the minerals iron, copper and potassium as well as fat-soluble 
vitamins, such as vitamin A, D, E, K and B12, are stored within the liver, harmful endogenous and 
exogenous substances are biochemically modified in a process called biotransformation, which 
increases the water solubility of the hazardous metabolites and allows excretion via urine or feces 
[51].  
Responsible for the vast repertoire of liver functions are hepatocytes, the main cell type of the liver, 
which account for around 80 % of the liver’s mass and express a plethora of metabolic enzymes 
enabling carbohydrate, protein and lipid biosynthesis, transformation and breakdown [52]. Besides 
synthesising and secreting essential circulating proteins, such as cargo proteins, components of 
the complement immune system and coagulation factors, hepatocytes also produce bile that is 
secreted into the small intestine and facilitates the absorption of lipids and other fat-soluble 
substances [53].  
In conjunction with adipose tissue, the liver plays a key role in controlling lipid metabolism, as 
hepatocytes are the major source of fatty acid synthesis, which exported as lipoproteins provide an 
additional energy source and membrane structural components for peripheral tissues [54]. As 
hepatocytes take up 90 % of the intestinally absorbed glucose for further procession and 
redistribution [55], thereby precisely controlling blood glucose levels, the liver represents both the 
central hub governing whole body energy metabolism as well as the major metabolic organ 
regulating glucose homeostasis. 
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1.2.1. Hepatic regulation of glucose homeostasis 
The liver is the key metabolic organ balancing blood glucose levels within a narrow physiological 
range in order to ensure the supply of peripheral organs with glucose, and hence survival of the 
organism, but also to prevent tissue damage by detrimental hyperglycemia. The tight hepatic 
regulation of glucose homeostasis is orchestrated by an intricate network of inter-organ 
interactions, including the pancreas, the brain, adipose tissue and skeletal muscle, all of which 
impact on the liver’s capability to produce, store and release glucose into the circulation [56, 57]. 
By releasing glucoregulatory hormones into the blood stream, the pancreas regulates the hepatic 
production and release of glucose, known as hepatic gluconeogenesis, as well as hepatic glucose 
storage in the form of glycogen, known as glycogenesis, and its counterpart, the glycogen 
breakdown into glucose, called glycogenolysis [58]. When blood glucose levels are low, during 
sleep or in between meals, pancreatic α-cells release the peptide hormone glucagon, which 
promotes hepatic glycogenolysis to increase endogenous blood glucose levels. In case of 
prolonged fasting, when hepatic glycogen stores are depleted, glucagon also triggers hepatocytes 
to de novo synthesise glucose through gluconeogenesis using other metabolites, such as free fatty 
acids, glycerol, lactate and amino acids [59]. During prolonged fasting periods, hepatic 
gluconeogenesis is the primary source of glucose production, accounting for 90 % of 
endogenously produced glucose [60]. Driven by elevated glucose levels in the postprandial state, 
pancreatic ß-cells secrete insulin, another peptide hormone that acts antagonistically to glucagon 
and directly inhibits gluconeogenesis and raises glycogenolysis in hepatocytes. In addition, insulin 
also indirectly hinders hepatic glucose production through inhibition of free fatty acid and glycerol 
release by adipose tissue, major precursors of hepatic gluconeogenesis [61].  
As the brain accounts for around 25 % of glucose utilisation, it also directly partakes in the 
regulation of hepatic glucose homeostasis via both the sympathetic nervous system (SNS) and the 
parasympathetic nervous system (PNS) [62]. The liver is highly innervated by hypothalamic 
neurons, which transmit both SNS signals to promote glucose production and mobilisation of fuels 
for extrahepatic tissues as well as PNS stimuli to lower glucose production and increase fuel 
storage in the liver [57].  
The rate of hepatic gluconeogenesis is determined by two major factors: the availability of 
gluconeogenic substrates, like free fatty acids, glycerol, lactate and amino acids, as well as by the 
expression of gluconeogenic enzymes (see chapter 1.2.2.2.). Whereas amino acids result from 
general protein degradation during prolonged fasting, the other substrates are mainly produced 
and released by extrahepatic tissues as a response to elevated energy consumption and demand. 
During exercise or fasting, skeletal muscle produce high amounts of pyruvate, which is converted 
into lactate, released into the circulation and ultimately utilised by hepatocytes to synthesise 
glucose through gluconeogenesis [57]. In a similar role, adipose tissue contributes to the rate of 
hepatic gluconeogenesis by providing glycogenic substrates, which are generated as a product of 
lipolysis, the breakdown of body fat. Upon exercise or fasting, adipocytes extract energy from 
triglyceride degradation, thereby generating and releasing free fatty acids and glycerol, both of 
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which serve as progenitors for hepatic glucose production and consequently limit gluconeogenesis 
[63]. 
Insulin action constitutes the main anabolic trigger balancing glucose uptake by the liver and 
peripheral tissues as well as hepatic glycogenesis and gluconeogenesis. However, people 
suffering from diminished insulin secretion and/or sensitivity as well as T2DM patients exhibit a 
pathological condition called insulin resistance, which is characterised by an insufficient cellular 
response towards insulin, leading to uncontrolled hepatic glucose production and decreased 
glucose uptake by peripheral tissues, hence ultimately resulting in chronic and detrimental 
hyperglycemia [64]. 
F i g u r e 2 : M a i n t e n a n c e o f 
physiological blood glucose levels 
b y h e p a t i c g l y c o g e n e s i s , 
g l y c o g e n o l y s i s a n d 
g l u c o n e o g e n e s i s . H o r m o n a l 
regulation, mainly by insulin and 
glucagon, precisely orchestrates liver 
f u n c t i o n i n o r d e r t o m a i n t a i n 
physiological blood glucose levels. In 
fed states with high blood glucose 
levels, insulin is released by the 
pancreas to stimulate glucose uptake 
by peripheral organs as well as 
glycogenesis, the storage of glucose in 
the liver in the form of glycogen. In 
addit ion, insul in inhibits hepatic 
production and release of glucose from 
the liver (gluconeogenesis, top). In 
fasted states with low blood glucose 
levels, glucagon is secreted by the 
p a n c r e a s t o p r o m o t e h e p a t i c 
breakdown of glycogen into glucose 
(glycogenolysis) as well as hepatic 
gluconeogenesis (bottom). Figure taken 
from [59]. 
 
 
 
1.2.2. Molecular mechanisms of hepatic energy homeostasis 
On a molecular level, hepatic energy homeostasis is orchestrated by a complex, yet not fully 
understood signaling network, involving several ramified and interwoven metabolic pathways that 
reciprocally stimulate or inhibit each other by a myriad of direct and indirect interactions. 
For the understanding of this work, the regulatory pathways controlling glucose uptake and 
release, gluconeogenesis, fatty acid beta-oxidation, fatty acid synthesis and insulin signaling will be 
introduced. Yet, other intricate signaling networks contribute to liver energy homeostasis, i.a. 
mammalian target of rapamycin (mTOR), peroxisome proliferator-activated receptor (PPAR), cyclic 
AMP response element-binding protein (CREB), cAMP-dependent protein kinase (PKA), CCAAT-
enhancer-binding protein (C/EBP) and peroxisome proliferator-activated receptor-gamma 
coactivator 1α (PGC1α) signaling (reviewed in [65-70]). 
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1.2.2.1. Glucose uptake and release 
Although several glucose transporters have been described (reviewed in [71]), hepatocytes 
predominantly control glucose uptake and release via glucose transporter-2 (GLUT2, also known 
as solute carrier family 2, member A2 or SLC2A2), a uniporter transporter protein that mediates 
bidirectional fluxes of glucose in and out of hepatocytes along a concentration gradient of glucose 
[50]. Interestingly, hepatocyte-specific deletion of GLUT2 abrogates hepatic glucose uptake in 
mice, but does not impinge on hepatic gluconeogenesis, pointing to alternative mechanisms of 
glucose release by hepatocytes [72]. In humans, mutations of GLUT2 result in Fanconi-Bickel 
syndrome, a rare type of glycogen storage disease which is characterised by hepatic glycogen 
accumulation, fasting hypoglycemia as well as glucose intolerance, underlining the key role of 
GLUT2 in hepatic glucose uptake and release [73]. 
In contrast to GLUT2, which constitutes a low-affinity glucose transporter, but is highly expressed 
in response to elevated blood glucose levels, also high-affinity glucose transporters which shuttle 
glucose close to maximum velocity are expressed in liver, such as glucose transporter-1 (GLUT1, 
also known as solute carrier family 2, member A1 or SLC2A1) and glucose transporter-4 (GLUT4, 
also known as solute carrier family 2, member A4 or SLC2A4) [74]. Humans with mutations of 
GLUT1 develop De Vivo disease, a severe disruption of brain glucose supply due to impaired 
glucose transport across the blood brain barrier, which leads to cerebral energy deficiency and 
cognitive impairments, yet no apparent malfunctions in liver energy metabolism [75]. Targeted 
disruption of GLUT4 in murine adipocytes and muscle impact on liver energy homeostasis as 
affected mice exhibit fasting hyperglycemia and glucose intolerance, underlining the importance of 
inter-tissue interactions to regulate liver energy homeostasis [76]. Yet, both GLUT1 as well as 
GLUT4 deficiency do not directly impinge on hepatic glucose homeostasis, pointing to GLUT2 as 
the main regulator of hepatic glucose uptake and release. 
1.2.2.2. Hepatic gluconeogenesis 
During short-term fasting the liver mainly generates and releases glucose through glycogenolysis. 
However, during prolonged fasting, when glycogen stores are depleted, hepatocytes de novo 
synthesise glucose through gluconeogenesis by converting other metabolites such as lactate, 
pyruvate, glycerol and amino acids to glucose 6-phosphate [61]. The gluconeogenic substrates are 
mostly delivered to the liver through circulation from extrahepatic tissues, such as skeletal muscle 
or adipose tissue. During fasting or exercise, skeletal muscle release amino acids as well as 
lactate, which can be converted to pyruvate, whereas adipose tissue provides hepatocytes with 
fatty acids and glycerol, all of which are metabolised to oxaloactetate in the hepatic mitochondrial 
tricarboxylic acid (TCA) cycle [57].  
The key rate-limiting enzymes controlling gluconeogenesis are phosphoenolpyruvate 
carboxykinase (PCK1), which triggers the conversion of oxaloacetate to phosphoenolpyruvate, 
fructose 1,6-bisphosphatase (FBP1) which mediates dephosphorylation of fructose 1,6-
bisphosphate to glucose 6-phosphate and glucose 6-phosphatase, subunit C (G6PC) which 
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facilitates dephosphorylation of glucose 6-phosphate to glucose (reviewed in [77], see also Figure 
3). The expression levels of PCK1 and G6PC, and thus the rate of hepatic gluconeogenesis, are 
tightly controlled by numerous gluconeogenic transcription factors, which translate extracellular 
cues, such as metabolic hormones [78], nutrient availability [79] and inflammatory cytokines [80], 
into gluconeogenic transcriptional responses. 
The predominant role of PCK1 in hepatic gluconeogenesis has been demonstrated in several 
transgenic mouse models. Whereas systemic deletion of PCK1 in mice results in severe 
hypoglycemia leading to early postnatal death [81], mice with hepatocyte-specific deletion of PCK1 
are viable, but are incapable of producing glucose via gluconeogenesis when fasted, leading to 
accumulation of TCA metabolites and the development of dramatic hepatic steatosis, a tryglyceride 
fat accumulation [82]. Concordantly, transgenic mice overexpressing PCK1 are hyperglycemic and 
show increased basal rates of glucose production from pyruvate, demonstrating that the increase 
of PCK1 alone is sufficient to elevate hepatic gluconeogenesis and thus hepatic glucose output 
[83]. In humans, mutations have been reported that alter the activity or the subcellular localisation 
of PCK1, leading to severe and persistent hypoglycemia and/or liver failure and premature death, 
further underlining the vital role of PCK1 in hepatic gluconeogenesis [84-86]. 
Figure 3: Key enzymes of the 
gluconeogenesis pathway. During 
hepatic gluconeogenesis, glucose 
is generated by a mult is tep 
enzymatic conversion of metabolic 
substrates, such as pyruvate, 
lactate or glutamate, all of which 
are metabolised to oxaloactetate in 
the mitochondrial tricarboxylic acid 
(TCA) cycle. The three rate-limiting 
enzymes of gluconeogenesis are 
( 1 ) p h o s p h o e n o l p y r u v a t e 
ca rboxyk inase (PCK) wh ich 
c o n v e r t s o x a l o a c e t a t e t o 
phosphoenolpyruvate, (2) fructose 
1,6-bisphosphatase (FBP) which 
facilitates dephosphorylation of 
f ructose 1,6-bisphosphate to 
glucose 6-phosphate and (3) 
glucose 6-phosphatase, subunit C 
( G 6 P C ) w h i c h e x e r t s 
dephosphorylation of glucose 6-
phosphate to glucose. Figure 
adapted from [87]. 
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In another study, a transgenic mouse model was generated overexpressing the human Fbp1 gene 
specifically in the liver, which results in glucose intolerance and enhanced hepatic glucose 
production, demonstrating that enhanced expression of FBP1 can increase hepatic glucose output 
[88]. In humans, several mutations of the Fbp1 gene have been reported, all of which cause 
reduced or absent Fbp1 activity and ultimately hypoglycemia and lactic acidosis, as defined by the 
accumulation of lactate in the bloodstream due to impaired lactate utilisation by gluconeogenesis 
[89-91]. 
To assess the metabolic consequences of G6PC deficiency, other studies generated transgenic 
mice with hepatocyte-specific deletions of G6pc, which develop lactic acidosis and hepatic 
steatosis due to glycogen and triglyceride accumulation [92, 93]. Interestingly, mice with liver-
specific G6pc deficiency show normal blood glucose levels owing to compensatory glucose 
production from extrahepatic tissues, especially by the kidney and the intestines, pointing to 
alternative metabolic pathways that can overcome hepatic G6pc deficiency [94]. In contrast, 
humans with G6pc deficiency develop glycogen storage disease I, which is clinically manifested by 
hypoglycemia and hepatic accumulation of glycogen and fat, illustrating the significance of G6PC 
in controlling hepatic gluconeogenesis [95]. 
1.2.2.3. Fatty acid beta-oxidation 
Besides glucose and amino acids, fatty acids can also be metabolised in hepatocytes to generate 
energy for metabolic homeostasis. The major pathway for the degradation of fatty acids is fatty 
acid beta-oxidation, which predominantly takes place in mitochondria and not only provides energy 
for hepatocytes, but also generates ketone bodies which are released into the circulation and 
provide metabolic fuels for extrahepatic tissues [96]. 
The important rate-limiting enzymes participating in fatty acid beta-oxidation are carnitine 
palmitoyltransferase 1 (CPT1), which shuttles the metabolic substrate acyl-CoA into mitochondria, 
acyl-CoA oxidase 1 (ACOX1), which catalyses the first step of the beta-oxidation pathway, and 
hydroxylacyl-CoA dehydrogenase (HADH), which mediates the final step of the beta-oxidation 
pathway (reviewed in [97]). 
Transgenic mice homozygously lacking Cpt1 expression die early during gestation, yet 
heterozygous Cpt1-deficient mice are viable and exhibit hypoglycemia as well as elevated levels of 
free fatty acids when fasted, pointing to impairments in physiological fatty acid conversion [98]. In 
concert with the Cpt1 mouse model, humans affected by Cpt1 mutations suffer from reduced levels 
of ketone bodies and blood glucose during fasting, a medical condition called hypoketotic 
hypoglycemia, which further indicates Cpt1 to play an essential role in metabolising fatty acids to 
ketone bodies and cellular energy stores that can be utilised to generate glucose [99]. 
Homozygous mice deficient for Acox1 expression are viable, but display growth retardation and 
accumulation of fatty acids in blood and in hepatocytes, resulting in alterations of hepatocyte 
morphology and hepatic steatosis [100]. Mutations of Acox1 in humans lead to the development of 
adrenoleukodystrophy, a disease that is characterised by accumulation of very long chain fatty 
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acids throughout the body, emphasising the critical role of Acox1 in hepatic fatty acid utilisation and 
beta-oxidation [101]. 
Transgenic mice deficient for Hadh have low birth weight and die within the first two days of life 
due to neonatal hypoglycemia, accumulation of fatty acid metabolites and resulting severe hepatic 
steatosis [102]. Humans suffering from mutations in Hadh develop hyperinsulinemic hypoketotic 
hypoglycemia, a metabolic condition featuring high levels of insulin as well as low levels of ketone 
bodies and blood glucose, which not only substantiates the key role of Hadh in fatty acid 
metabolism, but also points to undiscovered pathways linking fatty acid metabolism with insulin 
secretion by pancreatic ß-cells [103]. 
1.2.2.4. Fatty acid synthesis 
In the fed state, when excess nutrients are available, the liver not only metabolises carbohydrates 
into glucose and subsequently glycogen, but also converts glucose into fatty acids, the main long-
term form of energy storage within the body. Important enzymes controlling hepatic de novo 
lipogenesis are acetyl-CoA carboxylase alpha (ACACA), which catalyses carboxylation of acetyl-
CoA to malonyl-CoA, the rate-limiting step of lipogenesis [57], fatty acid binding protein 4 (FABP4), 
which mediates fatty acid uptake and transport [104], and sterol regulatory element-binding 
protein-1 (SREBP1), a transcription factor that activates the transcription of key genes in fatty acid 
biosynthesis [105]. 
In mice, Acaca deficiency is embryonically lethal as homozygous Acaca knockout mice not 
properly develop and die during early embryonic development, demonstrating a vital function of 
ACACA not only in hepatic lipogenesis, but also in systemic energy metabolism [106]. 
Interestingly, mice deficient for Fabp4 do not show developmental or metabolic alterations, most 
likely due to other fatty acid binding proteins compensating for the loss of FABP4. Yet, when 
exposed to diet-induced obesity, Fabp4 deficient mice do not develop insulin resistance or 
diabetes, indicating that FABP4 links fatty acid metabolism to the development of detrimental 
metabolic alterations, such as peripheral insulin resistance or pancreatic ß-cell dysfunction [107]. 
Elevated hepatic levels of SREBP1 protein have been detected in both obese mice [108] as well as 
in diabetic patients [109], both of which showed increased expression of SREBP1 target genes, 
higher rates of hepatic fatty acid synthesis and hepatic steatosis. In addition, hepatocyte-specific 
deletion of SCAP, an escort protein necessary for SREBP1 nuclear transport, reduced fatty acid 
synthesis and hepatic steatosis in mice with diet-induced obesity, suggesting that SREBP1 not only 
regulates fatty acid biosynthesis, but also contributes to the development of hepatic steatosis [110].  
 
1.2.2.5. Insulin signaling in hepatocytes 
The anabolic hormone insulin is a major mediator of hepatic metabolism as postprandial insulin-
mediated signaling simultaneously regulates the rates of hepatic lipogenesis, glycogenesis and 
gluconeogenesis as well as protein synthesis [111]. Binding of insulin to the insulin receptor (IR) 
tyrosine kinase results in conformational change-induced activation of the IR kinase activity, 
autophosphorylation of IR subunits and subsequently the recruitment and phosphorylation of 
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insulin receptor substrate (IRS) proteins, which act as molecular scaffolds and recruit and mediate 
other signaling complexes [112].  
The major signaling pathway linking insulin action to metabolic responses is facilitated by 
phosphatidylinositol 3-kinases (PI3K), which are activated by IRS proteins and catalyse the 
phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) phospholipids to 
phosphatidylinositol 3,4,5-triphosphate (PIP3), important second messenger lipid molecules [113]. 
Membrane-bound PIP3 triggers phosphoinositide-dependent kinase 1 (PDK-1) activity, which 
results in recruitment and phosphorylation of several downstream kinases, such as 
phosphorylation of threonine residue 308 (Thr308) of protein kinase B (also known as AKT), the 
key signaling molecule for several essential metabolic pathways [114]. Yet, for full kinase activity 
AKT is also phosphorylated at serine residue 473 (Ser473) by the mammalian target of rapamycin 
complex 2 (mTORC2), another protein complex regulated by insulin and nutrient availability [115]. 
Once fully activated by PDK-1 and mTORC2, AKT mediates phosphorylation of several 
downstream targets, such as glycogen synthase kinase 3 (GSK-3), forkhead box protein O1 
(FOXO1) and tuberous sclerosis complex protein 2 (TSC-2). AKT-mediated phosphorylation of 
glycogenesis repressor GSK-3 results in GSK-3 kinase inactivation and thus enhances the rate of 
glycogen synthesis [116]. By phosphorylation-induced degradation of TSC-2, AKT activates 
mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth and 
proliferation that induces lipid synthesis via sterol regulatory element-binding protein 1 (SREBP1) 
activation as well as protein synthesis [117]. Phosphorylation of the transcription factor FOXO1 by 
AKT leads to nuclear exclusion and degradation of FOXO1, resulting in reduced FOXO1-mediated 
expression of the key gluconeogenic genes glucose-6-phosphate, catalytic subunit (G6pc) and 
phosphoenolpyruvate carboxykinase 1 (Pck1) [118]. In addition, the combination of FOXO1 
degradation and mTORC1 activation increases the expression of glucokinase, the rate-limiting 
enzyme in glycogen synthesis and glycolysis, which contributes to increased glycolytic flux and 
promotes hepatic lipogenesis [111]. 
Mice lacking hepatocyte-specific expression of Foxo1 exhibit decreased rates of glycogenolysis 
and gluconeogenesis, resulting in neonatal and fasted hypoglycemia [119]. Yet, the blunted 
glucose production of Foxo1-deficient mice is normalised when Akt is concomitantly ablated in 
liver, indicating that additional signaling pathways contribute to insulin-stimulated hepatic glucose 
production, such as other members of the FOXO protein family [120]. Indeed, triple-transgenic 
mice deficient for the forkhead box O proteins FOXO1, FOXO3 and FOXO4 show increased rates 
of hypoglycemia compared to FOXO1-deficient mice, indicating that FOXO3 and FOXO4 also 
mediate hepatic gluconeogenesis [121]. In addition, hepatic glucose output is also orchestrated by 
FOXO6, as hepatocyte-specific deletion of FOXO6 causes fasting hypoglycemia in mice and 
overexpression of a constitutively active FOXO6 variant in mice resulted in elevated rates of 
hepatic glucose output [122]. 
The main molecules transmitting signals from the insulin receptor to the intracellular signaling 
pathways are insulin receptor substrate 1 (IRS-1) and insulin receptor substrate 2 (IRS-2), both of 
which have mutated alleles in humans that are associated with reduced insulin sensitivity and 
obesity [123, 124]. Knockout mice deficient for Irs-1 display impaired systemic insulin action and 
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growth retardation [125]. In contrast, Irs-2-deficient knockout mice also show impaired systemic 
insulin signaling, but only exhibit growth retardation in specific tissues, such as pancreatic islet 
cells, which in combination with defective hepatic insulin signaling results in premature 
development of diabetes [126]. Hepatocyte-specific deletion of Irs-1 and Irs-2 in mice completely 
abrogates hepatic insulin action and results in increased hepatic gluconeogenesis, hyperglycemia 
and T2DM, underlining not only the importance of IRS-1 and IRS-2 as key transmitters of insulin 
signaling, but also the impact of hepatic insulin signaling itself in the context of blood glucose 
control and development of T2DM [127]. 
 
Figure 4: Insulin-mediated signaling mechanisms to regulate glucose and lipid metabolism in hepatocytes. 
Extracellular binding of insulin to the insulin receptor (blue) results in autophosphorylation of the receptor, followed by 
recruitment and phosphorylation of insulin receptor substrates (IRS). IRS proteins recruit and activate 
phosphatidylinositol 3-kinases (PI3K), which trigger the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) 
to phosphatidylinositol 3,4,5-triphosphate (PIP3), which in turn promotes phosphoinositide-dependent kinase-1 (PDK1) to 
phosphorylate the protein kinase AKT at threonine residue 308 (Thr308). AKT is also phosphorylated at serine residue 
473 (Ser473) by the mammalian target of rapamycin complex 2 (mTORC2), another protein complex regulated by 
insulin. Once fully activated, AKT phosphorylates several downstream effectors mediating multiple metabolic pathways, 
such as glycogen synthesis, gluconeogenesis, glycolysis and lipid synthesis. In addition to indirect pathways inducing 
glycogen synthesis (dashed lines), AKT directly stimulates glycogen synthesis by phosphorylation-mediated inhibition of 
glycogen synthase kinase 3 (GSK-3) activity. AKT-induced phosphorylation of the transcription factor forkhead box 
protein O1 (FOXO1) results in polyubiquitination and degradation of FOXO1, thus reducing expression of the key 
gluconeogenic genes glucose-6-phosphate, catalytic subunit (G6pc) and phosphoenolpyruvate carboxykinase 1 (Pck1). 
Additionally, FOXO1 degradation leads to increased expression of glucokinase, the rate-limiting enzyme controlling both 
glycogen synthesis and glycolysis by converting glucose to glucose-6-phosphate. Finally, activated AKT induces protein 
as well as lipid synthesis by phosphorylating the tuberous sclerosis (TSC) protein complex, leading to activation of 
mammalian target of rapamycin complex 1 (mTORC1), which in turn induces lipid synthesis via sterol regulatory 
element-binding protein 1 (SREBP1) activation as well as protein synthesis. Figure taken from [111]. 
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1.3. The noncoding genome - a neglected layer of genomic regulators 
 
In recent years, advances in whole-genome transcriptome analyses and tremendous efforts by 
multinational sequencing consortia have led to the discovery that the vast majority of mammalian 
genomes is pervasively transcribed in a highly dynamic and cell type-specific pattern [128]. Yet, 
whereas only about 1.2 % of mammalian genomes encode for proteins, most transcribed genes fall 
into the category of noncoding RNAs (ncRNAs), which are not translated into proteins, but facilitate 
various fundamental cellular functions [129]. Among others, processes enabled or regulated by 
ncRNAs include translation (transfer RNAs and ribosomal RNAs) [130], splicing (small nuclear 
RNAs) and RNA editing (small nucleolar RNAs) [131] as well as gene expression (microRNAs, 
small interfering RNAs and piwi-associated RNAs) [132-134]. However, the largest portion of 
mammalian transcriptomes is constituted by a heterogenous and hitherto mostly uncharacterised 
class of ncRNAs, termed long noncoding RNAs (lncRNAs), which comprises all noncoding RNA 
transcripts longer than 200 nucleotides. In humans, more than 68 % of all genes transcribed are 
lncRNAs [135] and systematic databases, such as the NONCODE database, report more than 
96000 human and 87000 murine lncRNA genes, which express more than 172000 and 131000 
different lncRNA transcripts, respectively [136]. Owing to the arbitrary classification of lncRNAs and 
the resulting huge numbers of transcripts, lncRNA genes are inherently diverse in terms of genome 
locus and transcription product. Whereas some lncRNA genes are found far away from annotated 
gene loci (large intergenic noncoding RNAs or lincRNAs), other lncRNA genes are transcribed from 
the opposite strand of protein-coding genes (natural antisense transcripts or NATs) or are even part 
of protein-coding gene loci, as lncRNA genes that are situated in intronic regions (intronic 
lncRNAs) or lncRNA genes that are transcribed by a bidirectional promotor of a protein-coding 
gene (promotor upstream transcripts or PROMPTs) (reviewed in [137]). Additionally, lncRNA genes 
can also harbor transcriptional units for other ncRNAs, such as miRNAs [138], snoRNAs [139] or 
circular RNAs (circRNAs), which are covalently closed RNA loops that are formed by backsplicing 
of exons or lariat introns and exhibit increased RNA stability due to circularisation (reviewed in 
[140]). 
Although just a few lncRNA genes have been ascribed to specific molecular mechanisms to date, 
the reported functions cover a broad range of fundamental cellular processes, including X-
chromosome inactivation [141], telomere maintenance [142], gene imprinting [143] and cell 
differentiation [144]. Depending on their subcellular localisation and exerted functions, lncRNAs 
can be broadly classified into three groups: (1) lncRNAs that are strictly localised in the nucleus 
and execute their actions on genes adjacent to their own gene locus (cis-regulatory functions), (2) 
lncRNAs that are mainly localised in the nucleus and execute their actions on genes distant to their 
own gene locus (trans-regulatory functions) and finally (3) lncRNAs that predominantly localise and 
function in the cytoplasm (reviewed [137]). Cis-regulatory lncRNAs can mediate the expression of 
neighboring genes by recruiting transcription factors, chromatin organisers or chromatin modifiers 
to their site of transcription, thereby either enhancing or inhibiting the transcriptional activity of 
adjacent genes (reviewed in [145]). A well studied cis-regulatory human lncRNA is HOXA transcript 
at the distal tip (HOTTIP), which has been shown to regulate the expression of multiple adjacent 
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Hoxa genes. When brought in close proximity to the Hoxa gene locus via chromosomal looping, 
HOTTIP binds the histone methyltransferase complex WDR5-MLL, which facilitates transcriptional 
activation of the Hoxa gene locus via methylation of histone H3 on lysine residue 4 (H3K4me3) 
[146].  
F i g u r e 5 : C e l l u l a r 
processes regulated by 
long noncoding RNAs. 
L o n g n o n c o d i n g R N A s 
(lncRNAs) control a plethora 
o f v a r i o u s c e l l u l a r 
m e c h a n i s m s , s u c h a s 
transcript ional and post 
transcriptional regulation, 
epigenetic modification as 
well as small noncoding RNA 
( n c R N A ) p r o c e s s i n g . 
Transcriptional regulation by 
lncRNAs includes scaffolding 
functions to enable protein-
protein interactions as well as 
modulations of the activity, 
subcellular localisation or 
DNA-binding capacity of 
transcription factors and 
other proteins. By mediating 
activity and DNA binding of 
DNA methyltransferases and 
chromatin modifier proteins, 
lncRNAs can also facilitate 
epigenetic modifications at 
specific genomic regions like 
DNA methylation or histone 
m o d i f i c a t i o n s . 
P o s t t r a n s c r i p t i o n a l l y , 
l ncRNAs modera te the 
r e g u l a t i o n o f s p l i c i n g , 
translation or degradation of 
other RNA molecules and 
can also sequestrate, and 
t h u s i n a c t i v a t e , o t h e r 
ncRNAs molecules, such as 
miRNAs. Via binding to Dicer, the main enzyme involved in RNA processing, lncRNAs mediate processing of other RNA 
species or get processed themselves to generate inhibitory small interfering RNA (siRNA) molecules. Figure taken from 
[147]. 
In contrast to cis-regulatory lncRNAs, trans-regulatory lncRNAs perform their functions far from 
their sites of synthesis, for instance by binding to RNA-binding proteins, such as members of the 
heterogenous nuclear ribonucleoprotein family (hnRNPs), which modulate gene expression, 
alternative splicing and mRNA stability (reviewed in [148]). Additional functions exerted by lncRNAs 
in trans include scaffolding for protein-protein interactions [149], modulation of protein activity or 
localisation [150] and multiplex epigenetic silencing in response to major cellular pathways [151, 
152]. A prominent example for trans-regulatory lncRNAs is HOX Antisense Intergenic RNA 
(HOTAIR), a human lncRNA that acts as molecular scaffold binding two well-studied chromatin 
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modifying complexes, the polycomb repressive complex 2 (PRC2) and lysine-specific histone 
demethylase 1A (LSD1). By guiding these chromatin modifiers to the Hoxd gene locus, which is 
located on another chromosome than the HOTAIR transcription site, the HOTAIR lncRNA mediates 
epigenetic silencing of the Hoxd gene locus in trans [153].  
Cytoplasmic lncRNAs can also influence gene expression of other genes, but they perform their 
actions either on cytoplasmic proteins by binding to specific phosphorylation sites [154] or by 
interacting with components of the translation machinery [155] or the RNA molecules to be 
translated [156]. In addition, recent studies reported that cytoplasmic lncRNAs can act as decoys 
for miRNAs [157] or proteins [158], thereby modulating expression levels of the RNA molecules 
usually targeted by the titrated miRNAs or proteins. Interestingly, some lncRNAs were shown to be 
posttranscriptionally processed to give rise to cytoplasmic inhibitory siRNAs or other small RNA 
molecules [128]. In case of metastasis associated lung adenocarcinoma transcript 1 (MALAT1), a 
highly expressed human lncRNA that is localised to nuclear speckles [159], the nascent MALAT1 
transcript can be processed to a different transcripts that was called MALAT1-associated small 
cytoplasmic RNA (mascRNA) and is exclusively located within the cytoplasm [160].  
In contrast to protein-coding genes, lncRNA expression is intriguingly tissue- or cell type-specific 
[161], which - in regard of the huge numbers and myriad functions exerted by lncRNAs - suggests 
versatile key regulatory roles of lncRNAs in specific cellular contexts and biological processes, 
such as development, adaptation to environmental cues and disease states. 
1.3.1. Regulation of hepatic energy homeostasis by long noncoding RNAs 
Despite the fact that just a few long noncoding RNAs (lncRNAs) have been functionally 
characterised to date, there is growing evidence that hepatic lipid and glucose metabolism is 
modulated by lncRNAs in mice as well as in humans. In humans, several lncRNAs have been 
described to have an impact on liver energy metabolism, i.a. the lncRNA colorectal neoplasia 
differentially expressed (CRNDE), which constitutes a downstream target of PI3K/AKT/mTOR 
signaling and mediates expression levels of 316 genes, some of which are associated with hepatic 
lipid and glucose metabolism [162], long intergenic non-coding RNA for kinase activation (LINK-A), 
which links PIP3 and AKT to facilitate AKT enzymatic activation [163], and HCV regulated 1 
(lncHR1), which suppresses lipogenesis transcription factor SREBP1c promotor activity, resulting 
in lower hepatic and plasma triglyceride levels [164]. However, due to the inevitable lack of human 
in vivo model systems, more insightful studies focusing on mechanisms regulating lncRNA 
expression and regulatory functions exerted by lncRNAs have been conducted in mice.  
Gene expression analysis of murine key metabolic organs identified a liver-specific lncRNA, named 
liver-specific triglyceride regulator (lncLSTR), whose expression is significantly reduced in mice 
fasted for 24 hrs, but recovered when fasted mice were allowed to refeed for 4 hrs, indicating 
fluctuating expression of lncLSTR in response to the metabolic status [165]. Adenoviral-mediated 
knockdown of lncLSTR led to decreased levels of plasma triglycerides and glucose, both of which 
was implicated with lncLSTR-mediated alterations of bile acid synthesis and systemic lipid 
homeostasis [165]. 
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In another study, the same group reported a lncRNA, called liver GCK repressor (lncLGR, 
previously labelled as 4632424N07), whose expression in mouse liver was significantly increased 
in mice fasted for 24 hrs and reverted to baseline expression when mice were allowed to refeed for 
4 hrs after 24 hrs fasting [166]. Mechanistically, lncLGR was shown to repress the expression of 
the key metabolic enzyme glucokinase (GCK), resulting in suppressed hepatic GCK-mediated 
glycogenesis and glycogen storage during fasting [166]. 
In other studies hepatic fatty acid beta-oxidation was linked to the function of the lncRNA steroid 
RNA activator (SRA), which was initially described as transcriptional RNA co-activator for non-
steroid nuclear receptors [167] and implicated to adipocyte differentiation and function [168]. Yet, 
upon high-fat diet-induced obesity, global SRA knockout mice not only exhibited reduced fat mass, 
but also reduced liver mass as well as lower levels of liver triglycerides and fatty acids, which 
pointed to additional hepatic functions of SRA in controlling lipid metabolism [169]. Indeed, hepatic 
SRA expression levels were reduced in mice fasted for 16 hrs and SRA was shown to inhibit 
hepatic FOXO1 transcriptional activity, thus reducing fatty acid beta-oxidation in liver in response to 
organismal energy levels [170]. 
Another lncRNA, which was demonstrated to mediate FOXO1-regulated metabolic signaling, is 
maternally expressed gene 3 (MEG3), a lncRNA that is upregulated in mice fed a high-fat diet 
[171]. Increased hepatic levels of MEG3 resulted in higher expression levels of FOXO1 a well as of 
gluconeogenic genes G6pc and Pck1, ultimately leading to elevated rates of hepatic 
gluconeogenesis. Conversely, knockdown of MEG3 in high-fat diet mice abrogated high-fat diet-
induced hepatic triglyceride accumulation and facilitated higher hepatic glycogen content, 
demonstrating that lncRNA MEG3 not only mediates FOXO1-induced hepatic gluconeogenesis, 
but also glycogenesis in mouse liver [171]. 
Microarray analyses of mouse liver transcriptomes revealed 663 lncRNAs that were 
transcriptionally regulated by a 24 hour fasting regime. When mice were allowed to refeed for 4 hrs 
after 24 hrs fasting, 1723 hepatic lncRNAs showed significantly altered expression levels 
compared to mice subjected to 24 hour fasting. Interestingly, the fasting-induced regulation of 237 
hepatic lncRNAs were completely reversed by refeeding, suggesting that lncRNA expression in 
liver is tightly and dynamically controlled by nutrient availability [172]. The same study identified a 
liver-specific lncRNA, labelled Gm16551, whose expression in mice is reduced by 24 hrs fasting 
and reinstated when 24 hrs fasting was followed by 4 hrs refeeding. Functionally, Gm16551 was 
identified as transcriptional target gene of lipogenesis transcription factor SREBP1c and implicated 
in a negative feedback loop attenuating SREBP1c activity and resulting hepatic lipogenesis. Liver-
specific knockdown of Gm16551 expression in mice resulted in increased expression of key 
lipogenic enzymes and elevated circulating triglyceride levels. Consistently, hepatic overexpression 
of Gm16551 was shown to decrease lipogenic gene expression and increased levels of plasma 
triglycerides induced by liver-specific SREBP1c overexpression [172]. Another recent study 
employing high-throughput RNA sequencing of mouse livers identified 1320 liver-enriched lncRNAs 
that were transcriptionally regulated upon a 16 hour fasting regime [173]. By using an adenoviral 
overexpression vector, one of the identified lncRNAs, labelled Gm10768, was implicated in 
controlling hepatic gluconeogenesis, as Gm10768 overexpression in mouse liver resulted in 
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increased expression levels of the gluconeogenic genes G6pc and Pck1 as well as in elevated 
insulin and glucose serum levels. In accordance, adenoviral-induced knockdown of hepatic 
Gm10768 in mouse liver led to significantly decreased expression levels of G6PC and PCK1 and 
lead to abated de novo hepatic glucose synthesis, improved glucose and insulin tolerance, and 
reduced serum levels of insulin and glucose [173]. Combining bioinformatic predictions of 
microRNA binding sites and Gm10768-specific luciferase reporter assays, Gm10768 was shown to 
interact with miR-214, a microRNA that has been identified as negative regulator of 
gluconeogenesis by suppressing FOXO1-associated transcriptional co-regulator activating 
transcription factor (ATF4) [174]. As Gm10768 overexpression antagonised miR-214 abundance 
and function in mouse liver, thus relieving ATF4 suppression and increasing gluconeogenic gene 
expression, lncRNA Gm10768 was identified as additional regulatory entity controlling hepatic 
gluconeogenesis in response to nutrient availability [173].  
Collectively, an increasing number of recent studies demonstrated that lncRNAs represent 
multifaceted regulatory elements that fine-tune fundamental biological processes, like hepatic  fatty 
acid and glucose metabolism. Importantly, the expression rates of most investigated lncRNAs 
correlate with specific disease states or metabolic abnormalities and, as shown in microarray and 
transcriptome analyses, the expression levels of a vast number of hepatic lncRNAs is dynamically 
fluctuating in response to nutrient availability, suggesting an important role for lncRNAs as dynamic 
relays facilitating rapid cellular adaptions to environmental cues. 
 
1.3.2. CRISPR/Cas9-mediated genome engineering 
In recent years, the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 
system has attracted increasing attention as simple, but efficient genome-editing tool. In CRISPR/
Cas9 gene targeting systems, a three-component prokaryotic immune defense machinery is 
employed to specifically induce DNA double strand breaks (DSBs) at desired genomic positions 
[175]. CRISPR/Cas9-induced DSBs can be repaired by endogenous error-prone non-homologous 
end joining (NHEJ) or, if an additional donor template is provided, by homology-directed repair 
(HDR) [176]. Whereas NHEJ may result in random deletions and insertions of single nucleotides at 
the site of the DSB, eventually leading to gene-inactivating mutations, gene targeting via HDR can 
be used to precisely generate complex alleles [177]. 
Components of the CRISPR/Cas9 system include the RNA-guided DNA endonuclease CRISPR 
associated protein 9 (Cas9) as well as the guide RNA (gRNA), a RNA hybrid molecule composed 
of two different RNA molecules, known as the CRISPR RNA (crRNA) and the trans-activating RNA 
(tracrRNA) [178]. Whereas the spacer sequence of the crRNA determines the genomic sequence 
where a DSB will be induced by endonuclease Cas9, the tracrRNA is essentiell for crRNA 
maturation and the activity of the crRNA-tracrRNA-Cas9 ribonucleoprotein complex [179].  
Using a 4-nucleotide linker, the 5’end of a tracrRNA can be fused to the 3’end of a crRNA to create 
a chimeric single guide RNA (sgRNA) molecule that exhibits all features of naturally occurring 
crRNA:tracrRNA hybrid molecules [176]. In this way, the gRNA hybrid can be produced as a single 
oligonucleotide, which may be beneficial for cost-intensive in vitro screenings. 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In the last few years, CRISPR/Cas9 gene editing technology has been successfully established in 
several model organisms to facilitate targeted genetic mutations, including Caenorhabditis elegans 
[180], Drosophila melanogaster [181], Danio rerio [182] and Mus musculus [183]. However, to our 
knowledge CRISPR/Cas9-mediated genome engineering has not yet been used to generate 
lncRNA knockout mouse models and still remains an unexplored resource in the field of lncRNA 
biology. 
1.3.3. The therapeutical potential of RNA interference-based agents 
With microRNA-targeting therapeutics already reaching clinical development [184], lncRNAs have 
recently also been recognised as promising targets for RNA therapeutics. The main principle 
behind RNA therapeutic agents is a natural intracellular mechanism called RNA interference, which 
uses RNA molecules to inhibit the expression of other RNA molecules in a post-transcriptional 
manner [185]. Endogenous RNA molecules central to RNA interference are microRNAs (miRNAs) 
and small interfering RNAs (siRNAs), both of which are used as templates by the RNA-induced 
silencing complex (RISC) to cause sequence-specific targeting of other RNA species [185]. Gene 
silencing is achieved through imperfect base pairing between target RNAs and miRNAs, resulting 
in translation repression and finally RNA degradation, or through complement base pairing 
between target RNAs and siRNAs, followed by endonucleolytic cleavage of the target RNA 
(reviewed in [186]). Yet, whereas miRNAs and siRNAs are natural RNA templates produced by the 
organism to fine-tune expression of other genes in response to environmental cues or metabolic 
states, the endogenous RNAi machinery can also be exploited by exogenous RNA molecules like 
artificial siRNA or short hairpin RNA (shRNAs) therapeutics to specifically target expression of 
disease-associated genes, including lncRNAs [187]. However, RNA molecules are inherently 
unstable due to rapid degradation by the organism and hence require chemical modifications and/
or delivery vehicles for efficient uptake by the targeted cell type [187].  
In previous years, several studies have identified nucleic acid analogs with chemical modifications 
that promote RNA stability, target specificity and affinity, or decreased susceptibility to 
endonuclease degradation (reviewed in [188]). These modifications include 2’-O, 4’-C-methylene 
linked bicyclic ribonucleotides, which are known as locked nucleic acids (LNAs) and possess 
improved targeting potency and resistance to nucleases [189]. In combination with 
phosphorothioate-modified backbones that additionally increase nuclease resistance [190], LNA 
analogs can be utilised in single-stranded antisense oligonucleotides (ASO) that provide specific 
and efficient targeting of complementary RNA molecules. A very potent form of synthetic ASOs are 
GapmeRs, which are chimeric molecules containing a central block (‘gap’) of DNA nucleotides that 
mediate target recognition flanked by terminal LNA analogs that protect the ASO from exonuclease 
activity [191]. Upon binding of complementary RNA molecules to GapmeRs, the ubiquitously 
expressed ribonuclease H (RNase H) mediates cleavage of the RNA strand of the RNA-LNA 
heteroduplex, resulting in efficient degradation of the target RNA and the GapmeR remaining 
active after target RNA cleavage [192]. 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Collectively, RNA therapeutics such as LNA GapmeRs promise a molecular pharmaceutical 
approach enabling specific and versatile targeting of all genes expressed, including lncRNAs. 
Importantly, the high tissue specificity of lncRNAs allows site-specific manipulation of lncRNA 
expression levels without undesirable side effects in other tissues. However, improved delivery 
strategies need to be developed in order to guarantee effective and immuno-compatible transport 
of the agent through the body to ultimately fully harness the power of RNA-based therapeutics. 
1.4. Research objectives 
Obesity has reached global epidemic dimensions and concomitant deregulations of glucose and 
lipid metabolism foster the development of obesity-associated diseases like cardiovascular 
pathologies and T2DM. The liver represents the central hub of energy homeostasis as it is not only 
the major site for carbohydrate and lipid biosynthesis, but also a precise regulator of blood glucose 
levels. Although many signaling pathways and key molecules controlling liver energy homeostasis 
have been identified, the molecular mechanisms integrating nutrient availability and organismal 
energy demand remain insufficiently understood.   
Long noncoding RNAs represent a vast, yet poorly characterised class of functional RNA elements, 
some of which have been implicated in fine-tuning several major developmental processes in 
response to environmental cues or disease conditions. However, just a few studies have identified 
lncRNAs governing liver energy homeostasis and a multitude of lncRNA genes have not yet been 
ascribed to specific molecular functions. 
By combining next-generation sequencing with RNA biology and mouse transgenics, the present 
study aimed to elucidate (1) if hepatic lncRNA expression globally correlates with metabolic 
conditions, such as obesity, T2DM and short-term alterations of nutrient availability, (2) if selected 
murine hepatic lncRNAs functionally contribute to the regulation of liver energy homeostasis in vivo 
and (3) how selected lncRNAs affect metaboregulatory signaling circuits. 
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Chapter 2 - Materials 
 
2.1. General materials 
- Cell scraper [25 cm, 39 cm]  
(Product IDs: 83.1830, 83.1831, Sarstedt AG & Co., Nümbrecht, DE) 
- Cell strainer, EASYstrainer™, 40 µm  
(Product ID: 542040, Greiner Bio-One GmbH, Kremsmünster, AT) 
- Centrifugation tubes, Falcon®, polypropylene [15 ml, 50 ml] 
(Product IDs: 352096, 352070, Corning Corp., Corning, US) 
- Ceramic beads, Precellys® zirconium oxide beads, 1.4 mm 
(Product ID: 03961-1-103, Cayman Chemical, Ann Arbor, US) 
- Chromatography paper, Whatman™  
(Product ID: 3030-861, GE Healthcare, Chicago, US) 
- Cover glasses, 24 x 32 mm 
(Product ID: 0102112, VWR International GmbH, Radnor, US) 
- Cryo tubes, CryoPure®, 1.8 ml  
(Product ID: 72.379.005, Sarstedt AG & Co., Nümbrecht, DE) 
- Density gradient medium, Percoll® 
(Product ID: GE17-0891-02, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Disinfectant, Bacillol® AF 
(Product ID: 9733803, BODE Chemie GmbH, Hamburg, DE) 
- Dispenser, Multipette® E3  
(Product ID: 4987000010, Eppendorf AG, Hamburg, DE) 
- Dispenser-tips, Combitips advanced® [0.2 ml, 2.5 ml] 
(Product IDs: 613-2059, 613-2062, Eppendorf AG, Hamburg, DE) 
- DNA gel loading dye, 6X 
(Product ID: R0611, Thermo Fisher Scientific, Waltham, US) 
- DNA ladder mix, GeneRuler™  
(Product ID: SM0331, Thermo Fisher Scientific, Waltham, US) 
- Dulbecco’s modified eagle medium (DMEM), GlutaMAX™, high glucose (4.5g/l), 1X  
(Product ID: 10569010, Thermo Fisher Scientific, Waltham, US) 
- Dulbecco’s modified eagle medium (DMEM), low glucose (1g/l), 1X  
(Product ID: 11880036, Thermo Fisher Scientific, Waltham, US) 
- Dulbecco’s modified eagle medium (DMEM), no glucose, 1X  
(Product ID: 11966025, Thermo Fisher Scientific, Waltham, US) 
- Dulbecco’s phosphate-buffered saline (DPBS), 10X  
(Product ID: 14190169, Thermo Fisher Scientific, Waltham, US) 
- Earle’s balanced salt solution (EBSS), calcium, magnesium, phenol red, 1X  
(Product ID: 24010043, Thermo Fisher Scientific, Waltham, US) 
- Earle’s balanced salt solution (EBSS), no calcium, no magnesium, no phenol red, 1X  
(Product ID: 14155048, Thermo Fisher Scientific, Waltham, US) 
- LB-Medium Powder, according to Miller 
(Product ID: A0954, AppliChem GmbH, Darmstadt, DE) 
- L-Glutamine solution, 100X  
(Product ID: 25030081, Thermo Fisher Scientific, Waltham, US) 
- Multichannel pipette, Transferpette® S-8  
(Product ID: 703708, Brand GmbH + CO KG, Wertheim, DE) 
- Neubauer improved cell counting chamber, 0.01 mm 
(Product ID: N/A , W. Schreck, Hofheim am Taunus, DE) 
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- Needles, Sterican®, 0.45 x 12mm  
(Product ID: 4665457, B. Braun Melsungen AG, Melsungen, DE) 
- Nitrocellulose western blotting membrane, Amersham™ Protran® Premium, 0,45 µm  
(Product ID: 10600047, GE Healthcare, Chicago, US) 
- Non-essential amino acids (NEAA) solution, 100X  
(Product ID: 11140050, Thermo Fisher Scientific, Waltham, US) 
- Nucleic acid staining solution, Midori Green Advance®  
(Product ID: 617004, Biozym Scientific GmbH, Hessisch Oldendorf, DE) 
- Optical 384-well reaction plate with barcode, MicroAmp™  
(Product ID: 4309849, Thermo Fisher Scientific, Waltham, US) 
- Optical adhesive film, MicroAmp™  
(Product ID: 4311971, Thermo Fisher Scientific, Waltham, US) 
- Pasteur pipettes, non-sterile  
(Product ID: 612-1701, VWR International GmbH, Radnor, US) 
- PCR lid strips, Multiply® 8-lid chain, flat  
(Product ID: 65.989.002, Sarstedt AG & Co., Nümbrecht, DE) 
- PCR tubes, Multiply®-µStrip, 0.2 ml  
(Product ID: 72.985.002, Sarstedt AG & Co., Nümbrecht, DE) 
- Penicillin-streptomycin solution, 10.000 U/ml  
(Product ID: 15140122, Thermo Fisher Scientific, Waltham, US) 
- Petri dishes, 94 x 16 mm  
(Product ID: PP90, A. Hartenstein GmbH, Würzburg, DE) 
- Pipetboy, accu-jet® pro  
(Product ID: 26300, Brand GmbH + CO KG, Wertheim, DE) 
- Pipettes, Transferpette® S Starter Kit  
(Product ID: 613-3478, Brand GmbH + CO KG, Wertheim, DE) 
- Pipette-tips [10 µl, 200 µl, 1000 µl] 
(Product IDs: 771255, 739265, 686271, Greiner Bio-One GmbH, Kremsmünster, AT) 
- Pipette-tips, filtered [0.5-10 µl, 5-100 µl, 50-1000 µl]  
(Product IDs: 732724, 732730, 732734, Brand GmbH + CO KG, Wertheim, DE) 
- Pipette with tip, sterile [5 ml, 10 ml, 25 ml, 50 ml]  
(Product IDs: 606180, 607180, 760180, 768180, Greiner Bio-One GmbH, Kremsmünster, AT) 
- Precast gels, Mini-PROTEAN® TGX™,, 10-well [4-15 %, 7.5 %] 
(Product IDs: 4561084, 4561023, Bio-Rad Laboratories, Inc., Hercules, US) 
- Prestained protein ladder, PageRuler™, 10 to 180 kDa  
(Product ID: 26616, Thermo Fisher Scientific, Waltham, US) 
- PVDF transfer pack, Trans-Blot® Turbo™ Mini  
(Product ID: 1704156, Bio-Rad Laboratories, Inc., Hercules, US) 
- Reaction tubes, SafeSeal® [0.5 ml, 1.5 ml, 2.0 ml]  
(Product IDs: 72.704, 72.706, 72.695.600, Sarstedt AG & Co., Nümbrecht, DE) 
- Reduced serum medium, Opti-MEM™  
(Product ID: 31985062, Thermo Fisher Scientific, Waltham, US) 
- Syringes, Injekt®-F, 1 ml  
(Product ID: 9166017V, B. Braun Melsungen AG, Melsungen, DE) 
- Tissue culture dish, TPP®, 15 cm  
(Product ID: Z707694, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Tissue culture plate, Corning® BioCoat™, collagen I-coated [6-well, 12-well]  
(Product IDs: 356400, 356500, Corning Corp., Corning, US) 
- Tissue culture plate, Falcon®, polystyrene [6-well, 12-well]  
(Product IDs: 353046, 353043, Corning Corp., Corning, US) 
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- Tissue culture plate, Falcon®, polystyrene ,10 cm  
(Product ID: 353003, Corning Corp., Corning, US) 
- Tissue freezing medium  
(Product ID: 14020108926, Leica Biosystems Nussloch GmbH, Nussloch, DE) 
- Water, BioXtra, for embryo transfer, sterile-filtered 
(Product ID: W1503, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Western blocking reagent, solution 
(Product ID: 11921673001, Roche Diagnostics GmbH, Mannheim, DE 
2.2. Technical equipment 
- Analysis system, Agilent 2100 Bioanalyzer  
(Agilent Technologies, Inc., Santa Clara, US) 
- Analytical balances, Quintix® 124-1S & Quintix® 612-1S  
(Sartorius AG, Göttingen, DE) 
- Blood glucose monitoring system + sensors, Contour® XT  
(Bayer Healthcare, Leverkusen, DE) 
- Cell culture cabinet, Scanlaf Mars, safety class II  
(LaboGene ApS, Allorød, DK) 
- Centrifuge, 5810 R  
(Eppendorf AG, Hamburg, DE) 
- Chemiluminescence imaging system, Fusion Solo  
(Vilber Gourmet Deutschland GmbH, Eberhardzell, DE) 
- CO2-Incubator, C 170  
(BINDER GmbH, Tuttlingen, DE) 
- CO2-Incubator, Heracell™ 150i  
(Thermo Fisher Scientific, Waltham, US) 
- Digital printer, P95DE  
(Mitsubishi Electric Corporation., Chiyoda, JP) 
- Electrophoresis and blotting system, Mini-PROTEAN Tetra Cell  
(Bio-Rad Laboratories, Inc., Hercules, US) 
- Electrophoretic transfer module, Mini Trans-Blot Cell  
(Bio-Rad Laboratories, Inc., Hercules, US) 
- Fume cupboard, CC-30  
(Caspar & Co. Labora GmbH, Aachen, DE) 
- Gel documentation system, FastGene® FAS V  
(Nippon Genetics Europe GmbH, Düren, DE) 
- Gel electrophoresis chamber, PerfectBlue™ Mini  
(VWR International GmbH, Radnor, US) 
- Homogenizer, FastPrep-24™ 5G  
(MP Biomedicals Germany GmbH, Eschwege, DE) 
- Inverted microscope, DM IL LED  
(Leica Microsystems CMS GmbH, Wetzlar, DE) 
- Laboratory freezer, Forma™ 88000  
(Thermo Fisher Scientific, Waltham, US) 
- Laboratory freezer, LGex 3410 Mediline  
(Liebherr-International AG, Bulle, CH) 
- Microcentrifuge, refrigerated, Micro Star 17R  
(VWR International GmbH, Radnor, US) 
- Microplate reader, FilterMax™ F5  
(Molecular Devices, LLC, San José, US) 
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- PCR-Thermocycler, FlexCycler2  
(Analytik Jena AG, Jena, DE) 
- PhenoMaster, Automated Home Cage Phenotyping 
(TSE Systems GmbH, Bad Homburg vor der Höhe, DE) 
- Platform shaker, Polymax 1040  
(Heidolph Instruments GmbH & Co. KG, Schwabach, DE) 
- Power Supply, PowerPac™ HC  
(Bio-Rad Laboratories, Inc., Hercules, US) 
- Real-Time PCR System, QuantStudio™ 7 Flex  
(Applied Biosystems, Foster City, US) 
- Refrigerator, KT 1730-26  
(Liebherr-International AG, Bulle, CH) 
- Shaker, IKA® MS 3  
(IKA Werke GmbH & Co. KG, Staufen im Breisgau, DE) 
- Spectrophotometer, NanoDrop™ ND-1000  
(NanoDrop Technologies, LLC, Wilmington, US) 
- Thermoshaker, MKR 23  
(Hettich Benelux B.V., Geldermalsen, NL)  
- Ultracentrifuge, Heraeus™ Megafuge™ 16R  
(Thermo Fisher Scientific, Waltham, US) 
- Vortex mixer, Vortey-Genie 2  
(Scientific Industries, Inc., Bohemia, US) 
- Water bath, model 1003  
(GFL Gesellschaft für Labortechnik mbH, Burgwedel, DE) 
- Water purification system, Milli-Q® Advantage A10  
(Merck Millipore, Darmstadt, DE) 
- Western blotting transfer system, Trans-Blot® Turbo™  
(Bio-Rad Laboratories, Inc., Hercules, US) 
2.3. Chemicals 
- 2-Propanol (isopropanol), for molecular biology, min. 99.5%  
(Product ID: I9516, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- 5-Bromo-4-chloro-3-indolyl-ß-D-galactopyranoside (X-Gal), min. 99%  
(Product ID: R0404, Thermo Fisher Scientific, Waltham, US) 
- ß-Glycerophosphate disodium salt hydrate, min. 99%  
(Product ID: G9422, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- ß-Mercaptoethanol, min. 99%  
(Product ID: A1108, AppliChem GmbH, Darmstadt, DE) 
- Acetic acid, glacial, min. 90%  
(Product ID: BAKR9522, VWR International GmbH, Radnor, US) 
- Acrylamide-bisacrylamide stock solution, Rotiphorese® Gel 30  
(Product ID: 3029, Carl Roth GmbH + Co. KG) 
- Agarose, for molecular biology  
(Product ID: A9539, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Agarose, UltraPure™  
(Product ID: 16500100, Thermo Fisher Scientific, Waltham, US) 
- Ammonium persulfate (APS), pure  
(Product ID: 1610700, Bio-Rad Laboratories, Inc., Hercules, US) 
- Ampicillin sodium salt, min. 91%  
(Product ID: A0839, AppliChem GmbH, Darmstadt, DE) 
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- Aprotinin, from bovine lung, 3-8 TIU/mg  
(Product ID: A3428, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Bovine serum albumin (BSA), min. 98%  
(Product ID: A8806, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Calcium chloride dihydrate (CaCl2-2H2O), min. 99%  
(Product ID: C7902, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Chemiluminescense substrate, SuperSignal™ West Dura Extended Duration  
(Product ID: 34076, Thermo Fisher Scientific, Waltham, US) 
- D-(+)-Glucose, min. 99.5%  
(Product ID: G7021, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Dexamethasone, min. 97%  
(Product ID: D4902, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Diethylpyrocarbonate (DEPC)-treated and sterile filtered water  
(Product ID: 95284, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Dimethylformamide (DMF), min. 99%  
(Product ID: D4551, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Dimethylsulfoxide (DMSO), 99 %  
(Product ID: 1096780100, Merck Millipore, Darmstadt, DE) 
- DNA/RNA purification reagent, peqGOLD TriFast™  
(Product ID: 30-2010, VWR International GmbH, Radnor, US) 
- Ethanol absolut, AnalaR NORMAPUR®, min. 99.8%  
(Product ID: 20821.296, VWR International GmbH, Radnor, US) 
- Ethylene glycol-bis(2-aminoethylether)-tetraacetic acid (EGTA), min. 99%  
(Product ID: A0878, AppliChem GmbH, Darmstadt, DE) 
- Ethylenediaminetetraacetic acid (EDTA), min. 98%  
(Product ID: E6758, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Fetal Bovine Serum (FBS), South America Premium  
(Product ID: P30-3301, Pan - Biotech GmbH, Aidenbach, DE) 
- Forskolin, min. 98%  
(Product ID: F3917, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Glucagon, human recombinant, min. 95%  
(Product ID: G2044, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Glucose-solution 20 %, ad us. vet.  
(Product ID: 2069.97.99 (prescription drug), bela-pharm GmbH & Co. KG, Vechta, DE) 
- Glycine, biotechnology grade  
(Product ID: 444495D, VWR International GmbH, Radnor, US) 
- Hydrochloric acid (HCl), 37%  
(Product ID: 211020, AppliChem GmbH, Darmstadt, DE) 
- Insulin solution, human recombinant, 9.5 - 10.5 mg/ml  
(Product ID: I9278, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Insulin solution, Insuman® Rapid, 40 I.E./ml  
(Product ID: 08923000, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, DE) 
- Isopropyl-ß-D-thiogalactopyranoside (IPTG), dioxane-free, min. 99%  
(Product ID: R0392, Thermo Fisher Scientific, Waltham, US) 
- Isotonic sodium chloride solution, ad us. vet.  
(Product ID: 1409.99.99 (prescription drug), bela-pharm GmbH & Co. KG, Vechta, DE) 
- Ketamin injection solution, Anesketin®, 100 mg/ml  
(Product ID: 401780.00.00 (prescription drug), Albrecht GmbH, Aulendorf, DE) 
- Laemmli sample buffer, 4X  
(Product ID: 1610747, Bio-Rad Laboratories, Inc., Hercules, US) 
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- Magnesium chloride hexahydrate (MgCl2-6H2O), min. 99%  
(Product ID: M2393, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Membrane staining solution, Ponceau S, 0.1 %  
(Product ID: P7170, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Methanol, ROTIPURAN®, min. 99.9%  
(Product ID: 4627.1, Carl Roth GmbH + Co. KG) 
- N-2-hydroxyethylpiperazine-N-2-ethane sulfuric acid (HEPES) buffer solution, 1M  
(Product ID: 15630049, Thermo Fisher Scientific, Waltham, US) 
- N, N, N’, N’-Tetramethylethylendiamin (TEMED), min. 99.5%  
(Product ID: A1148, AppliChem GmbH, Darmstadt, DE) 
- Nonylphenylpolyethylenglycol (NonidetTM P40), min. 99%  
(Product ID: A1694, AppliChem GmbH, Darmstadt, DE) 
- Phenylmethylsulfonyl fluoride (PMSF), min. 98.5 %  
(Product ID: P7626, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Phosphatase inhibitor tablets, PhosSTOP™ 
(Product ID: 04906837001, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Potassium chloride (KCl), min. 99%  
(Product ID: P9333, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Protease inhibitor tablets, Complete™ Mini 
(Product ID: 4693159001, Roche Diagnostics, Rotkreuz, CH) 
- RNase decontamination solution, RNAseZAP™  
(Product ID: R2020, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- RNase inhibitor, RNasin® Plus  
(Product ID: N2511, Promega GmbH, Mannheim, DE)  
- Sodium acetate (NaAc), min. 99% 
(Product ID: S5636, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Sodium chloride (NaCl), pure  
(Product ID: 443827W, VWR International GmbH, Radnor, US) 
- Sodium dodecyl sulfate (SDS), min. 99%  
(Product ID: A1112, AppliChem GmbH, Darmstadt, DE) 
- Sodium fluoride (NaF), min. 99 %  
(Product ID: S6776, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Sodium hydroxide (NaOH), AnalaR NORMAPUR®, solid  
(Product ID: 28244.295, VWR International GmbH, Radnor, US) 
- Sodium pyruvate solution, 100 mM  
(Product ID: 11360070, Thermo Fisher Scientific, Waltham, US) 
- Transfection reagent, Lipofectamine™ 2000  
(Product ID: 11668019, Thermo Fisher Scientific, Waltham, US) 
- Transfection reagent, Lipofectamine™ RNAiMAX  
(Product ID: 13778150, Thermo Fisher Scientific, Waltham, US) 
- Trichlormethane (chloroform), min. 99.8 %  
(Product ID: 4432.1, Carl Roth GmbH + Co. KG) 
- Tris-(hydroxymethyl)-aminomethane (Tris), AnalaR, solid  
(Product ID: 103156X, VWR International GmbH, Radnor, US) 
- Tris hydrochloride (Tris-Cl), solid  
(Product ID: A3452, AppliChem GmbH, Darmstadt, DE)) 
- Trypan blue solution, 0.4%  
(Product ID: T8154, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Trypsin-EDTA (0.5%), no phenol red, 10X  
(Product ID: 15400054, Thermo Fisher Scientific, Waltham, US) 
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- Trypsin inhibitor from Glycine max (soybean)  
(Product ID: T6522, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- Tween® 20 (polysorbate), for molecular biology  
(Product ID: 437082Q, VWR International GmbH, Radnor, US) 
- Xylazine injection solution, Rompun® 2%  
(Product ID: 6293841.00.00 (prescription drug), Bayer Vital GmbH, Leverkusen, DE) 
 
2.4. Molecular biology reagents 
- Agilent RNA 600 Nano Kit  
(Product ID: 5067-1511, Agilent Technologies, Inc., Santa Clara, US) 
- Agilent RNA 600 Pico Kit  
(Product ID: 5067-1513, Agilent Technologies, Inc., Santa Clara, US) 
- Alt-R® S.p. Cas9 Nuclease 3NLS  
(Product ID: 1074181, Integrated DNA Technologies, Inc., Skokie, US ) 
- Cas9 mRNA (5meC, Psi)  
(Product ID: L-6125-20, TriLink BioTechnologies, Inc., San Diego, US) 
- Collagenase, Type 4  
(Product ID: LS004189, Worthington Biochemical Corporation, Lakewood, US) 
- DNAse I (RNase-free) 
(Product ID: M0303, New England Biolabs GmbH, Ipswich, US) 
- dNTP set, 100 mM solutions 
(Product ID: R0182, Thermo Fisher Scientific, Waltham, US) 
- DreamTaq Green DNA Polymerase (5 U/µl) 
(Product ID: EP0714, Thermo Fisher Scientific, Waltham, US) 
- ERRC RNA Spike-In Mix  
(Product ID: 4456740, Thermo Fisher Scientific, Waltham, US) 
- High-Capacity cDNA Reverse Transcription Kit  
(Product ID: 4368814, Thermo Fisher Scientific, Waltham, US) 
- High Fidelity PCR Master Kit  
(Product ID: 12140314001, Roche Diagnostics GmbH, Mannheim, DE) 
- HiScribe™ T7 High Yield RNA Synthesis Kit  
(Product ID: E2040, New England Biolabs GmbH, Ipswich, US) 
- MinElute PCR Purification Kit  
(Product ID: 28006, QIAGEN N.V., Venlo, NL) 
- NEBNext® rRNA Depletion Kit (Human/Mouse/Rat) 
(Product ID: E6310, New England Biolabs GmbH, Ipswich, US) 
- NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina® 
(Product ID: E7420, New England Biolabs GmbH, Ipswich, US) 
- Nuclei EZ Prep Nuclei Isolation Kit  
(Product ID: NUC101, Sigma-Aldrich Chemie GmbH, Schnelldorf, DE) 
- NucleoBond® Xtra Maxi  
(Product ID: 740414, Macherey-Nagel GmbH & Co., Düren, DE) 
- NucleoSpin® RNA Kit  
(Product ID: 740955, Macherey-Nagel GmbH & Co., Düren, DE) 
- PCR Mycoplasma Test Kit  
(Product ID: A3744, AppliChem GmbH, Darmstadt, DE) 
- pGEM®-T Easy Vector System I  
(Product ID: A1360, Promega Corp., Madison, US) 
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- Phusion® High-Fidelity DNA Polymerase  
(Product ID: M0530, New England Biolabs GmbH, Ipswich, US) 
- Pierce BCA Protein Assay Kit  
(Product ID: 23225, Thermo Fisher Scientific, Waltham, US) 
- Proteinase K, recombinant, PCR grade  
(Product ID: 03115844001, Roche Diagnostics GmbH, Mannheim, DE) 
- pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid  
(Plasmid #42230, Addgene, Cambridge, US) 
- QIAquick® Gel Extraction Kit  
(Product ID: 28706, QIAGEN N.V., Venlo, NL) 
- QIAshredder® Cell Homogenization Kit 
(Product ID: 79656, QIAGEN N.V., Venlo, NL) 
- Quick Start™ Bradford Protein Assay Kit 1 
(Product ID: 5000201, Bio-Rad Laboratories, Inc., Hercules, US) 
- Ribo-Zero rRNA Removal Kit (Human/Mouse/Rat) 
(Product ID: RS-122-2001/2, Illumina, San Diego, US) 
- RNase A, DNase and protease-free (10 mg/ml) 
(Product ID: EN0531, Thermo Fisher Scientific, Waltham, US) 
- RNeasy® Mini Kit  
(Product ID: 74106, QIAGEN N.V., Venlo, NL) 
- SYBR™ Select Master Mix  
(Product ID: 4472903, Thermo Fisher Scientific, Waltham, US) 
- T4 DNA Ligase  
(Product ID: M0202, New England Biolabs GmbH, Ipswich, US) 
- T7 Endonuclease I  
(Product ID: M0302, New England Biolabs GmbH, Ipswich, US) 
- TaqMan™ Gene Expression Master Mix  
(Product ID: 4369016, Thermo Fisher Scientific, Waltham, US) 
- TruSeq RNA Library Prep Kit v2 
(Product ID: MRZH116/124, Illumina, San Diego, US) 
- TURBO DNA-free™ Kit  
(Product ID: AM1907, Thermo Fisher Scientific, Waltham, US) 
- Ultracompetent cells, XL10-Gold® 
(Product ID: 200314, Agilent Technologies, Inc., Santa Clara, US) 
2.5. Antibodies 
Antigen   Source  Dilution Company & Product ID    
 
AKT (pan) (11E7)   Rabbit   1:1000  Cell Signaling Technology, ID: 4685 
Calnexin (C-term. 575-593) Rabbit  1:5000  Merck Millipore, ID: 208880 
Phospho-AKT (Ser473)  Rabbit   1:1000  Cell Signaling Technology, ID: 9271 
Rabbit (IgG)    Goat   1:5000  Sigma-Aldrich, ID: A6154 
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2.6. PCR primer 
 
Genotyping primer                                     Sequence (5’ -> 3’) 
4833411C07Rik-delta external PCR forward (#409)      TGCGCAATAGGTCCCCACAAACAC 
4833411C07Rik-delta external PCR reverse (#408)      TTTCTTTCTTTCTTTCTCGTCTGA 
4833411C07Rik-delta internal PCR forward (#407)      GGTGGGGTCAGGAGCTTGTTTACT 
4833411C07Rik-delta internal PCR reverse (#410)       CTAGAAACAGACCACCAATCAGC 
Gm15441-delta external PCR forward (#411)               GACCCTTGTTCTTGTGTGGC  
Gm15441-delta external PCR reverse (#242)               AGAGCACAGACAGACAGACC 
Gm15441-delta internal PCR forward (#239)               TCTAGAGCCTGGAAAAGCGC 
Gm15441-delta internal PCR reverse (#240)                CTCTAGCTCCCAAAGGCACC 
 
Primer for sgRNA synthesis     Sequence (5’ -> 3’) 
pX330-5’ reverse primer                              AAAAAGCACCGACTCGGTGCC  
Gm15441-5’-1 (18) 
TTAATACGACTCACTATAGGAGGCAGAACTCTACGGGAGTTTTAGAGCTAGAAATAGC  
Gm15441-5’-2 (18) 
TTAATACGACTCACTATAGGCCTTGGCTCACTAGGTGAGTTTTAGAGCTAGAAATAGC  
Gm15441-3’-1 (18) 
TTAATACGACTCACTATAGGTCCATCAGACTAGTCTGTGTTTTAGAGCTAGAAATAGC  
Gm15441-3’-2 (18) 
TTAATACGACTCACTATAGGCACCGTAGGCGGTTCATTGTTTTAGAGCTAGAAATAGC  
lncIRS2–5’-1 (18) 
TTAATACGACTCACTATAGGAGATGTTTATTTTGTCGCGTTTTAGAGCTAGAAATAGC  
lncIRS2–5’-2 (18) 
TTAATACGACTCACTATAGGTTAAACACATTCCGGGTGGTTTTAGAGCTAGAAATAGC  
lncIRS2–3’-1 (18) 
TTAATACGACTCACTATAGGCAGTCCTCAAATGCTGATGTTTTAGAGCTAGAAATAGC  
lncIRS2–3’-2 (18) 
TTAATACGACTCACTATAGGAGCACTGAACAGCCAATCGTTTTAGAGCTAGAAATAGC  
Gm15441-5’-1 (20) 
TTAATACGACTCACTATAGGCCTGTTCTAAGCACCCTGACGTTTTAGAGCTAGAAATAGC  
Gm15441-5’-2 (20) 
TTAATACGACTCACTATAGGCAAGGCAGAACTCTACGGGAGTTTTAGAGCTAGAAATAGC  
Gm15441-3’-1 (20) 
TTAATACGACTCACTATAGGAGTATTGAATGAACCGCCTAGTTTTAGAGCTAGAAATAGC  
Gm15441-3’-2 (20) 
TTAATACGACTCACTATAGGGCTCTCCTAAGTACCTGTGGGTTTTAGAGCTAGAAATAGC  
lncIRS2–5’-1 (20) 
TTAATACGACTCACTATAGGTGTAGCGCTCTAGCTGCATCGTTTTAGAGCTAGAAATAGC  
lncIRS2–5’-2 (20) 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TTAATACGACTCACTATAGGTCTAGCTGCATCGGGTTTGTGTTTTAGAGCTAGAAATAGC  
lncIRS2–3’-1 (20) 
TTAATACGACTCACTATAGGAAATGGGACATCTATCAATGGTTTTAGAGCTAGAAATAGC  
lncIRS2–3’-2 (20) 
TTAATACGACTCACTATAGGGTGTGCTCACACAGGCACTTGTTTTAGAGCTAGAAATAGC  
 
All sgRNA synthesis primer were designed using the CRISPR design tool and the CRISPOR 
prediction software. 
 
Primer for T7 endonuclease assays                  Sequence (5’ -> 3’) 
Gm15441-5’-1 (18) forward                               GCGCACGTTTAACTGACTCTC  
Gm15441-5’-1 (18) reverse                                ATAAGCAGCACCCCTCCATG  
Gm15441-5’-2 (18) forward                              CACAGAAGGGAGATAAAGCGC  
Gm15441-5’-2 (18) reverse                               TTGCCTTCCCTCACTGATGG  
Gm15441-3’-1 (18) forward                               ATCAGTGAGGGAAGGCAAGG  
Gm15441-3’-1 (18) reverse                               AGCAAGCCAGTATCACATGC  
Gm15441-3’-2 (18) forward                               ATGGAGGGGTGCTGCTTATC  
Gm15441-3’-2 (18) reverse                               GCAGGAAGGCTAACAGGAGG  
lncIRS2–5’-1 (18) forward                               GGAGGAGACAGCAGTTGGG  
lncIRS2–5’-1 (18) reverse                                TGTGTGTGTGCAATGCTCTC  
lncIRS2–5’-2 (18) forward                              TTTTGTCGCTGGTTGAGGTG  
lncIRS2–5’-2 (18) reverse                               CACTTTGAGATGGGCTTGGC  
lncIRS2–3’-1 (18) forward                               ACCGGGTGAACTCTGTGTAG  
lncIRS2–3’-1 (18) reverse                                GATTGGCTGTTCAGTGCTCTC  
lncIRS2–3’-2 (18) forward                               TTGAGGACTGGAGAGATGGC  
lncIRS2–3’-2 (18) reverse                                GTGCCTGTGTGTGTATGTGC  
 
Gm15441-5’-1 (20) forward                               GCTCCTACTCAGACCCTTGTTC  
Gm15441-5’-1 (20) reverse                                CTCCCTGAGTTGCTTTTGGTC  
Gm15441-5’-2 (20) forward                               GAAGGGAGATAAAGCGCACG  
Gm15441-5’-2 (20) reverse                               ATGGGGAGCAAGCCGATAAG  
Gm15441-3’-1 (20) forward                               GACTAGTCTGATGGAGGCATC  
Gm15441-3’-1 (20) reverse                               TGTGTGTGTGTGTGAGAGAGAG  
Gm15441-3’-2 (20) forward                               TCAGCCTGCTTTCTTATATGGC  
Gm15441-3’-2 (20) reverse                               TGCAAACACAGACATGCACAC  
lncIRS2–5’-1 (20) forward                               ACATTCCAGTAAGTTCCCCG  
lncIRS2–5’-1 (20) reverse                                TCTCTTTCCTGTGCTCATGACC  
lncIRS2–5’-2 (20) forward                              ACATTCCAGTAAGTTCCCCG  
lncIRS2–5’-2 (20) reverse                              TCTTTCCTGTGCTCATGACCA  
lncIRS2–3’-1 (20) forward                              GCACACACACATACAGGCAC  
lncIRS2–3’-1 (20) reverse                              GGCTGTTGTTCTCTCTCGGG  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lncIRS2–3’-2 (20) forward                               ATGAATGAATGAAGCTGGGC  
lncIRS2–3’-2 (20) reverse                               AACAGGGTTATTTCACACTTTG  
 
If not stated otherwise, all primers have been designed using the Primer3web online tool. 
 
All primer oligonucleotides have been purchased in 0.025 µmole stocks  
from Sigma-Aldrich Chemie GmbH, Schnelldorf, DE. 
 
2.7. Primer for SYBR™ Green Quantitative PCR 
Top15 lncRNAs                                Sequence (5’ -> 3’) 
4833411C07Rik-202 forward                  TTTAATCGCCATGGAAACAGA 
4833411C07Rik-202 reverse                   TCGTGCTTTGGACTGTCAGA  
4933404O12Rik-201 forward                   TTGCCGCTGAAAACTCTGGG 
4933404O12Rik-201 reverse                   TTGCCGCTGAAAACTCTGGG 
9030616G12Rik-201 forward                  GTCAGAGAGGCATGCTTCCC  
9030616G12Rik-201 reverse                  CAGTAGCAGCCTTCCACCAG 
B930025P03Rik-201 forward                  CTCTCAGGAACGTCTCTCGG 
B930025P03Rik-201 reverse                   GGCTGTTGATGTCTTGGCTT  
C730036E19Rik-201 forward                  AGCAAGCAACCATTGAGACC 
C730036E19Rik-201 reverse                  TTCCTATGGGCTGTCGTTGT 
Gm2788-201 forward                       CTGACCGTCCCTTCATCCAC  
Gm2788-201 reverse                        GAAGAACCCAAACAAGCCACC  
Gm2814-201 forward                          TCTCCGTGACATGCTCAGAG  
Gm2814-201 reverse                           GCTGTGGTCCTTTGGGTTTC  
Gm8883-203 forward                            TGTGTTACACGTGAGGAGCG  
Gm8883-203 reverse                              AGCTGTTTCCATTGCTGGAG  
Gm10319-202 forward                           GGACTTGTTCCAATGTGTTTCC  
Gm10319-202 reverse                           TTTTGCTGAATTCGTGGGTT  
Gm11342-203 forward                            GCTAGGACCACAGTTGCAGG  
Gm11342-203 reverse                             GAATCTGTCATCCCGGCGAC  
Gm11789-005 forward                    TTCTCCCTTTCCCTCCCCTC  
Gm11789-005 reverse                    AGGCTCACAGTCTGCAGTAAC  
Gm12265-201 forward                          GCTGGAGAACAAGGCTGCTC  
Gm12265-201 reverse                           GATGACAGAGACAGCCCAGG  
Gm13775-201 forward                          ATGAATGGGGAATGGTTAAACAG  
Gm13775-201 reverse                          TGTCAGAAGCCAGGATAATAGTG  
Gm15441-202 forward                          CCTTGCCTTCCCTCACTGAT  
Gm15441-202 reverse                          GATCAGACCATCCATCCTGG  
Gm15611-201 forward                          GAATGGACTCTAGCCAGCCC  
Gm15611-201 reverse                          CACCAAACCAGGCCTTTATGC  
 30
Gm16552-201 forward                            TGGTGCACGCCTTTAATCCC  
Gm16552-201 reverse                            CTTGGAGGAGCTGGTTGTGG  
 
Housekeeping genes     Sequence (5’ -> 3’) 
GAPDH forward                             TGGCAAAGTGGAGATTGTTGCC  
GAPDH reverse                             AAGATGGTGATGGGCTTCCCG  
HPRT forward                               TCATTATGCCGAGGATTTGG  
HPRT reverse                               GTCAGCAAAGAACTTATAGCCCC  
                       
Other genes      Sequence (5’ -> 3’) 
18s rRNA forward                        AGTCCCTGCCCTTTGTACACA  
18s rRNA reverse                        CGATCCGAGGGCCTCACTA  
ActB forward                               TTGAACATGGCATTGTTACCAA  
ActB reverse                               TGGCATAGAGGTCTTTACGGA  
DANCR forward                          AACCCGTGACTGAATGGCTC  
DANCR reverse                          GACATGAAGAAGGGGTGGGG  
Malat1 forward                           AGGCGGGCAGCTAAGGA  
Malat1 reverse                           CCCCACTGTAGCATCACATCA  
MT-RNR1 forward                      ATTTCATTGGCCGACAGCTA  
MT-RNR1 reverse                      AGGTAGAGCGGGGTTTATCG  
Rpl37a forward                          CATCGTCGGCAAGTACGGG  
Rpl37a reverse                           CACCGGCCACTGTTTTCATG  
Rps16 forward                           GCTCATCAAGGTGAACGGAC  
Rps16 reverse                           ATTTGGGCCACATGTCCACC  
TBP forward                             CCAGACCCCACAACTCTTCC  
TBP reverse                               ACAGCCAAGATTCACGGTAG  
Txnip forward                           GTCAGTGTCCCTGGCTCCAAGA  
Txnip reverse                            AGCTCATCTCAGAGCTCGTCCG  
U6 snRNA forward                    GTGCTCGCTTCGGCAGCACA  
U6 snRNA reverse                    GGAACGCTTCACGAATTTGCGTGTCAT  
U99 snoRNA forward               CCTCCTTTTCTTGGCGGGGA       
U99 snoRNA reverse                CGTCTGAGGATAGAACCCGC  
 
All primers have been designed using the Primer3web online tool and purchased in 0.025 µmole 
stocks from Sigma-Aldrich Chemie GmbH, Schnelldorf, DE. 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2.8. TaqMan® Assays 
 
TaqMan® assay                                                                          TaqMan® ID  
ACACA (Acetyl-coenzyme A carboxylase alpha)                             Mm01304257_m1 
ACOX1 (Acyl-coenzyme A oxidase 1, peroxisomal)                      Mm01246834_m1 
CPT1A (Carnitine palmitoyltransferase 1a, liver isoform)                  Mm01231183_m1 
FABP4 (Fatty acid binding protein 4)                                              Mm00445878_m1  
FBP1 (Fructose bisphosphatase 1)                                               Mm00490181_m1  
FOXO1 (Forkhead box protein O1)                                                Mm00490671_m1  
G6PC (Glucose-6-phosphate)                                                        Mm00839363_m1  
GAPDH (Glyceraldehyde-3-phosphate dehydrogenase)              Mm99999915_g1 
HADHB (Trifunctional enzyme subunit beta, mitochondrial)           Mm00695255_g1 
HPRT (Hypoxanthine guanine phosphoribosyl transferase 1)         Mm00446968_m1 
IRS-1 (Insulin receptor substrate 1)                                                  Mm01278327_m1  
IRS-2 (Insulin receptor substrate 2)                                                  Mm03038438_m1  
PCK1 (Phosphoenolpyruvate carboykinase 1)                              Mm01247058_m1 
SLC2A1 (Solute carrier family 2 member 1)                                   Mm00441480_m1  
SLC2A2 (Solute carrier family 2 member 2)                      Mm00446229_m1 
SLC2A4 (Solute carrier family 2 member 4)                               Mm00436615_m1  
SREBF1 (Sterol regulatory element binding transcription factor 1) Mm00550338_m1 
 
All TaqMan® assays have been purchased from Thermo Fisher Scientific, Waltham, US. 
 
2.9. RNA Oligonucleotides 
 
Alt-R® CRISPR/Cas9 crRNAs Sequence (5’ -> 3’) 
4833411C07Rik 5’-crRNA               GGCAGTTACATAATCACG GCGTTTTAGAGCTATGCT 
4833411C07Rik 3’-crRNA            CAGACTATGGCGGATAAGCAGTTTTAGAGCTATGCT 
Gm15441 5’-crRNA                           GGCCTTGGCTCACTAGGTGAGTTTTAGAGCTATGCT  
Gm15441 3’-crRNA                           TTCCCAGATGACTTTAGTTGGTTTTAGAGCTATGCT  
 
The part of the sequence highlighted in red represents the spacer sequence, whereas the other 16 
nucleotides facilitate tracrRNA binding.  
 
Alt-R® CRISPR/Cas9 tracrRNA (Product ID: 1072532) 
5’-GTTGGAACCATTCAAAACAGCATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTG 
AAAAAGTGGCACCGAGTCGGTGCTTTTT-3’  
 
All RNA oligonucleotides have been purchased from  
Integrated DNA Technologies, Inc., Coralville, US. 
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2.10. Antisense Locked Nucleic Acid (LNA™) GapmeRs 
 
Target transcript    Sequence (5’ -> 3’) 
4833411C07Rik                                          CTCGATTAACCTGATA 
B930025P03Rik                                          ATCACGGATTGCTAAT 
Gm15441                                                  CTCGAAATGAATTGCG 
Negative control (scramble)                      AACACGTCTATACGC  
 
All LNAs™ have been purchased from Exiqon A/S, Vedbaek, DK. 
2.11. Chromatin immunoprecipitation sequencing (ChIP-Seq) data 
Histone modification     Mouse strain   Developmental stage    ENCODE project 
H3K4me3                                C57BL/6          Postnatal (p=0)                    ENCSR653AVN  
H3K27Ac                                         C57BL/6          Postnatal (p=0)                    ENCSR616TJM  
  
ChIP-Seq data sets were generated by Bing Ren, University of California, San Diego, US, and are 
publicly available under the listed ENCODE project numbers. 
2.12. Human Liver Biopsies 
Code  Group assignment  Age BMI Diagnosis  RIN 
0381 WSC  lean non-diabetic, male  52  24.5  rectal carcinoma  6.6 
1311 WER  lean non-diabetic, male  62  24.8  gastric carcinoma  6.2 
1651 HRU lean non-diabetic, male 55 21.9 rectal carcinoma 7.0 
3141 AZE lean non-diabetic, male 74 22.9 colon carcinoma 5.2 
0121 STR obese non-diabetic, male 21 52.8 obesity   7.0 
0311 RAN obese non-diabetic, male 35 49.1 obesity   8.3 
0861 NSC obese non-diabetic, male 50 47.9 obesity   6.3 
1941 JRO obese non-diabetic, male 48 54.2 obesity   6.6 
0951 LZU obese diabetic, male  46 63.0 obesity   4.9 
1781 DGR obese diabetic, male  42 33.5 obesity   6.3 
1701 GBO overweight diabetic, male 76 27.0 colon carcinoma 7.9 
3011 FHE overweight diabetic, male 75 25.0 pancreas carcinoma 7.3 
 
All samples were tested negative for hepatitis B (HBV) and hepatitis C (HCV). Sample preparation 
was previously described in [193]. The samples were kindly provided by Prof. Dr. Jörg Heeren, 
Institute for Biochemistry and Molecular Cell Biology, Medical Center Hamburg-Eppendorf, 
Hamburg, Germany. 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2.13. Software  
- 4Peaks, Nucleobytes B.V., version 1.8 
- Atom, GitHub community, version 1.24.1 
- Benchling Molecular Biology Design and Analysis Suite, Benchling Inc. 
web-based application, https://benchling.com/ [March, 2018] 
- biomaRt package, version 2.16.0 
designed as described in [194] 
- Bowtie2, version 2.2.9 
designed as described in [195] 
- Coding Potential Assessment Tool, version 1.2.4 
designed as described in [196] 
web-based application, http://lilab.research.bcm.edu/cpat/ [March, 2018] 
- Coding Potential Calculator 
designed as described in [197] 
web-based application, http://cpc.cbi.pku.edu.cn/programs/run_cpc.jsp [March, 2018] 
- CorelDraw Graphics Suite X6, Corel corp. 
- CRISPOR, version 4.3  
designed as described in [198] 
web-based application, http://crispor.tefor.net/ [March, 2018] 
- CRISPR Design Tool, Zhang Lab 
designed as described in [199] 
web-based application, crispr.mit.edu [March 2018] 
- Cufflinks suite, version 2.2.1 
designed as described in [200] 
- DESeq2, version 1.10.1 
designed as described in [201] 
- EndNote™ X7, Thomas Reuters, version 7.8 
- Ensemble BioMart [202] 
- flexbar, version 3.4.0 
designed as described in [203] 
- FUSION-CAPT, Vilber Lourmat Deutschland GmbH, version 16.15 
- ImageJ, Wayne Rasband/NIH, version 1.48v 
- Keynote, Apple Inc., version 7.3.1 
- NanoDrop™ 1000 software, Thermo Fisher Scientific Inc., version 3.8.1 
- Numbers, Apple Inc. version 4.3.1 
- Pages, Apple Inc., version 6.3.1 
- Primer3web, version 4.1.0 
designed as described in [204, 205] 
web-based application, http://primer3.ut.ee/ [March, 2018] 
- Prism, GraphPad Software Inc., version 7.0c 
- PyRAT, Scionics Computer Innovation GmbH, version 3.6-365 
- QuantStudio™ 6, Applied Biosystems, version 1.3 
- QuickNGS, version 1.2.2 
designed as described in [206] 
- R, R Core Team, version 3.1.2 
- RStudio, RStudio Inc., version 1.0.136 
- SeqBuilder™, DNASTAR Inc., version 14.1.0 
- SeqMan Pro™, DNASTAR Inc., version 14.1.0 
- SoftMax® Pro, Molecular Devices, version 6.3 
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- STAR, version 2.6.0c 
designed as described in [207] 
- Tophat2, version 2.0.10 
designed as described in [208] 
 
 35
Chapter 3 - Methods 
 
3.1. Molecular biological methods 
3.1.1. Polymerase chain reaction (PCR) 
Genotyping Polymerase Chain Reactions (PCRs) were performed using the DreamTaqTM Green 
DNA Polymerase Kit in a total reaction volume of 25 µL composed of:  
 2.5 µL    DreamTaqTM Green Buffer (10X) 
 1 µL    dNTP Mix (10mM)  
 0.25 µL  Forward primer (10 µM)  
 0.25 µL  Reverse primer (10 µM) 
 0.2 µL    DreamTaqTM Green DNA Polymerase  
 2 µL    Genomic template DNA 
 18.8 µL  Millipore® H2O 
PCR cycling parameters have been determined for each individual PCR according to the annealing 
temperature of the specific primer pair and the length of the DNA product (for protocols see 3.4.3.). 
All PCRs have been performed using FlexCycler2 PCR-Thermocycler. 
For subsequent applications requiring highly accurate DNA products proof-reading DNA 
polymerases have been used according to the manufacturer’s protocols. Detailed information on 
the High Fidelity PCR Master Kit (HiFi-PCR, see 3.1.3.) or the Phusion DNA Polymerase Kit 
(sgRNA synthesis, see 3.1.10.) can be found in the respective chapter. 
3.1.2. Agarose gel electrophoresis 
Amplified DNA fragments were electrophoretically separated by native gel electrophoresis. Via 
boiling, agarose was dissolved in 1X TBE buffer resulting in solutions with final agarose 
concentrations varying between 0.5 % and 2 %. For DNA visualization 5 µL Midori Green 
Advance® was added per 100 mL agarose solution. PCR samples originating from high-fidelity 
PCRs were mixed with the respective amount of 6X DNA gel loading dye before loading the 
samples into the gel, whereas other PCR samples were directly loaded into the gel. Loaded DNA 
fragments were separated at 80 – 130 V for varying time spans and visualized by UV-light on a 
FastGene® FAS V gel documentation system. 
 1X TBE buffer     
 89 mM Tris-Base  
 89 mM Boric acid  
 2 mM  EDTA  
 in Millipore® H2O, adjusted to pH 8.0  
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3.1.3. High fidelity polymerase chain reaction (HiFi-PCR) 
DreamTaqTM Green DNA Polymerase lacks 5’->3’ proof-reading capacity and thus has not been 
used for PCR reactions of important and/or limited samples. For the most accurate DNA 
sequencing results, PCR reactions were performed using the High Fidelity PCR Master Kit in a 
total reaction volume of 50 µL composed of:  
       Initial denaturation 94°C  3 min   
 25 µL  MasterMix 1 (HF - Enzyme Mix) Denaturation  94°C  10 s 
 23 µL  MasterMix 2 (HF - Water)  Annealing  58°C  45 s  14x 
 0.5 µL  Forward primer (10 µM)  Elongation  68°C  2 min   
 0.5 µL  Reverse primer (10 µM)  Denaturation  94°C  10 s 
 1 µL  DNA template    Annealing  58°C  45 s  26x 
       Elongation  68°C  3 min   
       Final elongation 68°C  3 min 
       Hold   4°C 
High fidelity PCR products lack 3’-end adenosine overhangs and thus cannot directly be integrated 
into stable plasmid vectors. 
3.1.4. Addition of A’-overhangs 
In order to achieve linear DNA fragments suitable for integration into the pGEM®-T Easy vector, 
high fidelity PCR reactions were incubated with the DreamTaqTM Green DNA Polymerase, which 
catalyzes a non-template directed addition of an adenine residue to the 3’-ends of both DNA 
strands. After completion of the initial high fidelity PCR reaction, 1 µL of DreamTaqTM Green DNA 
Polymerase was added to the reaction mix and incubated at 72°C for 10 min. DNA fragments were 
purified from the PCR reaction mix using the QIAquick® Gel Extraction Kit. Therefore, 150 µL of 
Buffer QG and 50 µL of isopropanol were added to the DNA solution and briefly vortexed, applied 
to a QIAquick® column and centrifuged for 1 min at 13000 x g. To remove remaining salt and 
agarose residues, the column was washed with 500 mL Buffer QG (2x) or 750 mL Buffer PE and 
centrifuged for 1 min at 13000 x g, respectively. Finally, bound DNA was eluted from the column by 
the addition of 25 µL Elution Buffer and centrifugation for 1 min at 13000 x g. Extracted DNA was 
immediately used in a DNA ligation reaction. 
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3.1.5. DNA ligation 
For preservation of high fidelity PCR products modified DNA fragments (+ 3’-A overhangs) were 
integrated into the pGEM®-T Easy Vector System, a pre-linearised plasmid vector with 3’-T 
overhangs at the insertion site. The insertion site is located within a ß-galactosidase gene (lacZ) 
whose expression is activated by isopropyl-ß-D-thiogalactopyranoside (IPTG) administration, but 
whose coding region is disrupted in case of a PCR product insertion.  
 
DNA ligation reactions were performed at RT for 2-4 hrs in a total reaction volume of 10 µL 
composed of:   
 5 µL  Rapid Ligation Buffer (2X) 
 1 µL  pGEM®-T Easy plasmid vector 
 1 µL  T4 DNA ligase  
 3 µL  PCR products (+ A’-overhangs) 
Resulting DNA ligation reactions were immediately used for transformation of competent bacteria 
3.1.6. Transformation of competent bacteria 
Aliquots (100 µL) of competent XL10-Gold® E. coli cells were thawed on ice for 20 mins, gently 
mixed with 2.5 µL of DNA ligation products and incubated on ice for 20 mins. Following a heat-
shock at 42°C for 45 s, the bacteria solution was kept on ice for 2 mins. Subsequently the solution 
was supplemented with 900 µL LB medium, transferred to a 15 mL Falcon® tube and incubated for 
90 mins at 37°C with constant shaking (300 rpm). After a short centrifugation (10 s, 1200 rpm), 900 
µL of the supernatant was removed and the remaining 100 µL bacteria solution was plated on 
bacterial culture plates and incubated at 37°C overnight.  
Following supplementation of bacterial culture plates with IPTG Solution and X-Gal Solution, 
bacterial clones carrying pGEM®-T Easy vectors with inserted DNA fragments could be detected 
by the lack of functional ß-galactosidase protein (lacZ) and the resulting white appearance on the 
bacterial culture plates. These colonies have been used to inoculate bacterial cultures. 
 Bacterial Culture Plates   Amp Solution     
 14 g     LB-Medium (autoclaved) 100 mg  Ampicillin sodium salt 
 200 µL    Amp Solution    in 1 mL Millipore® H2O 
 400 µL    X-Gal Solution 
 400 µL    IPTG Solution   IPTG Solution     
 in 400 mL Millipore® H2O   166.8 mg  IPTG 
 [20 mL per plate]    in 7 mL Millipore® H2O  
     
       X-Gal Solution     
       140 mg  X-Gal  
       in 7 mL DMF       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3.1.7. Small scale plasmid DNA isolation 
15 mL Falcon® tubes containing 4 mL LB medium and ampicillin antibiotic (30 mg/mL) were 
inoculated with a single bacterial colony and incubated for 6-12 hrs at 37°C with constant shaking 
(180 rpm). Afterwards, 2 mL of the bacterial culture was centrifuged (1 min, 6000 x g) and the 
supernatant was discarded. The remaining pellet was resuspended in 100 µL ice-cold Solution I 
and incubated at RT for 5 mins. For cell lysis, 200 µL freshly prepared Solution II was added to the 
cell solution, which then was mixed by inverting and incubated on ice for 5 mins. By adding 150 µL 
ice-cold Solution III and vortexing the sample for 10 s, the lysate was neutralized and subsequently 
centrifuged (10 min, 6000 x g, 4°C). The supernatant was transferred to a reaction tube and 
plasmid DNA was precipitated by adding 400 µL ice-cold isopropanol to the solution. After another 
centrifugation step (10 min, 12000 x g, 4°C) the supernatant was discarded, while the DNA pellet 
was washed with 500 µL ice-cold ethanol (70 % v/v, in Millipore® H2O) and centrifuged again (10 
min, 12000 x g, 4°C). The supernatant was removed completely by aspiration and the DNA pellet 
was resuspended in 30 µL TBE Buffer. Plasmid DNA concentrations were measured using a 
NanoDrop™ ND-1000 spectrophotometer and the samples were stored at -80°C. 
 Solution I     Solution II    
 10 mM   EDTA    200 mM     NaOH  
 50 mM   Tris-Cl, pH 8.0   1 %        SDS (w/v)  
 50 mM   Glucose   in Millipore® H2O 
 in Millipore® H2O  
 
 Solution III     TBE Buffer    
 5 M   NaAc    200 mM     Tris-Cl, pH 8.0  
 11.5 %  Glacial acetic acid (v/v) 10 mM       EDTA 
 in Millipore® H2O     36 mg/mL  RNAse A  
       in Millipore® H2O 
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3.1.8. Large scale plasmid DNA isolation 
For large scale plasmid DNA isolation the NucleoBond® Xtra Maxi was used following the 
manufacturer’s protocol. Briefly, 120 mL LB medium was supplemented with ampicillin (30 mg/mL) 
and inoculated with 50 µL of a preexisting bacterial culture. After incubating the culture overnight 
(37°C, 180 rpm) bacteria were harvested by centrifugation (15 min, 6000 x g, 4°C). The 
supernatant was discarded, whereas the pellet was resuspended in 8 mL Buffer RES and 
incubated at RT for 5 mins. For cell lysis, 8 mL Buffer LYS was added to the cell solution, which 
then was mixed by inverting the tube and incubated at RT for another 5 mins. The lysate was 
subsequently neutralized by adding 12 mL ice-cold Buffer NEU and thoroughly mixed, before being 
transferred onto a NucleoBond® Xtra Column Filter. The column filter was washed two times with 
15 and 25 mL of Buffer WASH and the bound plasmid DNA was finally eluted from the column by 
adding 15 mL Buffer ELU. Eluted plasmid DNA was precipitated by adding 10.5 mL ice-cold 
isopropanol to the solution. After centrifugation (30 min, 15000 x g, 4°C) the supernatant was 
discarded, while the DNA pellet was washed in 4 mL ice-cold ethanol (70 % v/v, in Millipore® H2O) 
and centrifuged again (15 min, 15000 x g, 4°C). Finally, the supernatant was removed completely 
by aspiration and the DNA pellet was resuspended in 30 µL TBE Buffer. Plasmid DNA 
concentrations were measured using a NanoDrop™ ND-1000 spectrophotometer and the samples 
were stored at -80°C. 
3.1.9. DNA sequencing 
DNA plasmids harvested from bacterial cultures were diluted to a final concentration of 50 ng/µL 
and sent for custom DNA sequencing to GATC Biotech, Ebersberg, DE.  
Integrated primer sequences on the pGEM®-T Easy Vector System which have been used as 
sequencing primers are M13 forward (M13Fwd) and M13 reverse (M13Rev). 
3.1.10. Generation of DNA templates for single guide RNA (sgRNA) synthesis 
In order to generate DNA templates for sgRNA synthesis, specific DNA oligonucleotides (forward 
primer, length of 58 or 60 bp) were designed for each sgRNA to be synthesized according to the 
following composition: 
T7 promotor  - 5’-TTAATACGACTCACTATAGG-3’  
gRNA of interest - variable (18-20 bp of specific gRNA)  
pX330-5’tracrRNA - 5’-GTTTTAGAGCTAGAAATAGC-3’  
PCR reactions were performed using the Phusion® High-Fidelity DNA Polymerase in a total 
reaction volume of 50 µL composed as shown on the next page.  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 10 µL  Phusion HF Buffer (5X)*   
 1 µL  dNTP Mix (10mM)   Initial denaturation 98°C 30 s   
 2.5 µL  sgRNA specific forward primer  Denaturation  98°C 10 s 
 2.5 µL  pX330-5’ reverse primer  Annealing        60-72°C 15 s 40x 
 0.5 µL  Phusion DNA Polymerase  Elongation  72°C 15 s   
  1.5 µL  DMSO (optional)   Final elongation 72°C 5 min 
 200 ng pX330 plasmid DNA   Hold   4°C 
 in Millipore® H2O 
*For PCR products with high GC content (>70 %) Phusion HF Buffer was replaced by Phusion GC 
Buffer (5X) and 1.5 µL DMSO was added to the reaction mix. 
 
Before proceeding to RNA synthesis DNA template PCR reactions were controlled for the 
appearance of a single specific band (120 or 122 bp) by agarose gel electrophoresis. 
3.1.11. DNA extraction from agarose gels 
Separated DNA fragments were extracted from agarose gels using the QIAquick® Gel Extraction 
Kit according to the manufacturer’s protocol. Briefly, excised DNA-containing gel slices were 
weighed, mixed with three volumes of Buffer QG and incubated for 10 mins at 50°C with constant 
shaking (300 rpm). After complete dissolving of the agarose slice, 1 volume of isopropanol was 
added to the DNA solution, which then was briefly vortexed, applied to a QIAquick® column and 
centrifuged at 13000 x g for 1 min. To remove remaining salt and agarose residues, the column 
was washed with 500 ml Buffer QG (2x) or 750 µL Buffer PE, respectively, and centrifuged at 
13000 x g for 1 min. Finally, bound DNA was eluted from the column by the addition of 25 µL 
Elution Buffer and centrifugation at 13000 x g for 1 min. Extracted DNA concentrations were 
measured using a NanoDrop™ ND-1000 spectrophotometer and directly used for RNA synthesis. 
3.1.12. sgRNA synthesis 
sgRNA oligonucleotides were synthesized using the HiScribe™ T7 High Yield RNA Synthesis Kit 
and previously generated sgRNA template DNA. GuideRNA PCR reactions were performed at 
37°C for 16-18 hrs in a total reaction volume of 20 µL composed as shown on the next page. 
Before using the produced RNA oligonucleotides, sgRNA template DNA as well as other reaction 
components need to be removed by DNase treatment and RNA purification, respectively. 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 sgRNA synthesis mix 
 2 µL  Reaction Buffer (10X)   
 1.5 µL  T7 RNA Polymerase Mix  
 1.5 µL  ATP Nucleotide Mix (100 mM)   
 1.5 µL  CTP Nucleotide Mix (100 mM)  
 1.5 µL  GTP Nucleotide Mix (100 mM)  
  1.5 µL  UTP Nucleotide Mix (100 mM)  
 200 ng sgRNA template DNA   
 in Millipore® H2O 
3.1.13. DNA digestion 
In order to remove the DNA template used for sgRNA synthesis, the RNA synthesis reaction mix 
was subjected to DNase I treatment as shown below and incubated at 37°C for 15min. 
 20 µL  RNA synthesis reaction mix 
 10 µL  DNase I Buffer (10X) 
 2 µL  DNase I 
 70 µL  RNAse-free H2O  
Finally, DNase I activity was heat-inactivated by incubating the reaction at 75°C for 10 min.  
3.1.14. sgRNA purification 
After removal of sgRNA template DNA, the RNA oligonucleotides were purified from the DNase 
reaction mix using the NucleoSpin® RNA Kit according to the manufacturer’s protocol. Briefly, the 
sgRNA reaction mix was mixed with 600 µL of a Buffer RA1 - absolute ethanol premix with ratio 1:1 
and loaded onto a NucleoSpin® RNA Column. After centrifugation (30 s, 11000 x g) the column 
was placed in a new Collection Tube and washed with 200 µL Buffer RAW2 (centrifugation: 30 s, 
11000 x g), 600 µL Buffer RA3 (centrifugation: 30 s, 11000 x g) and 250 µL Buffer RA3 
(centrifugation: 2 min, 11000 x g), respectively. Bound RNA was finally eluted from the column by 
the addition of 50 µL RNase-free H2O and centrifugation at 11000 x g for 1 min. Resulting sgRNA 
samples were split in two 22 µL aliquots, which were directly snap-frozen in liquid nitrogen and 
then stored at -80°C, and one 6 µL aliquot, which was used to determine RNA concentration and 
integrity. sgRNA concentrations were measured using a NanoDrop™ ND-1000 spectrophotometer 
and the remaining 5 µL sgRNA aliquot was run on an agarose gel to validate RNA product 
consistency and integrity. Importantly, before running the gel, the sgRNA aliquot was incubated at 
65°C for 30 mins to dissolve secondary RNA structures. High-quality synthesis results in a strong 
single band (length: 18 or 20 bp) with no other RNA products or background contaminations. 
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3.1.15. T7 endonuclease I assay 
Functionality of synthesized sgRNAs was tested in vitro by transfecting Cas9 mRNA and the 
sgRNA to be tested into NSC-34 cells (for details see 3.2.1.) and subsequently by analysing 
genomic DNA of transfected cells for CRISPR/Cas9-mediated mutations at the locus of interest. To 
detect genomic variations at the potentially mutated genomic loci, specific PCR primer pairs were 
designed for each sgRNA with the following characteristics: 
 - standardized primer annealing temperature of 60°C 
 - resulting PCR product of 400 - 800 bp length 
 - resulting PCR product containing the targeted CRISPR/Cas9 cutting site at its center 
Before utilising designed primer pairs for T7 Endonuclease I assays, all PCR reactions have been 
tested with unmodified genomic DNA for a specific and strong single band. Verified primer pairs 
have been used with genomic DNA of transfected cells in a total reaction volume of 25 µL 
composed of: 
 2.5 µL   DreamTaqTM Green Buffer (10X)  Initial denaturation 95°C  2 min   
 1 µL   dNTP Mix (10mM)    Denaturation  95°C 30 s 
 0.25 µL Forward primer (1 µM)   Annealing  60°C 30 s   35x 
 0.25 µL Reverse primer (1 µM)    Elongation  72°C 1 min   
 0.2 µL   DreamTaqTM Green DNA Polymerase  Final elongation 72°C 5 min 
 2 µL   Genomic DNA    Hold   4°C  
 in Millipore® H2O 
In case of functional synthesized sgRNAs, the PCR reaction yields different DNA amplicons with 
unmodified as well as mutated genomic sequences of the locus of interest. By boiling the PCR 
products as shown below, identical double-stranded DNA homoduplexes were separated from 
each other and randomly re-annealed with other single-stranded DNA sequences, allowing the 
formation of DNA heteroduplexes comprised of unmodified as well as mutated DNA sequences. 
   95°C 10 min   45°C 1 min 
   85°C 1 min   35°C 1 min 
   75°C 1 min   25°C 1 min 
   65°C 1 min   25°C hold 
   55°C 1 min 
DNA heteroduplexes feature base pair mismatches at the mutated genomic locus and can be 
visualized on an agarose gel after the re-annealed PCR products were subjected to T7 
Endonuclease I assays. In this assay DNA heteroduplexes are incubated with T7 Endonuclease I, 
a mismatch-specific DNA endonuclease that recognizes base-substitution mismatches as well as 
mismatches resulting from genomic deletions or insertions. Due to the position of the CRISPR/
Cas9 cutting site at the center of the PCR product, cleavage of heteroduplexes by T7 
Endonuclease I results in two PCR fragments of similar size. 
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 T7 Endonuclease I Assay 
 10 µL  Re-annealed PCR product 
 1.1 µL  NEBuffer 2    37°C 60 min 
 0.3 µL  T7 Endonuclease I 
After T7 Endonuclease I assays the PCR reactions were analyzed for cleaved DNA fragments of 
the specific PCR product by agarose gel electrophoresis (see 3.1.2.). 
3.1.16. Reverse transcription 
In order to convert single-stranded RNA molecules into more stable, double-stranded 
complimentary DNA (cDNA) molecules, total RNA solutions were subjected to reverse transcription 
using the High-Capacity cDNA Reverse Transcription Kit according to the manufacturer’s protocol. 
The synthesis of cDNA molecules in this protocol is based on random hexamer primers (6 bp DNA 
oligonucleotides), which allow conversion of all possible RNA sequences. Depending on total RNA 
abundance the RNA solutions used for cDNA synthesis were equally diluted to RNA concentrations 
of 400 ng/µL or 200 ng/µL. 
 2 µL  10X RT Buffer    
 2 µL  Random hexamer primers  Pre-primer extension 25°C 10 min 
 0.8 µL  dNTP Mix    cDNA synthesis 37°C 2 hrs 
 1 µL  Reverse Transcriptase  Inactivation  85°C 15 min  
 2 µg  RNA solution    Hold   4°C    
 in Millipore® H2O 
After the RT-PCR reaction, 180 µL Millipore® H2O was added to the PCR sample and the diluted 
cDNA molecules were stored at -20°C or directly used for RNA expression analysis in quantitative 
PCR (qPCR) experiments.  
3.1.17. Quantitative real-time PCR (qPCR) 
To quantify the expression of specific RNA molecules, prior synthesized cDNA solutions of the cells 
or tissue of interest were subjected to quantitative PCR (qPCR) analysis using a QuantStudio™ 7 
Flex Real-Time PCR System. For RNA molecules with commercially available gene expression 
assays the TaqMan™ Gene Expression Master Mix was used in combination with the respective 
transcript-specific TaqMan® Gene Expression Assays. For noncoding RNA genes and other genes 
with no available TaqMan® Gene Expression Assay the SYBR™ Select Master Mix was used in 
combination with self-designed and tested DNA primers. 
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 SYBR Green-based qPCRs      
 5 µL SYBR Select Master Mix (10X)  
 0.25 µL Forward primer (1 µM)  Initial denaturation 95°C  2 min   
 0.25 µL Reverse primer (1 µM)   Denaturation  95°C 30 s 
 2.5 µL   Millipore® H2O   Annealing  60°C 30 s 40x 
 2 µL   cDNA solution    Elongation  72°C 1 min   
       Final elongation 72°C 5 min 
 TaqMan™-based qPCRs   Hold   4°C  
 6 µL  TaqMan™ Master Mix 
 0.3 µL  TaqMan™ probes 
 4 µL  cDNA solution 
Relative expression of target RNA molecules was adjusted for total RNA content by measuring 
expression of housekeeping genes (HPRT and/or GAPDH) and calculated by the 2-∆∆CT method (as 
described in [209].  
All TaqMan® assays as well as the DNA primer used for qPCR experiments can be found in the 
materials section (2.7. & 2.8.). 
3.1.18. RNA sequencing 
Before isolated RNA solutions could be sent for sequencing, remaining traces of DNA were 
removed using the TURBO DNA-free™ Kit as shown below: 
 5 µL  10X TURBO DNase Buffer 
 1 µL  TURBO DNase   37°C 30 min 
 5 µg  RNA solution 
 in RNase-free H2O 
 
TURBO DNase activity was inactivated by adding 5 µL of DNase Inactivation Reagent and 
incubating the reaction mix at RT for 5 min. After centrifugation (2 min, 10000 x g, RT) the 
supernatant was transferred to an RNase-free tube and tested for RNA concentration and integrity. 
RNA concentrations were measured using a NanoDrop™ ND-1000 spectrophotometer and the 
samples were diluted to 100 ng/µL. 1 µL of the RNA sample was used to examine RNA integrity 
(see 3.1.19.) and the remaining samples were stored at -80°C. 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RNA sequencing experiments were performed at (1) the Max Planck-Genome-centre Cologne, 
Cologne, DE (obesity mouse models) or at (2) the Cologne Center for Genomics, Cologne, DE 
(others) with the following conditions: 
 - Sample input:  1 µg of total RNA (100 ng/µL) 
 - rRNA depletion:   (1) NEBNext® rRNA Depletion Kit (Human/Mouse/Rat) 
     (2) Ribo-Zero rRNA Removal Kit (Human/Mouse/Rat) 
 - cDNA library preparation: (1) NEBNext® Ultra™ Directional RNA Library Prep Kit  
      for Illumina® 
     (2) TruSeq RNA Library Prep Kit v2 
 - Normalization:  ERCC RNA Spike-In (ThermoFisher) 
 - Sequencing platform: HiSeq2500, paired-end flow cells (Obesity Experiment) 
     HiSeq4000, paired-end flow cells (Feeding Experiment) 
     HiSeq4000, paired-end flow cells (Human Liver Biopsies) 
 - Sequencing conditions: 2 x 100 bp read length, strand-specific (Obesity Experiment) 
     2 x 75 bp read length, strand-specific (Feeding Experiment) 
     2 x 75 bp read length, strand-specific (Human Liver Biopsies) 
 - Sequencing depth:  150-200 million reads per sample 
3.1.19. RNA integrity measurement 
RNA molecules are more prone to degradation than DNA molecules due to their chemical structure 
and the high prevalence of RNase enzymes. Thus, in order to obtain high-quality RNA sequencing 
results, it is critical to control RNA samples for intact RNA molecules. 
RNA integrity of samples intended to be sequenced were measured using an Agilent 2100 
Bioanalyzer Analysis System in combination with the Agilent RNA 600 Pico Kit for samples 
containing low amounts of RNA (less than 5 ng/µL) or the Agilent RNA 600 Nano Kit for samples 
containing higher amounts of RNA (more than 5 ng/µL). This system provides a detailed 
assessment of the 18S to 28S ribosomal RNA (rRNA) ratio and generates a RNA Integrity Number 
(RIN) for each given sample to interpret the respective RNA degradation. 
Both kits were performed according to the respective manufacturer’s protocols and only samples 
yielding high RNA Integrity Numbers (RIN ≥ 8.0 for murine RNA, RIN ≥ 6.0 for human RNA) were 
sent for sequencing. 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3.2. Cell biological methods 
       
3.2.1. Eukaryotic cell culture 
The following cell lines have been used during the in vitro experiments described in this thesis: 
NSC-34  
Mouse motor neuron-like hybrid cells (NSC-34) have been used as in vitro system for sgRNA 
validation. The NSC-34 cell line was produced by fusion of motor neuron enriched, embryonic 
mouse spinal cord cells with mouse neuroblastoma cells [210, 211] and provide a robust in vitro 
system with high proliferative capacity that can be maintained on standard cell culture plates. 
NSC-34 cells were kindly provided by Robin Schwarzer (Lab of Manolis Pasparakis, CECAD 
Research Center, Cologne). 
 
 NSC-34 Medium     
 DMEM GlutaMAX™, high glucose (4.5 g/L) 
 10% FBS 
 1%     L-Glutamine solution 
 1%     Penicillin-streptomycin solution 
 
Primary murine hepatocytes 
Primary murine hepatocytes have been used as in vitro system for all experiments concerning long 
noncoding RNA expression analysis. Hepatocytes are the major cell type in mouse liver and  
isolated primary hepatocytes resemble an appropriate in vitro cell culture system for the study of 
liver metabolic functions. Yet, primary hepatocytes gradually lose cuboidal morphology as well as 
differentiated, liver-specific functions after 4-5 days in culture. 
Primary hepatocytes were freshly isolated for each experiment (as described in 3.4.10.) and 
maintained on collagen I-coated cell culture plates. Due to gradual loss of hepatocyte-specific 
morphology and marker expression, primary hepatocytes were not maintained in culture for more 
than 4 days. 
 Attachment Medium    Fasting Medium    
 DMEM, low glucose (1 g/L)   DMEM, low glucose (1 g/L) 
 10%  FBS     1%  L-Glutamine solution    
 1%    L-Glutamine solution   1%  Penicillin-streptomycin solution 
 1%    Penicillin-streptomycin solution 
  
All eukaryotic cells were maintained under controlled conditions (37°C, 10% CO2) in C170 or 
Heracell 150i™ CO2 incubators. 
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Passage  
Tissue culture dishes harboring adherent eukaryotic cells were washed with PBS and then 
incubated with 5 mL trypsine solution at 37°C for 10 mins. Trypsinization was stopped by adding 15 
mL PBS and detached cells were collected by centrifugation (5 min, 300 x g), resuspended in 10 
mL of fresh medium and reseeded on fresh tissue culture dishes.  
Counting 
In order to determine the amount of cells in a given cell suspension, cells were collected by 
centrifugation (5 min, 300 x g) and resuspended in 10 mL of the respective buffer. 10 µL of the cell 
suspension were mixed with 10 µL trypan blue solution to achieve a final dilution of 1:1. Finally, cell 
numbers were determined by using a Neubauer improved cell counting chamber.  
Storage  
For long-term storage, eukaryotic cells were detached from tissue culture dishes by incubation with 
trypsin solution (10 min, 37°C), pelleted by centrifugation (5 min, 300 x g) and resuspended in 10 
mL freezing medium. Finally, 1.5 mL of cell suspension was transferred to CryoPure® cryotubes, 
which have been placed in a freezing container filled with isopropanol and subsequently stored at 
-80°C for 2 days before being placed in liquid nitrogen (-196°C).  
 Freezing Medium   
 95 % (v/v) NSC-34 Medium   
 5 % (v/v) DMSO  
Thawing cells 
Before taking frozen cells into culture, preserved cells were tested for mycoplasma contaminations 
(see 3.2.2.). Mycoplasma-negative samples were then mixed with 500 µL of pre-warmed (37°C) 
culture medium and gradually transferred to a 15 mL Falcon® tube containing 8.5 mL of culture 
medium. After centrifugation (5 min, 1200 x g, RT) the supernatant was discarded and the cell 
pellet resuspended in 10 mL culture medium. Finally, varying amounts (6 mL, 3 mL, 1 mL) of the 
cell suspension were mixed with the respective amount of culture medium (total volume 25 mL) 
and seeded on 15 cm cell culture dishes. 
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3.2.2. Mycoplasma test 
Mycoplasma species are a genus of bacteria which resemble the most common contaminants in 
laboratory cell culture and may induce changes in cell growth and metabolism [212]. Thus, all cell 
suspensions taken into culture have been tested for mycoplasma contaminations using the PCR 
Mycoplasma Test Kit as shown below: 
 
 Cell Suspension PCR       
 35 µL Millipore® H2O      
 10 µL  Reaction Mix     
 5 µL Cell Suspension   Initial denaturation 94°C 30 s   
       Denaturation  94°C 30 s 
 Positive Control PCR    Annealing  60°C 2 min 35 x 
 39 µL Millipore® H2O   Elongation  72°C 1 min   
 10 µL  Reaction Mix    Denaturation  94°C 30 s 
 1 µL  Positive Control Template  Annealing  60°C 2 min 
       Final elongation 75°C 5 min   
 Negative Control PCR   Hold   4°C  
 40 µL  Millipore® H2O 
 10 µL  Reaction Mix 
 
PCRs of mycoplasma-positive samples produce a band at 270 bp and were not taken into culture, 
but directly discarded. 
3.2.3. Transfection of primary murine hepatocytes with LNA oligonucleotides 
Freshly isolated primary hepatocytes were counted and seeded on collagen I-coated cell culture 
plates according to the specific experimental setup: 
 
- Protein expression analysis: 6-well plates, 400000 cells per well, 2 mL medium 
- RNA expression analysis:  12-well plates, 250000 cells per well, 1 mL medium 
The cells were seeded in the respective amount of Attachment Medium and allowed to adhere to 
the cell culture plates for 2 hrs. Afterwards the medium was changed to the same volume of 
Fasting Medium and the cells were incubated overnight. 
On the next morning, the cells were controlled for viability and hepatocyte-specific morphology, 
before being transfected with LNA antisense oligonucleotides (ASO) to reduce target gene 
expression. The cell culture medium was replaced by 800 µL of fresh Fasting Medium and then 
200 µL of TFX Mix was added dropwise.  
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 TFX Mix      
 DMEM, low glucose (1 g/L) 
 Lipofectamine RNAiMAX (6 µL / 100 µL solution) 
 LNA ASO (100 nM / 100 µL solution) 
To ensure a robust target gene downregulation the cells were incubated for another 24 hrs, before 
being stimulated with metabolic reagents. 
3.2.4. Metabolic stimulation of primary murine hepatocytes 
Primary hepatocytes were stimulated with metabolic reagents exactly 24 hrs after seeding or LNA 
transfection. Briefly, the Fasting medium was replaced by the same volume of the respective 
Stimulation Medium and the cells were incubated for varying durations. At the end of the respective 
stimulation the Stimulation Medium was removed and the cells were directly frozen at -20°C. Three 
technical replicates (400.000 cells in 6-wells) were performed for each biological replicate. 
 Insulin Predilution Mix (1 µM)  Insulin Stimulation Medium    
 10 mL DMEM, low glucose (1 g/L)  DMEM, low glucose (1 g/L) 
 5.8 µL Insulin, human recombinant  Insulin Predilution Mix (10 nM / 100 nM total) 
 
 Glucagon Solution (1 mg/mL)  Glucagon Stimulation Medium   
 1 mL Millipore® H2O     DMEM, low glucose (1 g/L) 
 1 mg Glucagon, human recombinant  Glucagon Solution (3 µM total) 
 
 Dexamethasone Solution (5 mM)  Dexamethasone Predilution Mix (10 µM)  
 10 mL Ethanol (100 %)   10 mL DMEM, low glucose (1 g/L) 
 19.62 mg Dexamethasone, min. 97 % 20 µL Dexamethasone solution 
 
 Forskolin Solution (10 mM)   Fasting Stimulation Medium    
 10 mL DMSO (99 %)    DMEM, low glucose (1 g/L) 
 41.05 mg Forskolin, min. 98 %  Dexamethasone Predilution Mix (100 nM total)  
       Forskolin Solution (10 µM total) 
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3.2.5. Transfection of NSC-34 cells with CRISPR/Cas9 components 
In order to validate gRNA functionality, NSC-34 cells were seeded on a 12-well plate (100000 cells 
per well) and transfected with Cas9 mRNA (5meC, Psi) and the sgRNAs to be tested.  
Briefly, cells were allowed to acclimatise to the cell culture plates for 24 hrs before starting the 
experiment. The TFX Mix was freshly prepared for every experiment and incubated at RT for 25 
min, while the cells were washed twice with 1X PBS. Subsequently, 500 µL of TFX Mix was added 
dropwise on every well and the cells were incubated in a CO2 incubator. After 4 hrs of incubation 
500 µL of NSC-34 Medium was added on top of the TFX Mix and the cells were incubated for 
another 48 hrs. At the end of the experiment the medium was removed and 200 µL Tail Lysis Buffer 
(see 3.3.1) was added to each well. After scraping the cells from the cell culture surface, the cell 
lysis solution was transferred into 1.5 mL reaction tubes and incubated for 2 hrs at 60°C, 800 rpm. 
Proteinase K activity was heat-inactivated by incubating the cell lysis solution for 15 min at 96°C. 
Finally, 800 µL DNase-free H2O was added to the cell lysis solution and it was directly used as 
genomic DNA template in T7 Endonuclease I Assays (see 3.1.15.). 
 
 TFX Mix         
 Opti-MEMTM Reduced Serum Medium 
 Lipofectamine® 2000 (8 µL/mL solution) 
 Cas9 mRNA (2 µg/mL solution) 
 gRNA to be tested (1 µg/mL solution) 
3.3. Biochemical methods 
3.3.1. Genomic DNA extraction from mouse tails 
In order to achieve genomic DNA samples for genotyping PCR reactions (see 3.4.3.), small tail 
biopsies were lysed by Proteinase K digestion in 300 µL Tail Lysis buffer and incubated overnight 
in a thermo mixer (56°C, 300 rpm). Finally, Proteinase K activity was heat-inactivated at 96°C for 
15 minutes and the samples were directly used for subsequent PCR reactions or stored at 4°C.  
 Tail Lysis Buffer   
 50 mM    KCl  
 10 mM    Tris-HCl, pH 8.3  
 1.5 mM   MgCl2  
 0.45 %    Tween® 20  
 0.45 %    NonidetTM P-40  
 100 µg/mL  Proteinase K  
 in Millipore® H2O 
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3.3.2. Subcellular fractionation 
Subcellular fractions were obtained using freshly isolated primary hepatocytes and the Nuclei 
Isolation Kit: Nuclei EZ Prep according to the manufacturer’s protocol. 
Briefly, 5 x 106 cells were centrifuged (5 min, 300 g, 4°C) and the supernatant was discarded, 
whereas the cell pellet was resuspended in 10 mL PBS and centrifuged again (5 min, 300 g, 4°C). 
After removal of the supernatant, 4 mL ice-cold Nuclei EZ Lysis Buffer was added to the cell pellet 
and the reaction tube was vortexed briefly and kept on ice for 5 min. Following centrifugation (5 
min, 300 g, 4°C), the supernatant was kept for later analysis (cytoplasmic fraction), while the pellet 
was again resuspended in 4 mL ice-cold Nuclei EZ Lysis Buffer, vortexed briefly and kept on ice for 
5 min. After a final centrifugation (5 min, 300 g, 4°C) the supernatant was discarded and the nuclei 
pellet was resuspended in 200 µL ice-cold Nuclei EZ Storage Buffer (nuclear fraction). If not 
directly processed for total RNA isolation, the cytoplasmic and nuclear fractions were stored at 
-80°C.  
3.3.3. Total RNA isolation from subcellular fractions 
Irrespective of the different volume of different subcellular fractions, 1 mL TriFast solution was 
added to the respective solution, homogenized by pipetting up and down and stored at RT for 10 
min. During the incubation time, nucleoprotein complexes dissociate and release previously bound 
RNA molecules, which subsequently were separated from DNA molecules and proteins by adding 
200 µL chloroform to the sample. Following vigorous shaking and 3 min incubation at RT, the 
samples were centrifuged (15 min, 12000 x g, 4°C) to separate the reaction mixture into a lower 
red phenol-chloroform phase, an interphase containing DNA and protein partitions as well as in an 
upper colorless aqueous phase that contains RNA molecules. After transferring the aqueous phase 
to a fresh tube, RNA was precipitated by adding 500 µL isopropanol, brief vortexing and incubation 
at RT for 10 min. After centrifugation (10 min, 12000 x g, 4°C), the supernatant was discarded, 
whereas the RNA pellet was washed with 1 mL ethanol (75 %, in DEPC-H2O), vortexed and 
pelleted by centrifugation (10 min, 12000 x g, 4°C). Subsequently, the supernatant was discarded 
and the RNA pellet was air-dried for 10 min, then resuspended in 50 µL DEPC-H2O and heated at 
55°C for 10 min. Finally, RNA concentrations were measured using a NanoDrop™ ND-1000 
spectrophotometer, diluted to identical concentrations with DEPC-H2O and directly used for 
subsequent RT-PCR reactions or stored at -80°C. 
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3.3.4. Total RNA isolation from primary hepatocytes 
Total RNA was isolated from primary hepatocytes using the RNeasy® Mini Kit according to the 
manufacturer’s protocol.  
Primary hepatocytes grow in a monolayer and were directly lysed on the cell culture dish by adding 
350 µL Buffer RLT and 3.5 µL ß-Mercaptoethanol. Using a cell scraper (12-well plate: 25 cm; 6-well 
plate: 39 cm) the cells were completely detached from the cell culture plate and subsequently 
loaded into a QIAshredder spin column and centrifuged at full speed for 2 min. Afterwards 350 µL 
ethanol (70 %, in Millipore® H2O) was added to the lysate and the mixture was loaded into a 
RNeasy spin column and centrifuged (15 s, 8000 x g). After discarding the flow-through, the 
column was loaded with 700 µL of Buffer RW1 and centrifuged again (15 s, 8000 x g). The flow-
through was discarded again and the column was washed with 500 µL of Buffer RPE and 
centrifuged (15 s, 8000 x g). Once more the flow-through was discarded and the column was 
washed again with 500 µL of Buffer RPE and centrifuged (2 min, 8000 x g). To elute the RNA, the 
column was placed on a fresh reaction tube and 30 µL RNase-free H2O was directly added on the 
center of the spin column membrane. Following centrifugation (1 min, 8000 x g) RNA 
concentrations were measured using a NanoDrop™ ND-1000 spectrophotometer, diluted to 200 
ng/µL and directly used for subsequent RT-PCR reactions or stored at -80°C. 
3.3.5. Total RNA isolation from liver tissue 
Before thawing frozen liver tissue, 1.5 mL reaction tubes were prepared for each tissue sample 
and loaded with a small volume of Precellys® zirconium oxide beads and 500 µL TriFast solution. 
Then small pieces of frozen liver tissue were cut on dry ice, directly transferred to the prepared 
reaction tubes and homogenized using a FastPrep-24™ 5G Homogenizer (program: mouse liver). 
After storing the homogenates at RT for 10 min, 200 µL chloroform was added to each sample and 
the samples were vigorously shaken and incubated at RT for 3 min. Following centrifugation (15 
min, 12000 x g, 4°C) the reaction mixture was separated into a lower red phenol-chloroform phase, 
an interphase containing DNA and protein partitions as well as in an upper colorless aqueous 
phase that contains RNA molecules. After transferring the aqueous phase to a fresh tube, RNA 
was precipitated by adding 500 µL isopropanol, brief vortexing and incubation at RT for 10 min. 
After centrifugation (10 min, 12000 x g, 4°C), the supernatant was discarded, whereas the RNA 
pellet was washed with 1 mL ethanol (75 %, in DEPC-H2O), vortexed and pelleted by centrifugation 
(10 min, 12000 x g, 4°C). Subsequently, the supernatant was discarded and the RNA pellet was 
air-dried for 10 min, then resuspended in 50 µL DEPC-H2O and heated at 55°C for 10 min. Finally, 
RNA concentrations were measured using a NanoDrop™ ND-1000 spectrophotometer, diluted to 
identical concentrations with DEPC-H2O and directly used for subsequent RT-PCR reactions or 
stored at -80°C. 
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3.3.6. Total protein isolation from primary hepatocytes 
To isolate total proteins from primary hepatocytes, 500 µL RIPA Working Solution were directly 
added in the wells of frozen cell culture dishes. Using a cell scraper (12-well plate: 25 cm; 6-well 
plate: 39 cm) the cells were completely detached from the cell culture plate and transferred into 1.5 
mL reaction tubes. For cell lysis the reaction tubes were snap-frozen in liquid nitrogen and thawed 
on dry ice for three consecutive times. Subsequently, the samples were centrifuged (10 min, 12000 
x g, 4°C) and the pellet was discarded, while the supernatant was transferred to a new reaction 
tube. By using the Quick Start™ Bradford Protein Assay Kit and a FilterMax™ F5 microplate 
reader, the protein concentrations of the samples were measured at 595 nM and diluted to 
equivalent concentrations with RIPA Working Solution. Finally, the respective amount of 4X 
Laemmli Buffer (containing 5 % ß-Mercaptoethanol) was added to every sample and the mixture 
was boiled at 96°C for 6 min, before being stored at -20°C. 
 RIPA Buffer     RIPA Working Solution    
 150 mM   NaCl    5 mL  RIPA Buffer 
 50 mM     Tris-HCl, pH 7.5  1 x Complete™ Mini Protease Inhibitor tablet 
 1 mM      EDTA    1 x PhosSTOP™ Phosphatase Inhibitor tablet 
 1 %       NonidetTM P-40  
 0.1 %      Tween® 20 (v/v)  
 in Millipore® H2O 
3.3.7. Total protein isolation from liver tissue 
Before thawing frozen liver tissue, 1.5 mL reaction tubes were prepared for each tissue sample, 
loaded with 500 µL IP Lysis Buffer and kept on dry ice. Then small pieces of frozen liver tissue 
were cut on dry ice, directly transferred to the prepared reaction tubes and homogenized using a 
FastPrep-24™ 5G Homogenizer (program: mouse liver). Afterwards, the samples were incubated 
on ice for 45 min, centrifuged (45 min, 12000 x g, 4°C) and then 400 µL of the supernatant was 
transferred to a fresh reaction tube. After another centrifugation step (45 min, 12000 x g, 4°C) 300 
µL of the supernatant was transferred to a fresh tube and 1 µL of the supernatant was mixed with 
39 µL of IP Lysis Working Solution to assess the respective protein concentration. By using the 
Quick Start™ Bradford Protein Assay Kit and a FilterMax™ F5 microplate reader, the protein 
concentrations of the samples were measured at 595 nM and diluted to equivalent concentrations 
with IP Lysis Working Buffer. Finally, the respective amount of 4X Laemmli Buffer (containing 5 % 
ß-Mercaptoethanol) was added to every sample and the mixture was boiled at 96°C for 6 min, 
before being stored at -20°C. 
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 IP Lysis Buffer     PMSF Solution (100 mM)  
 130 mM   NaCl    1 mL   isopropanol 
 50 mM     Tris-HCl, pH 7.4  17.4 mg  PMSF 
 5 mM  EDTA    
 1 % (v/v) Nonidet™ P-40  NaF Solution (100 mM)  
       1 mL   Millipore® H2O 
 IP Lysis Working Buffer   4.2 mg  NaF 
 15 mL   IP Lysis Buffer   
 150 µL  NaF Solution 
 150 µL  PMSF Solution   
 2 x Complete™ Mini Protease Inhibitor tablet 
3.3.8. SDS-PAGE 
Proteins lysates were separated according to their molecular weight by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Samples as well as molecular weight protein 
markers were loaded into precast polyacrylamide gels, the gel chamber was filled with 1X SDS 
Running Buffer and proteins were subsequently separated in an electric field of 90-120 V for 
varying time spans.  
For experiments with 12 samples polyacrylamide gels were prepared according to the following 
protocol: 
 
 Separating Gel (10 mL, 8 %)       Stacking Gel (2 mL, 5 %)    
 4.625 mL   Millipore® H2O   1.375 mL   Millipore® H2O 
 2.675 mL   Rotiphorese® Gel 30  325 µL       Rotiphorese® Gel 30 
 2.5 mL       Tris-Cl (1.5 M), pH 8.8  250 µL       Tris-Cl (1.0 M), pH 6.8  
 100 µL      10 % SDS (in Millipore® H2O) 20 µL         10 % SDS (in Millipore® H2O)  
 100 µL      10 % APS (in Millipore® H2O) 20 µL         10 % APS (in Millipore® H2O)  
 6 µL          TEMED    2 µL           TEMED 
 10X SDS Running Buffer          
 144 g Glycine      
 30 g  Tris(hydroxymethyl)aminomethane  
 10 mL  SDS     
 Millipore® H2O, up to 1 L 
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3.3.9. Western blot analysis 
After SDS-PAGE separated proteins were electrotransferred from the polyacrylamide gel to a 
previously activated PVDF membrane (30 s incubation in methanol). A transfer sandwich 
composed of three WhatmanTM papers, the PVDF membrane (facing the anode), the 
polyacrylamide gel (facing the cathode) and three additional WhatmanTM papers was assembled in 
1X Transfer Buffer and placed in a ice-cooled blotting chamber filled with 1X Transfer Buffer. The 
electrotransfer was performed for 2 hrs with 200 mA per membrane. 
After protein transfer the PVDF membrane was incubated with Ponceau solution to check for 
protein abundance. Afterwards, the membrane was rinsed with 1X TBS-T, cut into the membrane 
parts to be analyzed and incubated for 1 hour with 20 mL Blocking Solution with constant shaking. 
Following overnight incubation with 20 mL of the respective primary antibody solution (4°C, 
constant rotation, 200 rpm), the membrane parts were washed (3 x 10 mins, RT, shaking) with 
TBS-T and incubated with 20 mL of horseradish peroxidase (HRP)-coupled secondary antibodies 
(1 h, RT, permanent shaking). After additional washing with TBS-T (3 x 10 mins, RT, shaking), 500 
µL of chemoluminescent substrate (mix 1:1) was applied on the membrane and the 
chemoluminescence originating from HRP-conjugated antibodies bound to the proteins of interest 
has been detected using a FastGene® FAS V gel documentation system. 
 10X Transfer Buffer          1X Transfer Buffer     
 144 g  Glycine    200 mL  Methanol 
 30 g   Tris(hydroxymethyl)aminomethane 100 mL  10X Transfer Buffer 
 Millipore® H2O, up to 1 L   Millipore® H2O, up to 1 L  
  
 20X Tris Buffered Saline (TBS)        1X Tween 20-Tris Buffered Saline (TBS-T)  
 175.4 g NaCl     50 mL    20X TBS 
 48 g   Tris(hydroxymethyl)aminomethane 1 mL      Tween® 20 
 Millipore® H2O, up to 900 mL   Millipore® H2O, up to 1 L  
 adjust pH to 7.4 with HCl 
 Millipore® H2O, up to 1 L  
 
 Blocking Solution          Antibody Solutions     
 18 mL Tween 20-Tris Buffered Saline 19 mL Tween 20-Tris Buffered Saline 
 2 mL Western Blocking Reagent  1 mL Western Blocking Reagent 
       Protein-specific Antibody 
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3.4. Mouse procedures 
3.4.1. Animal care 
Experimental animals were housed in individually ventilated cages (IVC Type II long) in a specific 
pathogen-free (SPF) research facility with controlled temperature (22-24°C), relative air moisture 
(50-70 %) and light/dark cycle (12h/12h). Care of animals was within institutional animal-care 
committee guidelines. Unless stated otherwise, animals were allowed ab libitum access to food 
and drinking water. After experimentation procedures or before tissue collection animals were 
sacrificed by cervical dislocation. 
Animal housing and experimentation procedures were approved by local and regional authorities 
(Landesamt for Natur, Umwelt und Verbraucherschutz Nordrhein Westfalen) and can be found 
under the following internal reference numbers: 
 - 576.1.36.6.G 50/13 Be 
 - 84-02.04.2016.A460 
 - 84-02.05.40.14.134 
 - 84-02.05.40.16.009 
3.4.2. Experimental mouse models 
Wild type control mice were maintained on a C57BL/6N genetic background and purchased from 
Charles River Research Models and Services, Sulzfeld, DE, whereas diabetes model mice 
(C57BLKS/J Leprdb/db) as well as misty control mice (C57BLKS/J Dock7m/m) were purchased from 
The Jackson Laboratory, Bar Harbor, US. 
The Leprdb/db mouse line is characterized by a G-to-T transversion in the leptin receptor gene Lepr 
resulting in premature transcript termination and subsequently leptin receptor deficiency. 
Homozygous Leprdb mice develop morbid obesity and chronic hyperglycemia by 3 to 4 weeks of 
age. Further disease characteristics are hyperinsulinemia, hyperglycemia, insulin resistance, 
glucose intolerance and abnormal pancreatic beta cell morphology [213-215].  
As homozygous Leprdb mice are sterile, distributors of mouse models incorporated the misty 
mutation (Dock7m) into breeding stocks of the diabetes (db) mutation. The recessive coat color 
mutation misty is the result of a retrotransposon insertion into the gene Dock7, which is closely 
linked to the Lepr locus and therefore can be used as marker allele for the propagation of the db 
mutation. Yet, Dock7m/m mice not only exhibit a dilution of coat color, but also mild growth 
retardation, less inguinal adipose mass and the complete lack of brown adipose tissue [216]. 
Genome-edited mouse lines (lincIRS2∆, Gm15441∆) were generated by pronuclear injection of 
CRISPR/Cas9 components at the CECAD in vivo Research Facility, Cologne, DE. Donor oocytes 
originated from a C57BL/6N background and resulting offspring was maintained on a C57BL/6N 
background. 
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3.4.3. Genotyping of mice 
In order to identify genome-edited mice, genomic DNA was extracted from tail biopsies (see 3.3.1.) 
and used as template in two independent genotyping PCR reactions (3.1.1.):  
Genotyping protocol lincIRS2∆ (#1)  
 Forward primer: #407   Initial denaturation 94°C      3 min  
 Reverse primer: #410   Denaturation  94°C      30 s 
      Annealing  60°C      30 s     35x 
 Expected fragments    Elongation  72°C      1 min  
 WT -> 555 bp    Final elongation 72°C      10 min 
 KO -> no band   Hold   4°C      ∞ 
Genotyping protocol lincIRS2∆ (#2)  
 Forward primer: #409   Initial denaturation 94°C      3 min  
 Reverse primer: #408   Denaturation  94°C      30 s 
      Annealing  60°C      30 s     35x 
 Expected fragments    Elongation  72°C      1 min  
 WT -> 762 bp    Final elongation 72°C      10 min 
 KO -> 357 bp    Hold   4°C      ∞ 
Genotyping protocol Gm15441∆ (#1)  
 Forward primer: #239   Initial denaturation 94°C      3 min  
 Reverse primer: #240   Denaturation  94°C      30 s 
      Annealing  60°C      30 s     35x 
 Expected fragments    Elongation  72°C      1:30 min  
 WT -> 672 bp    Final elongation 72°C      10 min 
 KO -> no band   Hold   4°C      ∞ 
Genotyping protocol Gm15441∆ (#2)  
 Forward primer: #241   Initial denaturation 94°C      3 min  
 Reverse primer: #240   Denaturation  94°C      30 s 
      Annealing  60°C      30 s     35x 
 Expected fragments    Elongation  72°C      1:30 min  
 WT -> 713 bp    Final elongation 72°C      10 min 
 KO -> 306 bp    Hold   4°C      ∞ 
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3.4.4. Experimental diets 
During maintenance and breeding all mice were fed a normal chow diet (NCD) containing 57 % 
carbohydrates, 34 % protein and 9 % fat. For diet-induced obesity experiments, mice were fed a 
high-fat diet (HFD) containing 54 % fat, 24 % protein and 22 % carbohydrates or a control diet 
(CD) containing 67 % carbohydrates, 20 % protein and 13 % fat. 
 
Normal chow diet:  ssniff® R/M-H Low-Phytoestrogen  (Product-ID: V1554) 
High-fat diet:   ssniff® EF  acc. D12492 (I) mod.  (Product-ID: E15742) 
Control diet:   ssniff® EF D12450B* mod. LS (Product-ID: E15748) 
 
All diets were purchased from ssniff Spezialdiäten GmbH, Soest, DE 
3.4.5. In vivo LNA application 
Antisense LNATM GapmeRs were administered to mice via intraperitoneal (IP) injection. Starting 
from 6 weeks of age mice were injected every two weeks with 10 mg LNA (diluted in 0.9 % NaCl 
solution) per kg of body weight. 
3.4.6. Assessment of body weight progression 
Body weight of experimental mouse cohorts was assessed weekly for each individual mouse, 
starting from 6 weeks of age until euthanasia (week 18). 
3.4.7. Intraperitoneal insulin tolerance test (ITT) 
Experimental mouse cohorts were subjected to an intraperitoneal insulin tolerance test at 11 weeks 
of age. Before starting the experiment mice were weighed and basal glucose levels were recorded. 
Following intraperitoneal administration of insulin (0.75 U/kg body weight, in 0.9 % NaCl solution) 
blood glucose levels were measured after 15 min, 30 min, 60 min and 90 min. 
3.4.8. Intraperitoneal glucose tolerance test (GTT) 
Experimental mouse cohorts were subjected to an intraperitoneal glucose tolerance test at 12 
weeks of age. After 16 hrs of overnight fasting mice were weighed and basal glucose levels were 
recorded. Following intraperitoneal administration of glucose (2 g/kg body weight, in 0.9 % NaCl 
solution) blood glucose levels were measured after 15 min, 30 min, 60 min and 120 min. 
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3.4.9. Indirect calorimetry analysis 
Indirect calorimetric measurements were obtained using the TSE PhenoMaster platform. In detail, 
mice were allowed to adapt to single housing in metabolic cages (7.1 liter) for 4 days, followed by 3 
days of indirect calorimetry measurements. Access to food and water were provided ad libitum and 
metabolic parameters were measured automatically by the monitoring system.  
3.4.10. Isolation of primary murine hepatocytes 
For each experiment primary murine hepatocytes were freshly isolated from male wild type mice of 
12 to 20 weeks of age. Before surgery a peristaltic pump was equipped with a butterfly needle 
(0.45 x 12mm) and rinsed for 5 min with Ethanol (70 %) and for 5 min with Millipore® H2O. For high 
viability of cells it is critical to ensure that there are no air bubbles left in the tubing. During cleaning 
of the peristaltic pump Solution I, Solution II and Solution III were prepared and placed into a water 
bath at 40°C.  
Mice were anaesthetised by intraperitoneal injection of freshly prepared Ketamin/Xylazine Mix 
(0.01 mL/g BW), fixed on the working platform and the abdominal cavity was opened. Intestinal 
organs were pushed aside to have free access to the inferior vena cava as well as to the portal 
vein. The peristaltic pump was slowly started perfusing Solution I, while the canula was inserted 
into the inferior vena cava. If the cannulation was successful, the liver instantly began to clear and 
the portal vein was cut to relieve the pressure and allow the fluid to leave the circulation. Once the 
portal vein was cut, the flow rate of the peristaltic pump was increased to 7-9 mL / minute and the 
liver was perfused with 75 mL of Solution I. Shortly before the reservoir of Solution I was depleted, 
50 mL of Solution III was added to the same tube and used for the remaining perfusion. Before air 
bubbles could reach the liver, the perfusion was stopped and the canula as well as the gall bladder 
were removed from the perfused liver. Subsequently, the entire liver was carefully excised and 
transferred to a petri dish containing 10 mL of Solution II. By dissecting the lobes and gently 
shaking the liver, hepatocytes were brushed out of the liver and passed through a 40 µM cell 
strainer. The filtered cell solution was centrifuged two times (5 min, 200 g, 4°C) and resuspended 
in 10 mL of ice-cold Attachment Medium (see 3.2.1.). Afterwards, the cell solution was centrifuged 
again (5 min, 200 g, 4°C) and resuspended in 20 mL Attachment Medium and 16 mL Percoll 
Solution. After a final centrifugation (7 min, 200 g, 4°C) and removal of the supernatant (= dead 
cells), the cell pellet was resuspended in 10 mL of Attachment Medium and the primary 
hepatocytes were counted and seeded on collagen I-coated cell culture. 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 Solution I     Solution II      
 500 mL  EBSS without Ca/Mg  500 mL  EBSS with Ca/Mg 
 0.5 mL   0.5 M EGTA    5 mL   HEPES  
        
 Solution III     Ketamin/Xylazine Mix    
 50 mL Solution II (pre-warmed)  6 mL    0.9 % NaCl solution 
 13 mg Collagenase IV   1 mL    Anesketin® Ketamin solution 
 2 mg Trypsin Inhibitor    0.25 mL  Rompun® Xylazine solution 
 
 Percoll Solution   
 28 mL Percoll  
 2 mL PBS (10X) 
3.4.11. Mouse model generation 
LncRNA-specific KO mouse models were generated by pronuclear injection of CRISPR/Cas9 
ribonucleoprotein (RNP) complexes into zygotes of superovulated C57BL/6NRj females as 
described in [217].  
Briefly, before injection target-specific CRISPR RNAs (crRNAs) were incubated with trans-
activating crRNAs (tracrRNAs) to form annealed guideRNA (gRNA) molecules as shown below: 
 
 crRNA:tracrRNA Solution   
 16 µL  T10E0.1 Buffer     95°C 5 min 
 2 µL  crRNA #1 (100 µM)    cool down 5°C / min 
 2 µL  crRNA #2 (100 µM)    RT hold 
 2 µL  tracrRNA (100 µM)    
 
Subsequently, annealed gRNA molecules were incubated with Cas9 proteins to assemble 
functional RNP complexes as shown below: 
 
 RNP Solution         
 21 µL T10E0.1 Buffer     
 2 µL  Cas9 protein (5 µM)    RT 10 min  
 2 µL crRNA:tracrRNA Solution (10 µM) 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To achieve the Final Injection Solution additional Cas9 mRNA was added to the RNP solution and 
the solution was centrifuged (10 min, 12000 x g, 4°C) and kept on ice or directly used for injection. 
 
 Final Injection Solution  
 25 µL   RNP Solution  
 23.5 µL  T10E0.1 Buffer 
 1.5 µL   Cas9 mRNA 
 
Pronuclear injections of C57BL/6NRj zygotes were performed at the CECAD in vivo Research 
Facility, CECAD Research Center, Cologne, DE. 2-cell stage embryos were subsequently 
implanted into the oviduct of pseudopregnant 0.5 postcoital (p.c.) RjHan:NMRI females. Finally, 
offspring born from implanted embryos were genetically analyzed via DNA sequencing (3.1.9.) and 
- in case of CRISPR/Cas9-mediated genome-engineering of the desired locus - bred to create 
transgenic mouse lines. 
 Final Injection Solution composition  T10E0.1 Buffer    
 50 µL  T10E0.1 Buffer    24.25 mL embryo-tested H2O 
 Cas9 protein  (32.7 ng/µL)   500 µL     EDTA (5 mM) 
 Cas9 mRNA  (30 ng/µL)   209 µL     Tris-HCl (1 M) 
 tracrRNA  (12.5 ng/µL)   40.85 µL  Tris-base (1 M) 
 crRNA #1  (12.5 ng/µL) 
 crRNA #2  (12.5 ng/µL) 
3.5. Computational methods 
3.5.1. Coding potential predictions 
Coding potentials of lncRNA candidates were predicted using transcript sequence data (in FASTA 
format) obtained from the Ensembl Genome Browser (Mus musculus, version GRCm38.p6) and 
the following web-based applications [196, 197]: 
 Coding Potential Calculator (CPC) 
 - Coding probability cutoff: 0.0 
 - Positive controls: Gapdh (Gapdh-202), Hprt (Hprt-201) and Prox1 (Prox1-202) 
 - Negative controls: LeXis (LeXis-202), Malat1 (Malat1-201) and Neat1 (Neat1-201)  
 
 Coding Potential Assessment Tool (CPAT), version 1.2.4 
 - Species assembly: NCBI Build 37/mm9 
 - Coding probability cutoff: 0.44 
 - Positive controls: Gapdh (Gapdh-202), Hprt (Hprt-201) and Prox1 (Prox1-202) 
 - Negative controls: LeXis (LeXis-202), Malat1 (Malat1-201) and Neat1 (Neat1-201) 
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3.5.2. GuideRNA design 
Single guide RNAs (sgRNAs) have been designed using the CRISPOR online application [198] 
considering the following criteria:  
- exclusion of sgRNAs with off-targets for 1- or 2 mismatches 
- specificity score as high as possible, invariably higher than 50 
- score of Moreno-Mateos algorithm as high as possible 
 
Although high scores are desirable for all design algorithms, the algorithm by Moreno-Mateos [218] 
is best for sgRNAs expressed with a T7 promotor and thus needs to be privileged when designing 
sgRNAs intended for mouse oocyte injections.  
 
Target locus for 4833411C07Rik sgRNA design 
Mus musculus (GRCm38/mm10), genome coordinates: chr8:10,899,835-10,900,342 
 
Target locus for Gm15441 sgRNA design 
Mus musculus (GRCm38/mm10), genome coordinates: chr3:96,566,517-96,567,016 
3.5.3. RNA sequencing data analysis 
Mouse RNA-Seq data was processed utilising the GRCm38.p6 assembly of the mouse genome as 
gene sets from Ensembl release 90 [219]. Biotype and gene features were added manually using 
Ensembl BioMart [202]. The bioinformatic data analysis pipeline consists of five steps:  
(1) barcode and adapter removal using flexbar [203],  
(2) computational rRNA depletion by filtering reads that map to known murine rRNAs using 
Bowtie2 [195], 
(3) alignment of non-rRNA reads to the GRCm38.p6 reference genome using STAR [207], 
(4) transcript assembly using cufflinks followed by cuffmerge (Cufflinks suite 2.2.1) [220] and 
(5) differential gene expression analysis between experimental conditions using cuffdiff (Cufflinks 
suite 2.2.1) [200]. 
Human RNA-Seq data was analyzed using the QuickNGS workflow system based on Ensemble 
release 82 [206]. The bioinformatic data analysis pipeline consists of four steps: 
(1) alignment of reads to the GRCm38.p12 reference genome using Tophat2 [208], 
(2) transcript assembly using cufflinks followed by cuffmerge (Cufflinks suite 2.2.1) [220], 
(3) differential gene expression analysis between experimental conditions using DESeq2 [201] and 
(4) combination with multiple annotations using the biomaRt package [194]. 
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Chapter 4 - Results 
4.1. Hepatic lncRNA expression inversely correlates with mRNA expression in 
response to metabolic states 
4.1.1. Transcriptome profiling reveals global hepatic lncRNA downregulation in 
obesity mouse models 
In order to elucidate, if hepatic lncRNA expression correlates with metabolic disorders, such as 
obesity or T2DM, we performed global transcriptome profiling by performing RNA sequencing 
(RNA-Seq) in livers from four different cohorts of mice. This included (I) a diet-induced mouse 
model for obesity and (II) its control littermates as well as (III) a genetically-evoked mouse model 
for obesity and T2DM and (IV) its control breeding stock strain. In detail, we harvested seven 
metabolically relevant tissues (liver, kidney, brain, skeletal muscle, brown adipose tissue as well 
subcutaneous- and visceral white adipose tissue) from three mice of each respective groups: (I) 30 
weeks-old wild type mice (male) that had been fed a high-fat diet (HFD) for 24 weeks, with 
beginning of HFD feeding at 6 weeks of age, (II) 30 weeks-old wild type mice (male) that had been 
fed a low-fat or normal chow diet (NCD) for 30 weeks, (III) 10 weeks-old LepRdb/db mutant mice 
(male), a widely used genetic model for obesity and T2DM in mice [215], that had been fed a NCD 
for 10 weeks, and (IV) 10 weeks-old Dock7m/m mutant mice (male), which develop less adipose 
tissue and on average weigh 15 % less than wild type control mice [216], that had been fed a NCD 
for 10 weeks (Figure 6a). 
RNA was extracted from the harvested tissues of the respective mouse models and used for rRNA-
depleted (total) RNA-Seq. Liver samples yielded, on average, 201 million high-quality, paired-end 
RNA sequencing reads (range 184.3 million - 238.9 million), among which 90.9 % were mapped to 
the mouse genome assembly GRCm38 (for summarised read information see Supplemental 
Figure 1). Homogeneity of liver RNA-Seq data sets were confirmed by principle component 
analysis (PCA), which demonstrated little variance within experimental groups and separate 
clustering of different mouse models (Figure 6b). 
For identification of hepatic lncRNAs that were differentially regulated between aforementioned 
mouse models, we performed differential gene expression analysis and detected 50 hepatic 
lncRNA transcripts that were differentially regulated between HFD and NCD mice and 83 hepatic 
lncRNA transcripts that exhibited differential expression levels between LepRdb/db and Dock7m/m 
mutant mice (Figure 6c).  
Intriguingly, when we globally compared the expression levels of hepatic transcripts, we observed 
a significant overrepresentation of downregulated lncRNA transcripts compared to protein-coding 
mRNAs in response to HFD feeding. Whereas protein-coding mRNAs generally displayed a 
profound tendency to upregulated transcription upon diet-induced obesity, most of the lncRNA 
transcripts were downregulated. Interestingly, we also found the same global trend of lncRNA 
downregulation and mRNA upregulation in the genetic-evoked obesity model system, albeit less 
pronounced than in the diet-induced obesity model system (Figure 6d + e).  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Collectively, these results indicate that chronic obesity affects lncRNA expression levels, leading to 
lncRNA repression upon diet-induced as well as genetic-evoked obesity, and that global lncRNA 
and mRNA expression levels are independently and inversely regulated in obesity mouse models. 
 
Figure 6: Transcriptome 
p r o f i l i n g o f t w o 
independent mouse model 
systems of obesity.  
(a) Schematic representation 
of the global transcriptome 
profiling approach using two 
independent mouse model 
systems of chronic obesity. 
Diet-induced obesity was 
represented by feeding male 
C57BL/6 mice a normal chow 
(NCD) or high-fat diet (HFD); 
genetic-evoked obesity by 
male LepRdb/db and Dock7m/m 
mice (n=3 each). Livers (LIV), 
k idneys (KID) , ske le ta l 
muscle (SM), brain (BRAIN), 
subcutaneous white adipose 
tissue (SCAT), visceral white 
adipose tissue (VAT) and 
brown adipose tissue (BAT) 
were harvested and send for 
R N A s e q u e n c i n g . ( b ) 
Principal component analysis 
(PCA) score plot depicting 
differences in gene expression between liver RNA-Seq data sets derived from the obesity mouse models cohorts NCD, 
HFD, LepRdb/db and Dock7m/m. Gene expression was estimated using fragments per kilobase of exon per million reads 
[FPKM] values of the respective RNA-Seq data sets. (c) LncRNA-specific filter criteria of liver transcriptome data for 
identification of differentially regulated hepatic lncRNAs. (d-e) Cumulative frequency distribution of log2-transformed fold 
changes of hepatic mRNA (blue) and lncRNA (orange) expression between HFD and NCD mice (d) or LepRdb/db and 
Dock7m/m mice (e). Graphs represent mean expression values with all data points plotted. Log2-transformed expression 
fold changes of all hepatic transcripts are shown as dotted black line. Statistical differences between mRNA and lncRNA 
expression changes were assessed using non-parametric Kolgomorov-Smirnov (KS) tests. p-values are given in the 
panels. 
4.1.2. Hepatic lncRNA expression is dynamically adapted to organismal energy 
states 
In addition to the transcriptome data obtained from the chronic obesity mouse models, we also 
wanted to assess rapid transcriptional alterations of hepatic transcript expression upon short-term 
changes in nutrient availability. Therefore, three groups of C57BL/6 mice (male, 16 weeks-old, n=4) 
were subjected to a differential feeding experiment, with (I) a cohort being allowed to eat ad libitum 
for 16 hrs, (II) a cohort forced to fast for 16 hrs and (III) a cohort forced to fast for 16 hrs followed 
by 6 hrs of ad libitum refeeding. At the end of the respective feeding/fasting periods, we harvested 
the metabolically relevant tissues of the animals and performed total RNA-Seq of whole liver RNA 
in order to check for differential transcript expression upon the varying feeding conditions (Figure 
7a).  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On average, 137 million high-quality, paired-end RNA sequencing reads have been obtained from 
each liver sample (range 121,6 million - 149.9 million), among which 94.3 % were mapped to the 
mouse genome assembly GRCm38 (for summarised read information see Supplemental Figure 1). 
Principal component analysis confirmed homogeneity of liver RNA-Seq data sets with little 
variance within biological replicates and separate clustering of different experimental cohorts 
(Figure 7b). 
To identify differentially expressed hepatic lncRNAs between experimental groups, we performed 
differential gene expression analysis and detected 92 lncRNAs with altered hepatic expression 
levels between mice fasted for 16 hrs compared to mice allowed to feed for 16 hrs. Additionally, 59 
lncRNAs were identified that were differentially expressed in livers of mice allowed to refeed for 6 
hrs after 16 hrs of fasting compared to mice fasting for 16 hrs (Figure 7c).  
Figure 7: Transcriptome 
p r o f i l i n g i n l i v e r s o f 
differentially-fed mice.  
(a) Schematic representation 
of the liver transcriptome 
profil ing approach using 
three cohorts of male C57BL/
6 mice (n=4 each) subjected 
to 16 hrs ad libitum feeding 
(AL), 16 hrs fasting (FA) or 
16 hrs fasting followed by 6 
hrs of ad libitum refeeding 
(RF). Livers (LIV) were 
harvested and send for RNA 
sequencing. (b) Principal 
component analysis (PCA) 
s c o r e p l o t d e p i c t i n g 
d i f f e r e n c e s i n g e n e 
expression between liver 
RNA-Seq data sets derived 
from the differentially-fed 
mouse cohorts AL, FA and 
RF. Gene expression was 
estimated using fragments 
per kilobase of exon per 
million reads [FPKM] values 
of the respective RNA-Seq data sets. (c) LncRNA-specific filter criteria of liver transcriptome data for identification of 
differentially regulated hepatic lncRNAs. (d-e) Cumulative frequency distribution of log2-transformed fold changes of 
hepatic mRNA (blue) and lncRNA (orange) expression between FA and AL mice (d) or RF and FA mice (e). Graphs 
represent mean expression values with all data points plotted. Log2-transformed expression fold changes of all hepatic 
transcripts are shown as dotted black line. Statistical differences between mRNA and lncRNA expression changes were 
assessed using non-parametric Kolgomorov-Smirnov (KS) tests. p-values are given in the panels. 
Similar to the expression data of the chronic obesity mouse models, we observed opposite 
transcriptional regulations for coding and long noncoding hepatic transcripts in the differentially-fed 
mouse cohorts. Global differential gene expression analysis between mice fasted for 16 hrs and ab 
libitum fed mice resulted in a significant upregulation of lncRNA transcripts as compared to mRNA 
transcripts. After 16 hrs of fasting, hepatic lncRNA regulation was globally upregulated in 
comparison to ad libitum fed mice, whereas hepatic mRNAs showed a tendency to global 
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downregulation (Figure 7d). Conversely, we detected a tendency towards global downregulation of 
lncRNAs between fasted mice allowed to short-term refeeding and fasted mice. But in contrast to 
the highly significant reciprocal regulation between fasted and ad libitum fed mice, the differential 
regulation between lncRNA and mRNA transcripts between refed and fasted mice was not 
significant, but an inverted trend to the fasting-induced upregulation of lncRNAs (Figure 7e). 
In conclusion, these results suggest a dynamic regulation of lncRNA expression levels in response 
to short-term alterations of nutrient availability, manifesting in increased global lncRNA expression 
upon fasting and diminished global lncRNA expression after only 6 hrs of refeeding after the fasting 
regime. In line with previous results obtained from the chronic obesity mouse models, global 
regulation of lncRNA levels again inversely correlates with global mRNA regulation. 
4.1.3. Anticorrelative regulation of lncRNAs and mRNAs in human liver biopsies 
To corroborate the finding of inverse global regulations of lncRNA and mRNA transcripts in mouse 
models for chronic obesity and short-term changes in nutrient availability, we decided to analyse 
human liver biopsies for differential transcript regulation. Examined biopsies were part of a 
previously described cohort of human patients [193] and were selected according to the patient’s 
gender (male) and body mass index (BMI) as well as to the fact if the patient was suffering from 
T2DM. In detail, we assembled three groups of human males (n=4), with (I) one group composed 
of lean (BMI: 21.9 - 24.8) and non-diabetic men, (II) one group consisting of obese (BMI: 47,9 - 
54,2) and non-diabetic men and (III) one group made up of overweight or obese  men (BMI: 27,0 - 
63,0) with clinically-manifested T2DM (Figure 8a). 
For each patient, total RNA-Seq was performed using whole liver RNA extracted from the 
respective liver biopsies. From each sample we obtained, on average, 138.2 million high-quality, 
paired-end RNA sequencing reads (range 127.6 million - 148.6 million), among which 87.6 % were 
mapped to the human genome assembly GRCh38 (for summarised read information see 
Supplemental Figure 1). Principal component analysis reflected heterogeneity of RNA-Seq data 
sets, potentially due to (apart from genetic differences) strong variance in patient’s age (range 
21-75 years) and disease etiology. Also, differences in lifestyle and diet could account for the high 
variance in these datasets. Highest differences were observed between RNA-Seq data sets of 
lean, non-diabetic patients, all of which were suffering from different types of cancer (see also 
2.11.). However, data sets of obese, non-diabetic patients displayed transcriptional homogeneity 
and clustered together with data sets of obese diabetic patients, but not with overweight diabetic 
patients (Figure 8b). When performing differential gene expression analysis, we detected 297 
hepatic lncRNA transcripts that were differentially regulated between lean, non-diabetic patients 
and obese, non-diabetic patients. In addition, we identified 504 hepatic lncRNA transcripts that 
exhibited altered expression levels between lean, non-diabetic patients and overweight or obese, 
diabetic patients (Figure 8c). 
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Figure 8: Transcriptome 
profiling in liver biopsies of 
human patients.  
(a) Schematic representation 
of the transcriptome profiling 
approach using liver biopsies 
of three groups of male 
patients (n=4 each), with one 
group composed of lean, 
non-diabetic man (Lean), one 
group consisting of obese, 
non-diabetic man (Obese) 
and one group made up of 
o b e s e / o v e r w e i g h t m a n 
suffering from T2DM (T2DM). 
RNA extracted from livers 
biopsies (LIV) were send for 
R N A s e q u e n c i n g . ( b ) 
Principal component analysis 
(PCA) score plot depicting 
d i f f e r e n c e s i n g e n e 
expression between liver 
RNA-Seq data sets derived 
from the patient groups Lean, 
Obese and T2DM. Gene 
expression was estimated 
using fragments per kilobase 
of exon per million reads [FPKM] values of the respective RNA-Seq data sets. (c) LncRNA-specific filter criteria of liver 
transcriptome data for identification of differentially regulated hepatic lncRNAs. (d-e) Cumulative frequency distribution of 
log2-transformed fold changes of hepatic mRNA (blue) and lncRNA (orange) expression between the patient groups 
Obese and Lean (d) or T2DM and Lean (e). Graphs represent mean expression values with all data points plotted. Log2-
transformed expression fold changes of all hepatic transcripts are shown as dotted black line. Statistical differences 
between mRNA and lncRNA expression changes were assessed using non-parametric Kolgomorov-Smirnov (KS) tests. 
p-values are given in the panels. 
Consistent with the results of the murine RNA-Seq data, global differential gene expression 
analysis revealed inverse transcriptional regulations for lncRNAs and mRNAs in liver biopsies of 
the respective groups. Comparison of hepatic expression levels between lean, non-diabetic 
patients and obese, non-diabetic patients revealed a highly significant downregulation of lncRNA 
transcripts compared to mRNA transcripts upon obesity (Figure 8d). Interestingly, the same, yet 
even more pronounced correlation was found between lean, non-diabetic patients and obese/
overweight patients suffering from T2DM (Figure 8e). 
Taken together, these results reveal that human hepatic lncRNA regulation correlates with 
metabolic health in liver, more precisely a strong repression of hepatic lncRNAs was observed 
upon obesity and T2DM. Consistent with murine liver transcriptome data analysis, regulation of 
global lncRNA expression correlates reciprocally with global mRNA expression in human livers, 
indicating that anticorrelative regulation of hepatic lncRNAs is not only induced in mice in response 
to chronic or short-term nutrient challenges, but also in humans suffering from obesity or T2DM. 
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4.2. In vitro screening for metabolically relevant lncRNAs implicated in liver 
energy homeostasis 
4.2.1. Identification of liver-enriched lncRNAs regulated upon chronic obesity, food satiety 
and food deprivation  
To better explore how lncRNAs could partake in regulation of hepatic energy homeostasis, we 
screened the achieved murine transcriptome data for hepatic lncRNAs that could be further 
functionally investigated. Potential lncRNA candidates were selected according to three criteria, 
namely (I) tissue-selective expression in liver, (II) biological regulation across obesity and 
differentially-fed mouse models and (III) accurate bioinformatic attribution to annotated genes. 
Tissue-specific expression of lncRNA transcripts was assessed by analysing RNA-Seq data of 
seven metabolically active tissues of an independent, NCD-fed cohort of 17-18 weeks-old C57BL6 
mice [221]. Filtering normalised RNA-Seq data (in fragments per kilobase of exon per million reads 
[FPKM]) for liver-enriched lncRNA transcripts resulted in 372 potential candidates, whose RNA-
Seq reads were predominantly found (FPKM[LIV]/FPKM[ALL] ≥ 0.5) in the liver samples (Figure 
9a). When considering the biological regulation of the potential candidates in the mouse models of 
diet-induced and genetic-evoked obesity, we detected 61 lncRNA transcripts, which were 
consistently regulated in both mouse models (Figure 9b). After manually reviewing aligned RNA-
Seq reads of potential candidates for proper alignment to annotated genes and precise exon-intron 
boundaries, we selected 15 lncRNA transcripts to be further investigated in vitro.  
Differential expression of the selected candidate lncRNAs upon obesity was validated via qPCR 
gene expression analysis using total liver RNA of both the diet-induced as well as the genetic-
evoked obesity mouse models (Figure 9c). Yet, owing to sporadic high variances among biological 
replicates, a significant regulation (p=0.05) in both mouse model system for obesity could not be 
validated for all lncRNA transcripts. 
Additionally, we performed qPCR gene expression analysis of the selected lncRNA candidates in 
livers of the differentially-fed mouse cohorts and detected strong transcriptional regulation of some 
transcripts in response to short-term alterations of nutrient availability.  
Interestingly, transcriptional alterations caused by the 16 hrs fasting regime appeared to be 
reversed in re-fed mice, as most of the significantly regulated transcript levels abated to control 
levels when fasted mice were allowed to re-feed for 6 hrs (Figure 9d). 
In conclusion, upon validation of previously obtained transcriptome data for liver-enriched lncRNA 
transcripts by qPCR, we found that 15 lncRNAs are regulated upon chronic obesity, some of which 
are strongly affected by alterations in feeding status and thus constitute interesting candidates for 
further investigations. 
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Figure 9: Identification 
of liver-enriched lncRNA 
transcripts regulated by 
chronic obesity and 
short-term changes in 
nutrient availability. 
(a) Heatmap of fractional 
r ead coun t s f o r t he 
tissues brain (BRAIN), 
skeletal muscle (SM), liver 
( L IV ) , k i dney (K ID ) , 
s u b c u t a n e o u s w h i t e 
adipose tissue (SCAT), 
brown adipose tissue 
(BAT) and visceral white 
adipose tissue (VAT) in 
RNA-Seq data of mouse 
m o d e l s f o r c h r o n i c 
obesity. (b) Scatter plot 
d e p i c t i n g m e a n 
expression fold changes 
of liver-enriched lncRNAs 
between mice fed a high-
fat diet (HFD) and mice 
fed a normal chow diet 
(NCD) as well as between 
LepRdb/db and Dock7m/m 
mice (n=3 each). Black 
dots represent l iver-
enriched lncRNAs. Green 
d o t s i n d i c a t e l i v e r -
enriched lncRNAs that are 
regulated (p=0.1) in both 
mouse models of chronic 
obesity. Yellow dots show 
liver-enriched lncRNAs 
that are consistent ly 
regulated (p=0.1) in both 
mouse models of chronic 
obesity. (c) qPCR gene 
expression analysis of 
s e l e c t e d l n c R N A 
candidates between HFD-
fed and NCD-fed mice as 
well as between LepRdb/db 
and Dock7m/m mice (n=3 
each). (d) qPCR gene expression analysis of selected lncRNA candidates between mice subjected to 16 hrs ad libitum 
feeding (AL), 16 hrs fasting (FA) or 16 hrs fasting followed by 6 hrs of ad libitum refeeding (RF) (n=4 each). Graphs (c+d) 
represent mean ± s.e.m. Statistical differences were calculated using unpaired two-tailed t-tests (UP2T-TT). *p<0.05; 
**p<0.01; ***p<0.001; ns, not significant. 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4.2.2. Further characterisation of selected lncRNA candidates by expression profiling and 
coding predictions 
Before selecting lncRNA transcripts for further investigations, we aimed to gain more information 
about the previously selected list of transcripts. 
Due to technical variability RNA sequencing results may be affected by inconsistent detection of 
exons at low levels of coverage [222]. Prompted by the low expression levels of most of our 
candidates, we intended to validate tissue-specific expression of the selected lncRNAs by 
performing qPCR gene expression analysis in the harvested tissues of C57BL/6 mice. Surprisingly, 
whereas liver-enriched expression of most of the transcripts could be confirmed, we also found two 
potential candidates with pronounced expression in several non-hepatic tissues (Figure 10a). 
Figure 10: Addit ional 
characteristics of selected 
lncRNA candidates. 
(a) qPCR gene expression 
analysis of selected lncRNA 
candidates in indicated 
tissues of C57BL/6 wildtype 
mice (n=3 each). BAT, 
brown ad ipose t issue; 
B R A I N , b r a i n ; S C AT, 
s u b c u t a n e o u s w h i t e 
adipose tissue; SM, skeletal 
muscle; KID, kidney; VAT, 
v isceral whi te adipose 
tissue; LIV, liver. (b) Coding 
potential predictions of 
i nd i ca ted lncRNA and 
mRNA transcripts using 
w e b - b a s e d t r a n s c r i p t 
classifier tools. Published 
lncRNA (LeXis, MALAT1, 
N E A T 1 ) a n d m R N A 
transcripts (GAPDH, HPRT, 
PROX1) were used as 
controls. (c) qPCR gene 
expression analysis of 
selected lncRNA candidates 
in nuclear and cytosolic 
subcellular fractions (n=3 
each) derived from livers of 
16-20 weeks-old C57BL/6 
wildtype mice. Graphs (a+c) 
represent mean ± s.e.m. 
abundance in the respective 
subcellular fraction relative 
to total abundance. 
Recent studies suggested that putative lncRNAs can also encode for micropeptides, small 
peptides consisting of less than 100 amino acids [223, 224]. To exclude potential candidates with 
coding capabilities, we evaluated the coding potential of the selected lncRNAs by using the web-
based transcript classifier tools ‚Coding Potential Calculator‘ (CPC, [197]) and ‚Coding Potential 
Assessment Tool‘ (CPAT, [196]). Both algorithms concordantly verified the coding capabilities of 
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published control transcripts (LeXis, MALAT1, NEAT1, GAPDH, HPRT, PROX1), yet also predicted 
coding potentials for two selected lncRNAs, whereas the remaining lncRNA candidates were not 
predicted to encode for (micro-)peptides (Figure 10b). 
After discarding four lncRNA candidates due to their abundant expression in multiple non-hepatic 
tissues or their predicted potential to encode for proteins, we further characterised the remaining 
11 lncRNAs by assessing the localisation of their transcripts. As lncRNAs can execute their 
molecular functions both in the nucleus as well as in the cytoplasm, we examined subcellular 
fractions of wildtype primary hepatocytes for the expression of the candidate lncRNA transcripts. 
qPCR gene expression analysis revealed that most of the transcripts were predominantly found in 
nuclear fractions, while only one gene product strongly accumulated in cytoplasmic fractions. 
However, we also found several candidates with noticeable expression in both subcellular 
fractions, indicating that the corresponding transcripts could execute multiple functions in both the 
nuclear and cytoplasmic compartments (Figure 10c). 
4.2.3. Candidate expression levels in primary hepatocytes are mediated by metabolic 
stimuli  
Next we wanted to investigate, whether selected lncRNAs are not only regulated by metabolic 
states, but could also affect energy homeostasis and hepatic metabolism. Thus, we aimed to 
generate in vivo mouse models with genetic loss of obesity-associated lncRNAs. We therefore 
manually reviewed our previously obtained RNA-Seq data and choose candidates for further 
investigations that were significantly regulated upon chronic obesity as well as dynamically 
expressed in response to short-term nutritional changes. We picked four transcripts fulfilling the 
aforementioned criteria, namely 4833411C07Rik, B930025P03Rik, Gm13775 and Gm15441, and 
performed metabolic stimulation of primary hepatocytes to check for differential gene expression of 
the selected transcripts (Figure 11a). 
Indeed, transcript levels of 4833411C07Rik and Gm15441 displayed strong reductions after 6 hrs 
stimulation with the anabolic hormone insulin and were also regulated by fasting mimicking 
metabolites such as forskolin and dexamethasone. Yet, whereas alterations in 4833411C07Rik 
expression levels were consistent with the opposing physiological effects of insulin and forskolin/
dexamethasone and consequentially increased after fasting stimulation, we surprisingly observed 
significant reductions of Gm15441 transcript levels in response to both metabolic stimuli. Transcript 
levels of B930025P03Rik and Gm13775 showed no significant alterations to 6 hrs insulin 
stimulation and only B930025P03Rik exhibited elevated expression levels upon 6 hrs fasting 
stimulation (Figure 11b-e). 
 
Collectively, we demonstrated that expression of some selected lncRNA candidates are mediated 
by essential anabolic and catabolic stimuli. Yet, as we could only detect partial transcriptional 
responses of B930025P03Rik and Gm13775 to feeding and fasting mimicking metabolites and due 
to limitations in time and work load, we decided to exclusively select 4833411C07Rik and 
Gm15441 as final lncRNA candidates to be studied in in vivo mouse models. 
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Figure 11: Metabolic 
r e g u l a t i o n o f 
s e l e c t e d l n c R N A 
c a n d i d a t e s i n 
primary hepatocytes.  
( a ) S c h e m a t i c 
representation of the 
experimental approach 
using 14-18 weeks-old 
C57BL/6 mice fo r 
isolation of primary 
hepatocytes, which 
were stimulated for 6 
hrs with 10 nM insulin 
( I n s ) o r 1 0 µ M 
forskolin and 100 nM 
dexamethasone (FD). 
Unst imulated cel ls 
have been used as 
controls (Ctrl). (b-e) 
q P C R g e n e 
expression analysis of 
lncRNA candidates 
4833411C07Rik (b), 
B930025P03Rik (c), 
Gm13775 (d ) and 
G m 1 5 4 4 1 ( e ) i n 
st imulated pr imary 
hepatocytes (n=4). 
Measurements fo r 
e a c h b i o l o g i c a l 
r e p l i c a t e w e r e 
p e r f o r m e d i n 3 
technical replicates. 
The expression value 
f o r t he b i o l og i ca l 
r e p l i c a t e s w a s 
calculated as mean of 
respective technical 
repl icates. Graphs 
r e p r e s e n t m e a n 
expression values with 
all data points shown. Statistical differences were calculated using unpaired two-tailed t-tests (UP2T-TT). *p<0.05; 
***p<0.001; ns, not significant. 
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4.3. Generation of lncRNA-deficient mouse models using CRISPR/Cas9-
mediated genome engineering  
4.3.1. Targeting strategies to abrogate lncRNA candidate expression 
In order to study the systemic impact of lncRNAs 4833411C07Rik and Gm15441 on liver energy 
homeostasis, we sought to generate in vivo mouse model systems devoid of 4833411C07Rik or 
Gm15441 expression, respectively. Due to its positioning ca. 80 kb upstream of the well-described 
insulin receptor substrate 2 (Irs-2, see also Supplemental Figure 2), we termed 4833411C07Rik as 
lincIRS2 in the following studies. To gain a comprehensive overview of the genomic loci to be 
targeted, we complemented the previously achieved RNA-Seq data with publicly available liver 
chromatin immunoprecipitation sequencing (ChIP-Seq) data for histone 3 lysine 4 trimethylation 
(H3K4me3) and histone 3 lysine 27 acetylation (H3K27ac) chromatin marks of postnatal (p=0) 
C57Bl/6 mice. 
Tissue-specific RNA-Seq data tracks indicated liver-specific expression of lincIRS2, yet also 
showed expression of another hepatic lncRNA locus, Gm2814, which is located in antisense 
direction on the opposing DNA strand and is overlapping with exon 2 of lincIRS2. Interestingly, both 
genes exhibited identical transcriptional regulations in chronic obesity mouse models, suggesting a 
potential conjoint expression of both genes by a bidirectional promotor or other regulatory genomic 
elements. ChIP-Seq data revealed the occurrence of H3K4me3 chromatin marks in close proximity 
to the transcriptional start site (TSS) of lincIRS2 and broad H3K27ac chromatin marks along the 
gene body, both of which are associated with active transcription of nearby genes [225]. To avoid 
removal of Gm2814 transcriptional units and to impact on both isoforms expressed by lincIRS2, 
which differ in exon 3 and exon 4 composition, but share exon 1 (Supplemental Figure 3), we 
decided to exclusively delete lincIRS2 exon 1. Of note, this targeting approach results in collateral 
elimination of genomic sites with accumulation of H3K4me3 and H3K27ac chromatin marks, which 
is an advantaged aspect of our targeting strategy to disrupt lincIRS2 expression (Figure 12). 
The targeting strategy for Gm15441 is similar to lincIRS2, as Gm15441 also partly overlaps with 
another transcript located in antisense direction on the opposing DNA strand, the protein-coding 
gene Txnip. Tissue-specific RNA-Seq data tracks suggested liver-enriched expression of 
Gm15441, with minor Gm15441 expression in kidney, whereas the overlapping Txnip was 
expressed independently of Gm15441 in multiple tissues. ChIP-Seq data tracks showed 
accumulations of H3K4me3 and H3K27ac chromatin marks in close proximity to the Txnip TSS and 
along its gene body, but only marginal chromatin marks for active transcription at the Gm15441 
TSS. Intriguingly, TXNIP is a well-studied modulator of energy metabolism, as it has been 
associated with regulation of cellular redox balance [226], hepatic glucose production [227], and 
diabetes in humans [228]. Due to the multiple contributions of TXNIP to liver energy metabolism, 
we aimed to avoid unnecessary disruptions of the Txnip locus or its gene function and decided to 
exclusively remove exon 1 of Gm15441 (Figure 13). 
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Figure 12: Gene target ing 
approach to abrogate lincIRS2 
expression. 
Illustration of RNA-Seq and ChIP-
Seq data tracks of genomic region 
8:10,897,922-10,902,636. Boxes 
represent annotated exons of 
lincIRS2 and Gm2814, arrows 
indicate start site and direction of 
transcription. Upper histograms 
depict RNA-Seq read counts of 
indicated tissues in male 30 weeks-
old C57BL/6 mice fed a normal 
chow diet (NCD) or liver RNA-Seq 
read counts in male 30 weeks-old 
C57BL/6 mice fed a normal chow 
diet (NCD, light blue), male 30 
weeks-old C57BL/6 mice fed a 
high-fat diet (HFD, dark blue), male 
10 weeks-old Dock7m/m mutant mice 
(orange) or male 10 weeks-old 
LepRdb/db mutant mice (red). Lower 
histograms illustrate liver ChIP-Seq 
read counts in postnatal (day p=0) 
C57BL/6 mice of mixed sexes for 
histone 3 lysine 4 trimethylation (H3K4me3, light green) and histone 3 lysine 27 acetylation (H3K27ac, dark green). 
Dotted lines show genomic sites targeted by CRISPR/Cas9-mediated genome engineering. BRAIN, brain; KID, kidney; 
SM, skeletal muscle; BAT, brown adipose tissue; SCAT, subcutaneous white adipose tissue; VAT, visceral white adipose 
tissue; LIV, liver. 
Figure 13: Gene target ing 
approach to abrogate Gm15441 
expression. 
Illustration of RNA-Seq and ChIP-
Seq data tracks of genomic region 
3:96,554,830-96,567,351. Boxes 
represent annotated exons of 
Gm15441 and Txnip , arrows 
indicate start site and direction of 
transcription. Upper histograms 
depict RNA-Seq read counts of 
indicated tissues in male 30 weeks-
old C57BL/6 mice fed a normal 
chow diet (NCD) or liver RNA-Seq 
read counts in male 30 weeks-old 
C57BL/6 mice fed a normal chow 
diet (NCD, light blue), male 30 
weeks-old C57BL/6 mice fed a 
high-fat diet (HFD, dark blue), male 
10 weeks-old Dock7m/m mutant mice 
(orange) or male 10 weeks-old 
LepRdb/db mutant mice (red). Lower 
histograms illustrate liver ChIP-Seq 
read counts in postnatal (day p=0) C57BL/6 mice of mixed sexes for histone 3 lysine 4 trimethylation (H3K4me3, light 
green) and histone 3 lysine 27 acetylation (H3K27ac, dark green). Dotted lines show genomic sites targeted by CRISPR/
Cas9-mediated genome engineering. BRAIN, brain; KID, kidney; SM, skeletal muscle; BAT, brown adipose tissue; SCAT, 
subcutaneous white adipose tissue; VAT, visceral white adipose tissue; LIV, liver. 
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4.3.2. In vitro validation of sgRNA activity using T7 endonuclease I assays  
Using the web-based applications CRISPR Design [199] and CRISPOR [198], we screened for 
suitable crRNA spacer sequences that could be used in the previously designed targeting 
approaches. Indeed, we identified crRNA spacer sequences flanking the first exons of lincIRS2 and 
Gm15441, respectively, and selected two 20-nucleotide spacer sequences for each 5’- and 3’end 
of the targeted regions. Upon simultaneous cleavage at both ends flanking the targeted exons, 
open genomic ends can be fused by endogenous end ligation repair mechanisms [229], ultimately 
resulting in the deletion of the flanked genomic region. As recent reports demonstrated that 
truncated gRNAs with 18 nucleotide spacer sequences exhibit increased target specificity [230], 
we additionally selected two 18-nucleotide spacer sequences for each genomic region to be 
targeted. 
Figure 14: Val idation of 
sgRNA activity using T7 
endonuclease I assays. 
(a) Schematic representation 
depicting the workflow of T7 
endonuclease I (T7E1) assays. 
To detect genome-edi t ing 
events induced by functional 
sgRNAs, genomic DNA is 
isolated from gene-targeted 
cells and the locus of interest is 
amp l i f i ed v ia PCR. A f te r 
denaturation and random re-
annealing of DNA strands, the 
PCR products are incubated 
with T7E1, which results in 
c l e a v a g e o f D N A 
heteroduplexes consisting of 
unmodified and gene-targeted 
D N A s t r a n d s . C l e a v e d 
heteroduplexes can be detected 
by gel electrophoresis and 
demonstrate successful gene-
editing by functional sgRNAs. To 
con t ro l fo r T7E1-spec i f i c 
appearance of additional bands, 
PCR products that have not 
b e e n s u b j e c t e d t o T 7 E 1 
digestion are also run on the 
same gel electrophoresis (T7E1 
control). (b) Representative 
agarose gel displaying PCR 
reactions with primers flanking exon 1 of lncRNA Gm15441 using genomic DNA isolated from NSC-34 cells transfected 
with different combinations of sgRNAs, including [1] Gm15441-5’-1 (20) + Gm15441-3’-2 (20), [2] Gm15441-5’-1 (18) + 
Gm15441-3’-2 (18) and [3] Gm15441-5’-2 (18) + Gm15441-3’-2 (18). C, negative control PCR using genomic DNA from 
untransfected NSC-34 cells. H, H2O control PCR using no template DNA. (c) Table of sgRNAs that have been evaluated 
for genome-editing activity, including the crRNA spacer sequence and the outcome of the T7E1 assay. The length of the 
spacer sequences is indicated in brackets behind the name of the respective sgRNA. 
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Before using the selected crRNA sequences to generate in vivo mouse models, we wanted to 
validate spacer sequence activity in vitro. Synthesised single guide RNA (sgRNA) molecules 
containing the spacer sequence to be evaluated were examined for gene targeting efficiency by 
transfecting NSC-34 cells with pairs of sgRNAs and evaluating the occurrence of gene-editing 
events via sequence-specific T7 Endonuclease I (T7E1) assays. To improve the detection of gene-
editing events, PCR primers for the amplification of the locus of interest were designed in such a 
way that T7E1-mediated cleavage of heteroduplexes results in two DNA fragments of equal 
lengths, which gives a strong single band during gel electrophoretic separation (Figure 14a). If both 
sites flanking the genomic region to be deleted were targeted by functional sgRNAs, the deletion 
event itself could also be visualized by standard PCR reactions using target region flanking 
genotyping primers (Figure 14b). Out of the 16 crRNA sequences evaluated, we detected four 20-
nucleotide spacer sequences and five 18-nucleotide spacer sequences with detectable genome-
editing events in T7E1 assays (Figure 14c). 
Taken together, we successfully validated genome-editing capacity of nine selected crRNA spacer 
sequences using T7E1 assays and genotyping PCRs. However, in order to reduce undesirable off-
target events, we selected the 20-nucleotide spacer sequences for the generation of lncRNA-
deficient in vivo mouse models. 
4.3.3. In vivo targeting approach - strategy for pronuclear microinjection 
To generate in vivo lncRNA mouse models, we decided to employ pronuclear injection (PNI) of 
CRISPR/Cas9 components into C57BL/6NRj zygotes, which were subsequently implanted into 
pseudopregnant RjHan:NMRI females. For maximum quality of the CRISPR components, synthetic 
cRNA and tracrRNA molecules were purchased from commercial distributors using the 20-
nucleotide cRNA spacer sequences that have been validated in vitro. To enhance CRISPR/Cas9 
genome-editing events, we additionally added Cas9 mRNA to the injection mix containing the 
guide RNA components (tracrRNA + 2x crRNAs) and Cas9 protein (Figure 15). 
When using CRISPR PNI technology to generate genome-engineered mouse models, the 
developmental time point of the genome-editing event as well as the exact result of the CRISPR-
induced genomic alteration occur in a random fashion [176]. Thus, the genomic alteration of the 
targeted locus can not only differ among individual animals of the F0 generation, but also in 
different somatic or gametic cells of the same animal (genetic mosaicism). In order to ensure 
stable germline transmission of the edited allele and ultimately the establishment of a new 
genome-edited mouse line, all animals obtained by CRISPR PNI as well as their F1 and F2 
offspring have been monitored for the composition of the targeted locus by DNA sequencing.  
 77
 
Figure 15: Experimental 
setup of the in vivo gene 
targeting strategy. 
Schematic representation 
o f t h e e x p e r i m e n t a l 
approach to generate in 
v i v o m o u s e m o d e l s , 
d e p i c t i n g t h e ( a ) 
c o m p o s i t i o n o f t h e 
CRISPR-Cas9 injection 
mix , con ta in ing Cas9 
mRNA, Cas9 protein as 
w e l l a s t h e g R N A 
components tracrRNA and 
crRNA, (b) pronuclear 
m i c r o i n j e c t i o n o f 
a s s e m b l e d 
r i b o n u c l e o p r o t e i n 
complexes into C57BL/
6NRj zygotes and (c) 
embryo transfer of 2-cell 
s t a g e e m b r y o s i n t o 
p s e u d o p r e g n a n t 
R jHan :NMRI fema les . 
Concentrat ions of the 
injection components are 
indicated in the panel. 
4.3.4. Generation of a mouse line deficient for lincIRS2-exon 1 (lincIRS2∆/∆)  
Selected 20-nucleotide spacer sequences for lincIRS2 gene targeting flanked a genomic region of 
415 bp, including entire lincIRS2 exon 1 and parts of lincIRS2 exon 2, but no transcriptional units of 
overlapping lncRNA gene Gm2814 (Figure 16a+b). PNI of CRISPR/Cas9 components into zygotes 
yielded 115 viable 2-cell stage embryos, which subsequently were transferred into four 
pseudopregnant foster females. Unfortunately, only two females became pregnant and only gave 
birth to 7 pups in total (Supplemental Figure 3).  
Although genotyping of CRISPR founder animals is not meaningful to determine the genomic 
configuration of progeny due to possible genetic mosaicism, we extracted genomic DNA from 
founder tail biopsies to check for CRISPR/Cas9-mediated alterations of the lincIRS2 locus in 
founder animals. Interestingly, two independent PCR reactions detected a truncated allele of the 
targeted locus matching the predicted size for a successful deletion event in one potential founder 
mouse (Figure 16c). Genotyping PCRs of F1 offspring showed deleted lincIRS2 alleles in progeny 
of the founder animal that previously showed an altered lincIRS2 allele in tail biopsy DNA, but no 
truncated lincIRS2 alleles in progeny of other potential founder animals. DNA sequencing of the 
positive founder line revealed identical genomic compositions among 21 sequenced animals of the 
F1 and F2 generation. In detail, CRISPR/Cas9-induced cleavage resulted in a 418 bp genomic 
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deletion, including the targeted 415 bp genomic region and three additional basepairs at the 5’ 
Cas9 cutting site. Surprisingly, DNA sequencing also detected four additional basepairs that were 
removed close to the proximal Cas9 cutting site, which indicates multiple repair procedures of 
Cas9-induced DSB and ultimately results in a total loss of 422 bp in the lincIRS2∆ allele (Figure 
16d+e). 
In conclusion, we successfully generated a truncated lincIRS2 allele, defined by a 422 bp genomic 
deletion comprising the gene-targeted exon 1 of lincIRS2, but no transcriptional units of 
overlapping lncRNA gene Gm2814. Of note, CRISPR/Cas9-induced DSB repair resulted in a 
random 4 bp deletion outside the targeted genomic region, which not impinges on our gene 
targeting strategy, but has to be considered for further genome-editing approaches. 
Figure 16: Generation of 
a gene-edited lincIRS2∆ 
allele. 
(a) Schematic illustration 
of the targeting strategy to 
delete exon 1 of lincIRS2. 
B r o w n h i s t o g r a m s 
represent RNA-Seq read 
counts in l iver of 30 
weeks-old C57BL/6 mice. 
B l u e b o x e s i n d i c a t e 
a n n o t a t e d e x o n s o f 
lncRNAs lincIRS2 (light 
blue) and overlapping 
Gm2814 (dark b lue) . 
D o t t e d l i n e s s h o w 
genomic s i t es t o be 
cleaved by CRISPR/Cas9-
m e d i a t e d g e n o m e 
e n g i n e e r i n g . ( b ) 
Schematic representation 
of the targeted lincIRS2 
locus. Spacer sequences 
of Cas9-recruiting crRNAs 
a r e s h o w n i n r e d . 
Protospacer ad jacent 
motifs necessary for Cas9 
activi ty are shown in 
g reen . B l ack a r rows 
ind icate the genomic 
coordinates bound by 
crRNA spacer sequences. 
Scissors depict Cas9 
cutting sites (c) Agarose 
gel e lect rophores is o f 
amplified PCR products using genomic DNA isolated from 7 individual founder mice, which have been obtained by 
pronuclear injection of CRISPR/Cas9 components. M, marker; wt, C57BL/6 wildtype control mouse; H2O, no template 
control PCR. (d) Scheme of the genomic locus of founder #5, depicting the lincIRS2∆ allele with proximal and distal 
breakpoints. Blue arrows indicate PCR primers P1, P2 and P3 used for genotyping and sequencing. (e) Chromatogram 
showing the genomic DNA sequence of the lincIRS2∆ allele in comparison to the wildtype allele. 
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4.3.5. Generation of a mouse line deficient for Gm15441-exon 1 (Gm15441∆/∆) 
For gene targeting of Gm15441, we selected 20-nucleotide spacer sequences flanking a genomic 
region of 407 bp, which contains the entire exon 1 of Gm15441, yet still remains approximately 4.9 
kb away from transcriptional units of overlapping protein-coding gene Txnip (Figure 17a+b). PNI of 
CRISPR/Cas9 components into zygotes resulted in 106 viable 2-cell stage embryos, which were 
transferred into five pseudopregnant foster females, out of which four females gave birth to 18 
pups overall (Supplemental Figure 4). 
 
 
Figure 17: Generation of 
a gene-edited Gm15441∆ 
allele. 
(a) Schematic illustration 
of the targeting strategy to 
d e l e t e e x o n 1 o f 
G m 1 5 4 4 1 . B r o w n 
h is tograms represent 
RNA-Seq read counts in 
l iver of 30 weeks-old 
C57BL/6 mice. Blue boxes 
indicate annotated exons 
of lncRNA Gm15441 (light 
blue) and overlapping 
protein-coding Txnip (dark 
blue). Dotted lines show 
genomic s i t es to be 
cleaved by CRISPR/Cas9-
m e d i a t e d g e n o m e 
e n g i n e e r i n g . ( b ) 
Schematic representation 
of the targeted Gm15441 
locus. Spacer sequences 
of Cas9-recruiting crRNAs 
a r e s h o w n i n r e d . 
Protospacer ad jacent 
motifs necessary for Cas9 
activi ty are shown in 
g reen . B lack a r rows 
ind icate the genomic 
coordinates bound by 
crRNA spacer sequences. 
Scissors depict Cas9 
cutting sites. (c) Agarose 
gel electrophoresis of 
amplified PCR products 
u s i n g g e n o m i c D N A 
isolated from 18 individual 
founder mice, which have 
b e e n o b t a i n e d b y 
pronuclear injection of CRISPR/Cas9 components. M, marker; wt, C57BL/6 wildtype control mouse; H2O, no template 
control PCR. (d) Scheme of the genomic locus of founder #1, depicting the Gm15441∆ allele with proximal and distal 
breakpoints. Blue arrows indicate PCR primers P1, P2 and P3 used for genotyping and sequencing. (e) Chromatogram 
showing the genomic DNA sequence of the Gm15441∆ allele in comparison to the wildtype allele. 
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Genotyping of founder animal tail biopsies demonstrated multiple successful alterations of the 
Gm15441 locus, including truncated alleles in range of predicted deletion events, but also 
unpredicted edited alleles with slightly increased or decreased genomic sizes. Interestingly, we 
also found four founder animals lacking the wildtype Gm15441 allele, suggesting homozygous 
CRISPR/Cas9-mediated alterations of the Gm15441 locus or genomic deletions of primer binding 
sequences (Figure 17c). Genotyping of F1 and F2 offspring validated successful germline 
transmission of truncated Gm15441 alleles by four potential founder animals (#1, #6, #11 and #13). 
Strikingly, one founder animal that did not harbor truncated alleles of Gm15441 in genomic tail 
biopsy DNA (#11) was found to give rise to a stable Gm15441∆ mouse line, which reflects genetic 
mosaicism among gametic and somatic cells in the respective F0 individual. DNA sequencing of 
positive founder lines showed identical genomic compositions among sequenced animals, but also 
identified minor variations of the genomic deletions (range 411 bp - 433 bp), potentially due to 
error-prone NHEJ repair of Cas9-induced DSBs (Supplemental Figure 4). For further studies we 
selected the truncated Gm15441 allele of the first founder (#1), which is characterised by deletion 
of the targeted 407 bp genomic region and an additional loss of 13 nucleotides at the 5’ Cas9 
cutting site, ultimately resulting in a genomic deletion of 420 bp (Figure 17d+e). 
In conclusion, we demonstrated that the performed gene targeting strategy can result in the 
generation of multiple, stable Gm15441-deficient mouse lines with slightly varying genomic 
compositions, including genetic mosaicism among potential founder animals. 
4.4. Gm15441-Exon 1 deficiency does not affect fertility or Txnip expression, 
but results in ablation of Gm15441 expression 
To assess potential physiological effects of the Gm15441∆ allele, we monitored all mice of the 
selected Gm15441∆ mouse line for fecundity, genetic inheritance of the Gm15441∆ allele as well as 
for behavioural or morphological changes. 
Breeding performance of mice harboring the selected Gm15441∆ allele showed unaltered fertility 
rates and genetic inheritance of the Gm15441∆ allele with no significant deviations from Mendelian 
inheritance (Figure 18a). Additionally, neither heterozygous nor homozygous mice carrying the 
selected Gm15441∆ allele exhibited noticeable behavioural alterations or developed visible 
morphological defects.   
Gene expression analysis in livers of mice harboring wildtype, heterozygous or homozygous 
compositions of the Gm15441∆ allele identified highly significant reductions of Gm15441 transcript 
levels (range 94 % - 97 % reduction) in homozygous Gm15441∆/∆ mice, but no changes in 
Gm15441 expression in heterozygous Gm15441wt/∆ mice. Unaltered Gm15441 expression levels in 
heterozygous Gm15441wt/∆ mice indicate that the wildtype allele of Gm15441 is sufficient to 
compensate the lack of Gm15441 expression by the Gm15441∆ allele. Importantly, expression 
levels of overlapping protein-coding gene Txnip remained unaltered upon heterozygous or 
homozygous deletion of Gm15441-Exon 1 (Figure 18b). 
Taken together, we report the generation of a stable and fertile Gm15441-deficient mouse lines, 
which is characterised by almost complete absence of Gm15441 transcript expression, without 
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disruptions of the genomic locus of overlapping protein-coding gene Txnip or alterations of TXNIP 
expression levels. Yet, due to limitations in time and animal husbandry, we were not able to further 
characterise phenotypical parameters of Gm15441∆/∆ mice. 
Figure 18: Physiological 
impact of allele Gm15441∆. 
(a) Table depicting genetic 
inheritance of the truncated 
allele Gm15441∆ in breedings 
of founder animals (F0) and 
their progeny. Statistical 
differences were calculated 
using chi-squared (x2)-tests 
w i t h s i gn i f i cance l eve l 
P=0.05. (b) qPCR gene 
exp ress ion ana lys i s o f 
l n c R N A G m 1 5 4 4 1 a n d 
overlapping protein-coding 
g e n e T X N I P i n m i c e 
h a r b o r i n g w i l d t y p e 
(Gm15441wt/wt), heterozygous 
( G m 1 5 4 4 1 w t / ∆ ) o r 
homozygous (Gm15441∆/∆) 
c o m p o s i t i o n s o f t h e 
Gm15441∆ a l le le (n=3) . 
Graphs represent mean 
expression values with all 
data points shown. Statistical 
differences were calculated 
using unpaired two-tailed t-
tests (UP2T-TT).***p<0.001; 
ns, not significant. 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4.5. LincIRS2 deficiency impacts on liver energy homeostasis by regulating 
expression levels of gluconeogenic and lipogenic genes 
4.5.1. LincIRS2 deficiency does not affect fertility or body weight, but results in 
hyperglycemia in lincIRS2∆/∆ mice 
In order to evaluate putative physiological effects of the gene-edited lincIRS2∆ allele, we controlled 
all mice harboring the lincIRS2∆ allele for fecundity, genetic inheritance of the deleted allele as well 
as for changes in behaviour or morphology. Animals carrying heterozygous and homozygous 
genomic compositions of the lincIRS2∆ allele demonstrated no noticeable alterations in behaviour 
or morphology and demonstrated conventional breeding performance and genetic inheritance of 
the lincIRS2∆ allele with no significant deviations from Mendelian inheritance (Figure 19). 
 
F i g u r e 1 9 : 
Physiological impact 
of allele lincIRS2∆ (I). 
Table depicting genetic 
i n h e r i t a n c e o f t h e 
t r u n c a t e d a l l e l e 
lincIRS2∆ in breedings of 
founder animals (F0) 
a n d t h e i r p r o g e n y. 
Statistical differences 
were calculated using 
chi-squared (x2)-tests 
with significance level 
P=0.05. 
Gene expression analysis in liver showed significant reductions in lincIRS2 levels in both 
heterozygous and homozygous lincIRS2∆ mice. Interestingly, lincIRS2 expression in heterozygous 
lincIRS2wt/∆ mice was reduced to approximately half the wildtype lincIRS2 expression levels (range 
26 % - 69 % reduction), whereas lincIRS2 expression was almost completely absent (range 98 % - 
99 % reduction) in homozygous lincIRS2∆/∆ mice. This finding suggests that two wildtype alleles of 
lincIRS2 are necessary for conventional lincIRS2 expression and that one wildtype allele alone can 
not compensate for the lack of lincIRS2 expression by a lincIRS2∆ allele. Importantly, we found 
similar reductions in expression levels of overlapping lncRNA Gm2814, pointing to interconnected 
transcriptional regulation of lncRNA genes lincIRS2 and Gm2814. Identical to lincIRS2, we 
detected that Gm2814 expression was reduced to approximately half of wildtype Gm2814 
expression levels (range 45 % - 74 % reduction) in heterozygous lincIRS2wt/∆ mice and almost 
completely absent (range 98 % - 99 % reduction) in homozygous lincIRS2∆/∆ mice (Figure 20a). 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To further characterise the systemic metabolic impact of lincIRS2, we examined metabolic 
parameters in cohorts of male wildtype and male lincIRS2∆/∆ mice (n=8 each). Whereas body 
weight progression showed no differences in weight gain between wildtype and lincIRS2∆/∆ mice 
(Figure 20b), we detected significantly elevated blood glucose levels in lincIRS2∆/∆ mice (Figure 
20c). To corroborate this finding, we also measured blood glucose levels in female siblings and 
again found significantly increased levels of blood glucose in lincIRS2∆/∆ mice (Figure 20d).  
 
Figure 20: Physiological 
impact of allele lincIRS2∆ 
(II). 
(a) qPCR gene expression 
a n a l y s i s o f l n c R N A s 
lincIRS2 and Gm2814 in 
ma le m ice ha rbo r ing 
wildtype ( l incIRS2wt/wt, 
b l u e ) , h e t e r o z y g o u s 
( l i nc IRS2wt /∆ , r ed ) o r 
homozygous (lincIRS2∆/∆, 
orange) compositions of 
the lincIRS2∆ allele (n=4). 
Graphs represent mean 
expression values with all 
data points shown. (b) 
Body weight progression in 
male mice with wildtype 
( l incIRS2wt/wt, blue) or 
homozygously deleted 
( l i n c I R S 2∆ /∆ , o r a n g e ) 
lincIRS2 genotypes (n=8). 
Graphs represent mean 
body weight ± s.e.m. (c+d) 
Blood glucose levels in 11 
weeks-old male (c) and 
female (d) siblings of the 
l inc IRS2∆ mouse l ine 
homozygously carrying 
wildtype ( l incIRS2wt/wt, 
blue) or deleted (lincIRS2∆/
∆ , o range) a l le les o f 
l i n c IRS2 ( n=8 each ) . 
Graphs represent mean 
blood glucose levels with 
all data points shown. 
(e+f) Blood glucose levels 
of male mice with wildtype 
( l incIRS2wt/wt, blue) or 
homozygously deleted 
( l i n c I R S 2∆ /∆ , o r a n g e ) 
genomic compositions of 
the lincIRS2∆ allele (n=8) upon insulin (e) and glucose tolerance tests (f). The insulin tolerance test was performed with 
11 weeks-old animals, the glucose tolerance test with 12 weeks-old animals. Insulin and glucose were administered at 
timepoint 0. Graphs represent mean blood glucose levels. Statistical differences were calculated using (a+c+d) unpaired 
two-tailed t-tests (UP2T-TT) or (b+e+f) two-way ANOVA with Bonferroni post-hoc test (2WA+B). p-values are given in the 
panels. *p<0.05; **p<0.01; ***p<0.001. 
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With 11 and 12 weeks of age, respectively, we performed insulin and glucose tolerance tests with 
the cohorts of male mice to check for differential metabolic responses to intraperitoneal insulin or 
glucose administration. Indeed, lincIRS2∆/∆ mice exhibited significantly different blood glucose 
levels compared to wildtype mice in both the insulin tolerance test (Figure 20e) as well as in the 
glucose tolerance test (Figure 20f). Strikingly, 60 mins after insulin administration and 120 mins 
after glucose administration, we observed similar blood glucose levels between wildtype and 
lincIRS2∆/∆ mice, which suggests that hyperglycemia of lincIRS2∆/∆ mice can temporarily abate to 
wildtype levels. 
Taken together, metabolic characterisation of lincIRS2∆/∆ mice demonstrated significant 
hyperglycemia in both male and female lincIRS2-deficient mice and showed strong tendencies 
towards impaired insulin and glucose resistance upon lincIRS2 deficiency, all of which indicate that 
lincIRS2 is essential for physiological hepatic glucose homeostasis in vivo.  
4.5.2. Indirect calorimetry analysis indicates unaltered energy expenditure and 
substrate mobilisation in lincIRS2∆/∆ mice 
Since lincIRS2∆/∆ mice exhibit hyperglycemia, we next wanted to further survey potential metabolic 
consequences of lincIRS2 deficiency by comparing (indirect) calorimetric metabolic parameters 
between wildtype and homozygous lincIRS2∆/∆ mice (n=8 each). Three-day indirect calorimetric 
measurements of 16 weeks-old wildtype and lincIRS2∆/∆ mice demonstrated no significant 
alterations in energy expenditure or respiratory exchange ratio as proxy for lipid versus 
carbohydrate substrate mobilisation, although we observed a tendency towards higher energy 
expenditure in lincIRS2∆/∆ mice (Figure 21a+b). As energy expenditure is calculated by oxygen (O2) 
consumption and carbon dioxide (CO2) production, we consequently found tendencies towards 
increased O2 consumption and CO2 production in lincIRS2∆/∆ mice (Figure 21c+d). Of note, the 
tendencies of increased energy expenditure, O2 consumption and CO2 production in lincIRS2∆/∆ 
mice were not linked to increased nutrition or activity, as we observed similar food (Figure 21e) and 
water intake (Figure 21f) as well as overall activity (Figure 21g+h) between wildtype and lincIRS2∆/
∆ mice.  
Taken together, indirect calorimetric measurements could not detect obvious differences in energy 
expenditure or substrate mobilisation between wildtype and lincIRS2∆/∆ mice, but point to elevated 
O2 consumption and CO2 production, consequently resulting in increased energy expenditure, in 
lincIRS2∆/∆ mice. However, due to the high variance among individual mice further studies are 
necessary to evaluate potentially increased energy expenditure of lincIRS2∆/∆ mice. 
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Figure 21: Indi rect 
calorimetric analysis of 
the lincIRS2∆/∆ mouse 
line.  
T h r e e - d a y i n d i r e c t 
calorimetric determination 
of energy expenditure (a), 
respiratory exchange 
r a t i o - m e d i a t e d 
assessment of substrate 
mobilisation (b), CO2 
p r o d u c t i o n ( c ) , O 2 
consumption (d), food (e) 
and water intake (f) as 
w e l l a s m o v e m e n t 
counted in steps (g) or 
total distance covered (h) 
in 16 weeks-old mice 
h a r b o r i n g w i l d t y p e 
(lincIRS2wt/wt, black) or 
homozygous (lincIRS2∆/∆, 
orange) compositions of 
the lincIRS2∆ allele (n=8 
each). Graphs represent 
mean ± s.e.m. (a, b, c, d, 
g, h) or mean food (e) or 
water (f) with all data 
points plotted. Statistical 
d i f f e r e n c e s w e r e 
calculated using two-way 
ANOVA with Bonferroni 
post-hoc test (2WA+B). 
p-values are given in the 
panels. 
 
4.5.3. LincIRS2∆/∆ mice exhibit altered expression levels of key gluconeogenic and 
lipolytic genes 
To identify potential molecular effects affected by altered lincIRS2 transcript levels, we examined 
the expression of key metabolic genes in livers of 18 weeks-old mice harboring wildtype 
(lincIRS2wt/wt), heterozygous (lincIRS2wt/∆) or homozygous (lincIRS2∆/∆) compositions of the 
lincIRS2∆ allele (n=4). Loss of lincIRS2 expression did not significantly change expression levels of 
metabolic genes controlling glucose transport or fatty acid synthesis. However, we observed 
genotype-dependent tendencies of altered expression levels for glucose transporters SLC2A2 and 
SLC2A4 as well as for lipogenesis enzymes ACACA and SREBP1. Interestingly, expression of 
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insulin signaling proteins showed a tendency to genotype-dependent transcriptional increases, 
including derepressed expression of insulin signaling proteins IRS-1 and IRS-2 as well as 
significantly increased expression levels of insulin-responsive transcription factor FOXO1 in 
heterozygous lincIRS2wt/∆ mice. Despite high variance among individual expression levels, we also 
detected strong genotype-dependent elevations of gluconeogenesis regulatory enzymes G6PC 
and PCK1 upon heterozygous and homozygous deletion of lincIRS2, with significantly increased 
PCK1 expression in lincIRS2∆/∆ mice. In addition, fatty acid beta-oxidation rate-limiting enzymes 
ACOX1 and CPT1A demonstrated borderline significant derepressed expression levels in both 
heterozygous lincIRS2wt/∆ and homozygous lincIRS2∆/∆ mice (Figure 22). 
 
Collectively, these findings indicate multiple molecular interactions of lincIRS2 and genes 
controlling major metabolic pathways, in particular hepatic gluconeogenesis and fatty acid beta-
oxidation. Of note, monitored changes in expression levels were dependent upon the gene dosage 
of lincIRS2, as homozygous lincIRS2∆/∆ mice exhibited stronger alterations as heterozygous 
lincIRS2wt/∆ mice. However, due to the limited number of animals tested and general high variance 
among individuals, further studies with more animals numbers are needed to corroborate the 
significant findings and observed tendencies.  
 
Figure 22: Gene expression analysis of key metabolic genes in the lincIRS2∆/∆ mouse line.  
(a) qPCR gene expression analysis of key metabolic genes in livers of 18 weeks-old mice harboring wildtype (lincIRS2wt/
wt, blue), heterozygous (lincIRS2wt/∆, red) or homozygous (lincIRS2∆/∆, orange) compositions of the lincIRS2∆ allele (n=4). 
Graphs represent mean expression values with all data points shown. Statistical differences were calculated using 
unpaired two-tailed t-tests (UP2T-TT). p-values are given in the panels. *p<0.05. 
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4.5.4. Knockdown of lincIRS2 in primary hepatocytes results in altered expression 
of key metabolic genes in response to metabolic stimuli 
In order to investigate molecular interactions of lincIRS2, primary hepatocytes were isolated from 
14-18 weeks-old C57BL/6 mice, transfected with antisense oligonucleotides (ASOs) to reduce 
lincIRS2 gene expression and evaluated for expression of key metabolic genes in response to 6 
hrs metabolic stimuli (Figure 23a). Using locked nucleic acid ASOs (LNA GapmeRs [192]) 
specifically targeting the shared exon 2 of both lincIRS2 isoforms, we could significantly reduce 
lincIRS2 gene expression (range of mean reduction 46 % - 75 %) in primary hepatocytes grown in 
unsupplemented growth medium or grown in growth medium supplemented with insulin, forskolin 
and dexamethasone, or glucagon. As expected, we also observed alterations of lincIRS2 
expression levels in response to the respective metabolic stimuli, including lincIRS2 
downregulation after insulin stimulation and lincIRS2 upregulation by both fasting mimicking 
stimulations (Figure 23b).  
LincIRS2 knockdown in primary hepatocytes grown in unsupplemented control medium did not 
significantly change expression levels of key metabolic genes controlling gluconeogenesis, glucose 
transport, beta-oxidation, fatty acid synthesis or insulin signaling (Figure 23c). However, we 
detected alterations in gene expression for genes of all aforementioned metabolic processes when 
transfected primary hepatocytes were stimulated with insulin (Figure 24a), forskolin and 
dexamethasone (Figure 24b) or glucagon (Figure 24c). 
Despite high variance among biological replicates, gluconeogenesis regulatory enzymes FBP1, 
G6PC and PCK1 exhibited similar transcriptional regulations upon the respective metabolic 
stimulations, including significantly reduced insulin-induced repression of G6PC and PCK1 
expression levels as well as significantly blunted increases of G6PC and PCK1 expression levels 
upon fasting mimicking stimulations. Metabolic genes encoding for glucose transporters showed no 
significant alterations in expression levels, but tendencies to reduced insulin-induced upregulation 
of Slc2a1 and diminished glucagon-stimulated upregulation of Slc2a4 upon lincIRS2 knockdown. 
LincIRS2 knockdown did not trigger transcriptional changes of key enzymes controlling beta-
oxidation of fatty acids with the exception of CPT1A, whose expression levels were significantly 
lowered in insulin-stimulated primary hepatocytes. We observed no significant changes in 
expression levels of key enzymes involved in fatty acid synthesis upon lincIRS2 knockdown in 
insulin or forskolin and dexamethasone stimulated primary hepatocytes, yet detected significantly 
increased expression levels of ACACA and SREBP1 after glucagon stimulation. Most interestingly, 
lincIRS2 knockdown led to significantly increased expression levels of insulin signaling proteins 
IRS-1 and IRS-2 when primary hepatocytes were stimulated with glucagon.  
Collectively, these results demonstrate that lincIRS2 influences the expression of multiple key 
metabolic genes in response to anabolic and catabolic metabolic signaling. 
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F i g u r e 2 3 : G e n e 
expression analysis of 
key metabolic genes 
u p o n l i n c I R S 2 
knockdown in primary 
hepatocytes (I). 
( a ) S c h e m a t i c 
representation of the 
experimental approach 
using 14-18 weeks-old 
C 5 7 B L / 6 m i c e f o r 
i so la t ion o f p r imary 
hepatocytes, which were 
transfected with LNA 
G a p m e R a n t i s e n s e 
oligonucleotides (LNA) 
and stimulated for 6 hrs 
w i t h m e t a b o l i c 
compounds. (b) qPCR 
gene expression analysis 
of lincIRS2 expression 
levels in transfected 
primary hepatocytes, 
which have been grown 
for 6 hrs in control 
growth medium (Ctrl) or 
c o n t r o l m e d i u m 
supplemented with 10 
nM insulin (Ins), 10 µM 
forskolin and 100 nM 
dexamethasone (FD) or 
3 mM glucagon (GCG). 
Pr imary hepatocytes 
were transfected with 
scramble control LNAs or 
l i n c I R S 2 L N A s 
specif ical ly targeting 
exon 2 of the lincIRS2 
gene. Measurements for 
each biological replicate 
(n=8) were performed in 
3 technical replicates. 
The expression value for the biological replicates was calculated as mean of respective technical replicates. Graphs 
represent mean expression values with all data points shown. Statistical differences were calculated using paired two-
tailed t-tests (P2T-TT). **p<0.01; ***p<0.001. (c) qPCR gene expression analysis of key metabolic genes in transfected 
primary hepatocytes grown in control growth medium for 6 hrs. Measurements for each biological replicate (n=8) were 
performed in 3 technical replicates. Graphs represent mean expression values with all data points shown. 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F i g u r e 2 4 : G e n e 
expression analysis of 
key metabolic genes 
u p o n l i n c I R S 2 
knockdown in primary 
hepatocytes (II). 
( a - c ) q P C R g e n e 
expression analysis of 
key metabolic genes in 
t r ans fec ted p r imary 
hepatocytes grown for 6 
hrs in growth medium 
supplemented with 10 
nM insulin (a), 10 µM 
forskolin and 100 nM 
dexamethasone (b) or 3 
m M g l u c a g o n ( c ) . 
Pr imary hepatocytes 
were transfected with 
scramble control LNAs or 
l i n c I R S 2 L N A s 
specif ical ly targeting 
exon 2 of the lincIRS2 
gene. Measurements for 
each biological replicate 
(n=8) were performed in 
3 technical replicates. 
The expression value for 
the biological replicates 
was calculated as mean 
of respective technical 
r e p l i c a t e s . G r a p h s 
r e p r e s e n t m e a n 
expression values with 
all data points shown. 
Statistical differences 
were calculated using 
paired two-tailed t-tests 
(P2T-TT). p-values are 
given in the panels. *p<0.05; **p<0.01. For a legend of the respective samples see Figure 23b.  
4.5.5. Knockdown of lincIRS2 indicates impaired insulin tolerance in LNA-treated 
mice 
As genetic deletion of a lncRNA locus does not unequivocally prove that the transcript itself is 
needed for the observed effects in lincIRS2∆/∆ mice, we additionally investigated the in vivo 
consequences of lincIRS2 knockdown using anti-lincIRS2 LNAs. Biweekly injection of C57BL/6 
wildtype mice with anti-lincIRS2 LNAs significantly reduced (range 38 % - 52 % reduction) hepatic 
lincIRS2 expression (Figure 25b), with no significant alterations of body weight progression (Figure 
25c). However, in contrast to hyperglycemic lincIRS2∆/∆ mice, we did not detect changes in blood 
glucose levels between 11 weeks-old C57BL/6 mice treated with control or anti-lincIRS2 LNAs 
(Figure 25d). With 11 and 12 weeks of age, respectively, LNA-treated mice were subjected to 
insulin and glucose tolerance tests to assess differential metabolic responses to intraperitoneal 
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insulin or glucose administration. Whereas we could not observe differences in glucose clearance 
between C57BL/6 mice treated with control or anti-lincIRS2 LNAs (Figure 25f), anti-lincIRS2 LNA-
treated mice exhibited significantly lower insulin-induced reductions of blood glucose levels 
compared to control LNA-treated mice, demonstrating a strong tendency towards insulin resistance 
upon reductions of hepatic lincIRS2 transcript levels (Figure 25e). 
These results further indicate that hepatic lncNRA lincIRS2 is essential for physiological glucose 
homeostasis and demonstrate that both genomic lincIRS2 deletion and transient lincIRS2 
knockdown are sufficient to impair glucose metabolism in vivo, albeit to different degrees. 
Figure 25: Knockdown of 
lincIRS2 transcript levels 
d o e s n o t e l i c i t 
h y p e r g l y c e m i a , b u t 
impairs insulin tolerance. 
(a) Schematic representation 
o f t h e e x p e r i m e n t a l 
a p p r o a c h u s i n g m a l e 
C57BL/6 mice, which were 
biweekly injected with 10mg/
kg body weight of control or 
anti-lincIRS2 LNAs for 12 
weeks (n=8 per group). All 
mice were subjected to 
insulin tolerance (ITT, 11 
weeks of age) and glucose 
tolerance tests (GTT, 12 
weeks o f age ) be fo re 
sacrifice with 18 weeks of 
a g e . ( b ) q P C R g e n e 
express ion analys is o f 
lincIRS2 transcript levels in 
livers of male 18 weeks-old 
mice after 12 weeks of 
control (Ctrl LNA) or anti-
lincIRS2 LNA (lincIRS2 LNA) 
treatment (n=4). Graphs 
represent mean expression 
values with all data points 
shown. (c) Body weight 
progression in male C57BL/
6 mice subjected to biweekly 
injection of control (Ctrl LNA) 
or anti-lincIRS2 (lincIRS2 
LNA) LNAs (n=8). Graphs 
represent mean body weight 
± s.e.m. (d) Blood glucose 
levels in male 11 weeks-old 
C57BL/6 mice subjected to 
control (Ctrl LNA) or anti-
lincIRS2 LNA (lincIRS2 LNA) treatment. Graphs represent mean blood glucose levels with all data points shown. (e+f) 
Blood glucose levels of male C57BL/6 mice subjected to control (Ctrl LNA) or anti-lincIRS2 LNA (lincIRS2 LNA) 
treatment (n=8) upon insulin (e) and glucose tolerance tests (f). The insulin tolerance test was performed with 11 weeks-
old animals, the glucose tolerance test with 12 weeks-old animals. Insulin and glucose were administered at timepoint 0. 
Graphs represent mean blood glucose levels. Statistical differences were calculated using (b+d) unpaired two-tailed t-
tests (UP2T-TT) or (c+e+f) two-way ANOVA with Bonferroni post-hoc test (2WA+B). p-values are given in the 
panels.**p<0.01; ns, not significant. 
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4.5.6. Knockdown of lincIRS2 results in reduced AKT phosphorylation in liver 
Before sacrificing the cohorts of LNA-treated C57BL/6 mice with 18 weeks of age, we 
intraperitoneally injected control LNA-treated and anti-lincIRS2 LNA-treated mice with insulin or 
NaCl solutions to assess molecular effector mechanisms of hepatic lincIRS2 upon acute insulin 
stimulation. As expected, when performing western blotting analyses of liver protein lysates, we 
observed insulin-induced phosphorylation of protein kinase AKT in both groups of LNA-treated 
C57BL/6 mice that were in injected with insulin. However, compared to control LNA-treated mice, 
we detected significant reductions in insulin-evoked AKT phosphorylation (pAKTS473) in anti-
lincIRS2 LNA-treated mice, without changes in total AKT abundance (Figure 26). 
This finding indicates that lincIRS2 influences insulin-evoked metabolic responses by mediating 
phosphorylation of AKT. As phosphorylated AKT constitutes a direct upstream effector of 
gluconeogenic genes G6pc and Pck1, reduced AKT phosphorylation conforms with observed 
increases in expression of G6PC and PCK1 in lincIRS2-deficient mice. 
Figure 26: Reduced insulin-induced AKT phosphorylation in lincIRS2 LNA-treated mice.  
(a) Representative immunoblots of liver protein lysates isolated from 18 weeks-old C57BL/6 mice after 12 weeks of 
control LNA (Ctrl LNA) or anti-lincIRS2 LNA (lincIRS2 LNA) treatment. Before sacrifice, mice were injected with 2.5 µL/g 
bodyweight of a 0.9 % NaCl solution (NaCl) or 0.1 U/mouse insulin (n=3 per group). (b) Densitometric quantification of 
AKT phosphorylation on serine residue 473 (pAKTS473) related to total AKT (t-AKT) and Calnexin (Clnx) abundance of the 
respective samples. Graphs represent mean expression values with all data points shown. Statistical differences were 
calculated using unpaired two-tailed t-tests (UP2T-TT). ***p<0.001. 
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Chapter 5 - Discussion 
5.1. Hepatic lncRNA expression adapts to chronic and acute nutrient 
challenges  
In order to shed light on the global regulation of lncRNAs in response to metabolic conditions, such 
as chronic obesity, type 2 diabetes mellitus (T2DM) or short-term alterations of nutrient availability, 
we performed RNA-Sequencing (RNA-Seq) in livers of mouse models for chronic obesity and 
short-term alterations of nutrient availability as well as in human liver biopsies. 
As a model system for chronic obesity, we exposed 6 weeks-old C57BL/6 mice for 30 weeks to 
high-fat diet (HFD) or low-fat diet (normal chow diet, NCD) feeding. As an independent model 
system for chronic obesity, we additionally used 10 weeks-old LepRdb/db mutant mice, a widely 
used genetic model for obesity and T2DM [215], and their control breeding strain, 10 weeks-old 
Dock7m/m mutant mice [216]. When analysing differential gene expression of the respective model 
systems, we detected 50 hepatic lncRNAs significantly altered between HFD- and NCD-fed mice 
and 83 hepatic lncRNAs that exhibited significant differential expression levels between LepRdb/db 
and Dock7m/m mutant mice. Global comparison of hepatic expression levels demonstrated a 
significant overrepresentation of downregulated lncRNAs compared to protein-coding mRNAs in 
response to HFD feeding and we could also observe the same anticorrelative global trend of 
lncRNA downregulation and mRNA upregulation in the genetic-evoked obesity model system, 
albeit less pronounced than in the diet-induced obesity model system. 
To assess rapid transcriptional alterations of hepatic transcript expression upon short-term 
changes in nutrient availability, we performed RNA-Seq in livers of 16 weeks-old C57BL/6 mice 
that were subjected to 16 hrs ad libitum feeding, 16 hrs fasting or 16 hrs fasting followed by 6 hrs 
of ad libitum refeeding. Differential gene expression analysis detected 92 lncRNAs with altered 
hepatic expression levels between fasted and ab libitum-fed mice and 59 lncRNAs that were 
differentially expressed in livers of refed mice compared fasted mice. In line with the expression 
data of the chronic obesity mouse models, we again observed pronounced opposite transcriptional 
regulations for lncRNA and mRNA transcripts when comparing global differential gene expression. 
Global hepatic lncRNA regulation was significantly upregulated in fasted mice compared to ad 
libitum fed mice, whereas hepatic mRNAs showed a tendency to global downregulation upon 
fasting. Between refed mice and fasted mice, we observed an inverted trend to the fasting-induced 
upregulation of lncRNAs, including global downregulation of lncRNA and global upregulation of 
mRNA transcript expression.  
To corroborate the findings of the murine RNA-Seq data sets, we finally performed RNA-Seq of 
human liver biopsies from a well-characterised cohort of lean, obese and T2DM patients [193]. 
Differential gene expression analysis detected 297 hepatic lncRNA transcripts that were 
differentially regulated between lean and obese patients. In addition, we identified 504 hepatic 
lncRNA transcripts that exhibited altered expression levels between lean and diabetic patients. 
Consistent with the results of the murine RNA-Seq data sets, we again observed opposite 
transcriptional regulations for lncRNAs and mRNAs in liver biopsies of the respective groups, 
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including a highly significant global downregulation of lncRNAs compared to mRNAs between lean 
and obese patients as well as between lean and T2DM. 
Taken together, our extensive RNA-Seq analyses revealed that both chronic and acute nutrient 
challenges elicit alterations of hepatic lncRNA expression levels. We interpret these transcriptional 
changes in liver as consequence of the respective metabolic status, which in turn elicits 
adaptations of lncRNA expression to adjust metaboregulatory signaling circuits. As regulation of 
global lncRNA expression demonstrated significant downregulations in chronic obesity mouse 
models as well as in liver biopsies of metabolically compromised humans, we conclude that global 
lncRNA downregulation is associated with obesity-associated, metabolic impairments. However, if 
this global lncRNA repression constitutes a cause or consequence of the respective metabolic 
status remains to be investigated in further studies. 
We also observed a significant global upregulation of hepatic lncRNA expression after 16 hrs of 
fasting and an inverted trend of global lncRNA downregulation when fasted mice were allowed to 
refeed for 6 hrs. This observation conforms with a previous study showing that the fasting-induced 
(24 hrs) upregulation of 237 hepatic lncRNAs were completely reversed by 4 hrs of refeeding [172], 
ultimately suggesting that lncRNA expression in liver is tightly and dynamically controlled in 
response to short-term alterations of nutrient availability. 
Most interestingly, all RNA-Seq analyses identified a pronounced anticorrelative transcriptional 
regulation of lncRNAs and protein-coding mRNAs in liver. This finding not only indicates that the 
global regulation of lncRNA expression is independent from global mRNA expression, but also 
points to differences in the global genomic architecture of lncRNA and mRNA genes that could 
explain the differential transactivation by nutrient-sensitive signaling pathways. However, further 
studies are needed to identify the common gene architectures of metabolically-relevant lncRNA 
genes and the upstream effectors integrating nutritional cues into the global regulation of lncRNAs. 
5.2. Selection procedure for liver-enriched lncRNAs proves sufficient to 
identify metabolically-instructive candidate transcripts 
To identify metabolically-relevant lncRNAs that partake in the regulation of hepatic energy 
homeostasis, we designed a selection procedure considering 5 characteristics of lncRNA 
transcripts. The evaluated lncRNA characteristics included liver-specific expression, biological 
regulation across obesity and differentially-fed mouse models, predicted protein-coding potential, 
subcellular localisation of the RNA products as well as transcriptional regulation upon metabolic 
stimuli. 
For identification of liver-specific lncRNAs, we analysed RNA-Seq data of seven metabolically 
active tissues of a NCD-fed cohort of 17-18 weeks-old C57BL/6 mice [221] and selected lncRNA 
transcripts, whose RNA-Seq reads were predominantly found in the liver samples. After 
considering significant regulations of the selected transcripts in the RNA-Seq data sets of both 
mouse models of chronic obesity as well as proper alignment to annotated genes, we identified 15 
lncRNA transcripts for further characterisations. Of note, during the course of this study, one of the 
selected transcripts (C730036E19Rik) was described as lncLSTR, a liver-enriched transcript which 
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regulates liver lipid metabolism and whose expression is significantly reduced in mice fasted for 24 
hrs, but recovered when fasted mice were allowed to refeed for 4 hrs [165]. This report is in line 
with the transcriptome data achieved in our study and provides an independent indication that the 
selected lncRNA candidates contain metabolically-relevant transcripts. As our RNA-Seq results 
could be affected by the low expression levels of most of our selected lncRNAs, we examined 
tissue-specific expression levels of the selected candidates by qPCR gene expression analysis in 
seven metabolically relevant tissues of 17-18 weeks-old NCD-fed C57BL/6 mice. Indeed, we found 
two candidates with pronounced expression in several non-hepatic tissues, but confirmed liver-
specific expression of the remaining lncRNAs. 
Differential expression of the selected lncRNAs across obesity and differentially-fed mouse models 
was analysed via qPCR gene expression analysis and identified significant regulations for the 
majority of the selected lncRNAs. Strinkingly, we observed that fasting-induced transcriptional 
alterations of most of the lncRNAs were reversed when fasted mice were allowed to re-feed for 6 
hrs, which further suggests dynamic transcriptional regulation of metaboregulatory lncRNAs in 
response to short-term changes in nutrient availability. 
Since several recent studies reported lncRNA genes to encode for micropeptides [223, 224], we 
utilised two independent, web-based algorithms to predict the coding capacities of our selected 
lncRNAs [196, 197]. Remarkably, two selected lncRNAs exhibited protein-coding potential, 
whereas the remaining lncRNA candidates were not predicted to encode for (micro-)peptides. 
Due to their abundant expression in multiple non-hepatic tissues or their predicted potential to 
encode for proteins, we discarded four lncRNA candidates and further characterised the remaining 
11 lncRNAs by assessing the subcellular localisation of their transcripts in nuclear and cytoplasmic 
fractions of primary hepatocytes. We observed that most of the transcripts were predominantly 
found in nuclear fractions, while only one gene product strongly accumulated in cytoplasmic 
fractions. Of note, we also found several candidates with noticeable expression in both subcellular 
fractions, which indicates that the corresponding transcripts execute multiple functions in both the 
nuclear and cytoplasmic compartments. 
Lastly, we investigated the transcriptional responses of four manually selected lncRNAs in primary 
hepatocytes upon 6 hrs stimulation with insulin or fasting-mimicking metabolites forskolin and 
dexamethasone. While we could not detect insulin-induced alterations in gene expression for 
B930025P03Rik and Gm13775, we monitored significantly repressed expression levels of 
4833411C07Rik and Gm15441 upon insulin stimulation. In addition, 4833411C07Rik and 
Gm15441 were also found to be strongly regulated in response to fasting mimicking stimulation, 
albeit with different transcriptional consequences, as fasting stimulation elicited upregulation of 
4833411C07Rik, but downregulation of Gm15441. 
In conclusion, the evaluated characteristics of our selection procedure proved sufficient to identify 
two hepatic lncRNAs that are strongly affected by chronic obesity, alterations in feeding status and 
metabolic stimuli. However, also the other transcripts identified by our selection procedure could 
constitute impactful metabolic lncRNAs, as demonstrated for C730036E19Rik [165], and should be 
investigated in further studies. Remarkably, the list of lncRNAs identified by our selection 
procedure did not contain previously reported regulators of hepatic energy homoeostasis 
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4632424N07 (termed lncLGR [166]), Gm10768 [173] or Gm16551 [172]. Yet, all of these lncRNAs 
were identified after fasting mice for 16 hrs or 24 hrs, respectively, and not upon chronic obesity as 
performed in our study. Most interestingly, the two lncRNAs 4833411C07Rik and Gm15441, which 
we selected for further molecular studies, were also identified in another report during the course of 
our study [173]. In that report, 4833411C07Rik and Gm15441 were identified as fasting-induced 
hepatic lncRNAs, which were strongly unregulated upon a 16 hrs fasting regime. These findings 
conform with the upregulated expression of 4833411C07Rik and Gm15441 that we detected in our 
RNA-Seq data of 16 hrs fasted mice and provide an independent indication that our selection 
procedure is sufficient to identify metaboregulatory hepatic lncRNAs. 
5.3. Successful generation of in vivo mouse models to study lncRNA-
mediated metabolic networks 
To study the systemic impact of lncRNAs 4833411C07Rik (termed lincIRS2) and Gm15441 on liver 
energy homeostasis, we wanted to generate in vivo mouse models devoid of lincIRS2 or Gm15441 
expression, respectively, using CRISPR/Cas9-mediated genome engineering. For precise design 
of targeting strategies, we complemented our liver-specific RNA-Seq data sets with publicly 
available liver chromatin immunoprecipitation sequencing (ChIP-Seq) data for histone 3 lysine 4 
trimethylation (H3K4me3) and histone 3 lysine 27 acetylation (H3K27ac) chromatin marks, both of 
which are associated with active transcription of nearby genes [225]. 
The genomic lincIRS2 locus demonstrated liver-specific expression in our RNA-Seq data sets, but 
also showed expression of another hepatic lncRNA, Gm2814, which is located in antisense 
direction on the opposing DNA strand and overlaps with exon 2 of lincIRS2. Of note, both lncRNA 
genes exhibited identical transcriptional regulations in both mouse models for chronic obesity, 
which indicates a putative conjoint expression of both genes by common regulatory genomic 
elements. When considering the publicly available ChIP-Seq data sets, we found H3K4me3 
chromatin marks in close proximity to the transcriptional start sites (TSSs) of lincIRS2 and Gm2814 
as well as broad H3K27ac chromatin marks along the respective gene bodies. We interpreted 
these accumulations of epigenetic histone modifications as reflections of active gene expression of 
both lncRNA genes in liver and considered the elimination of genomic sites with chromatin mark 
accumulations as advantaged aspect of possible targeting strategies. As we aimed to impact both 
isoforms expressed by lincIRS2, which differ in exon 3 and exon 4 composition, we decided to 
exclusively delete shared exon 1 to disrupt lincIRS2 expression. Importantly, this targeting 
approach avoids removal of Gm2814 transcriptional units, yet also results in collateral deletion of 
genomic sites with accumulation of H3K4me3 and H3K27ac chromatin marks.  
For lncRNA Gm15441, we designed a very similar targeting strategy, as our RNA-Seq data also 
revealed expression of another transcript overlapping the Gm15441 gene locus in antisense 
direction on the opposing DNA strand. Most interestingly, the overlapping gene is the well-studied 
protein-coding gene Txnip, which has been implicated in modulating energy metabolism by 
regulating cellular redox balance [226], hepatic glucose production [227] and diabetes in humans 
[228]. Tissue-specific RNA-Seq data sets demonstrated ubiquitous expression of Txnip in multiple 
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tissues, while Gm15441 expression was predominantly restricted to liver, but could also be found 
in kidney, albeit to lesser extent. Liver-specific ChIP-Seq data showed accumulations of H3K4me3 
and H3K27ac chromatin marks in close proximity to the Txnip TSS and along its gene body, but 
only marginal chromatin marks for active transcription at the Gm15441 TSS. As this finding did not 
indicate associations of Gm15441 expression with H3K4me3 or H3K27ac chromatin marks, we did 
not consider the removal of genomic sites with chromatin mark accumulations to disrupt Gm15441 
expression. Instead, and with respect to avoid disruptions of the Txnip locus, we decided to 
exclusively remove the genomic region encoding for exon 1 of Gm15441. 
By using two web-based algorithms to design guideRNA (gRNA) sequences for CRISPR/Cas9 
gene targeting, we identified several suitable spacer sequences flanking the first exons of lincIRS2 
and Gm15441, respectively. Considering differences in target specificity and potential off-target 
effects, we selected two 20-nucleotide and two 18-nucleotide spacer sequences for each 5’- and 
3’end of the genomic regions to be targeted and evaluated spacer sequence activity in vitro using 
sequence-specific T7 Endonuclease I assays and genotyping PCRs. Collectively, we could validate 
genome-editing capacity of four 20-nucleotide and five 18-nucleotide spacer sequences and 
decided to use the 20-nucleotide spacer sequences for the generation of lncRNA-deficient in vivo 
mouse models in order to maximise sequence-specific target recognition. 
The lincIRS2∆ mouse line 
The generation of in vivo lncRNA mouse models was performed utilising zygote pronuclear 
injection (PNI) of CRISPR/Cas9 components, including Cas9 protein, Cas9 mRNA and the 
respective target-specific gRNA components [217]. PNI using lincIRS2-targeting spacer sequences 
resulted in 7 pups, in which we could only detect a truncated lincIRS2 allele with the expected size 
for a successful deletion event in one of the founder animals. Importantly, genotyping PCRs also 
showed the deleted lincIRS2 allele in progeny of the previously mentioned founder animal, which 
demonstrated germline transmission of the edited allele. Yet, we could not detect edited lincIRS2 
alleles in the other founder animals or their offspring. To confirm the establishment of a new 
genome-edited mouse line, we examined the composition of the targeted genomic locus in the 
positive founder animal as well as in its F1 and F2 offspring. Indeed, DNA sequencing revealed 
identical genomic compositions among 21 sequenced animals and identified that our targeting 
approach led to a 422 bp genomic deletion, including the targeted 415 bp genomic region as well 
as 13 additional basepairs close to the 5’ Cas9 cutting site. We interprete the loss of additional 
basepairs at the 5’ Cas9 cutting site as consequence of multiple repair procedures of Cas9-
induced double strand breaks, which is a common phenomena in CRISPR/Cas9 technology [176], 
but does not impinge on our targeting strategy.  
When surveying physiological parameters of mice carrying the gene-edited lincIRS2∆ allele, we did 
not detect noticeable alterations in behaviour or morphology and found conventional breeding 
performance as well as genetic inheritance of the lincIRS2∆ allele with no significant deviations 
from Mendelian inheritance. Importantly, hepatic expression levels of lincIRS2 were significantly 
reduced in both heterozygous and homozygous lincIRS2∆ mice. Yet, whereas lincIRS2 expression 
was almost completely absent in homozygous lincIRS2∆/∆ mice, lincIRS2 expression was reduced 
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to approximately half of the wildtype lincIRS2 expression in heterozygous lincIRS2wt/∆ mice. This 
finding strongly indicates that both wildtype alleles of lincIRS2 are necessary for conventional 
lincIRS2 expression and that one wildtype allele alone is not sufficient to compensate for the lack 
of lincIRS2 expression by the lincIRS2∆ allele. Remarkably, we also detected reductions in the 
expression levels of overlapping lncRNA Gm2814, which were similar to the respective reductions 
of lincIRS2 in heterozygous and homozygous lincIRS2∆ mice. This observation points to an 
interconnected transcriptional regulation of lncRNA genes lincIRS2 and Gm2814, most probably by 
a common bidirectional promotor, parts of which have been removed by our genomic deletion. 
The Gm15441∆ mouse line 
PNI of CRISPR/Cas9 components using Gm15441-targeting spacer sequences resulted in 18 
pups, some of which exhibited multiple alterations of the Gm15441 locus, including truncated 
alleles in range of predicted deletion events, but also unpredicted edited alleles with slightly 
increased or decreased genomic sizes. Remarkably, we also observed four founder animals 
lacking the wildtype Gm15441 allele, which indicates homozygous CRISPR/Cas9-induced 
alterations of the Gm15441 locus or genomic deletions of primer binding sequences. When 
genotyping F1 and F2 offspring, we validated germline transmission of truncated Gm15441 alleles 
in four founder animals. Of note, one of the founders giving rise to a stable Gm15441∆ mouse line 
did not show truncated alleles of Gm15441 in genomic tail biopsy DNA, which demonstrates 
genetic mosaicism among gametic and somatic cells in the respective F0 individual. Identical 
genomic compositions among animals of the same founder line was successfully validated by DNA 
sequencing. However, we found minor variations of the targeted genomic deletions between all 
four founder lines, reflecting the error-prone repair of Cas9-induced DNA damage by endogenous 
cellular repair systems [177]. For further metabolic studies, we maintained one founder mouse line, 
which is defined by a 420 bp genomic deletion, including the targeted 407 bp genomic region as 
well as 13 additional nucleotides at the 5’ Cas9 cutting site. 
Homozygous as well as heterozygous mice carrying the selected gene-edited Gm15441∆ allele 
displayed no alterations in conventional fertility rates or exhibited obvious behavioural or 
developmental abnormalities. Additionally, the Gm15441∆ allele was inherited across generations 
with no significant deviations from Mendelian inheritance. Intriguingly, we detected highly 
significant reductions of Gm15441 expression levels in livers of homozygous Gm15441∆/∆ mice, yet 
did not observe changes of Gm15441 expression in heterozygous Gm15441wt/∆ mice. This 
remarkable finding demonstrates that one wildtype allele of Gm15441 is sufficient for conventional 
Gm15441 transcript levels, which points to monoallelic expression of the Gm15541 gene locus, as 
already described for some mammalian genes [221, 231], or compensatory feedback mechanisms 
that trigger transcriptional adaptations to meet physiological demands, which has been reported for 
several zebrafish and mouse models [232]. Most importantly, we did not observe transcriptional 
changes of overlapping protein-coding gene Txnip in heterozygous or homozygous Gm15441∆ 
animals, which displays successful abrogation of Gm15441 expression, without perturbing 
expression of the adjacent Txnip locus. 
Taken together, we demonstrate that the used protocols can result in the generation of multiple, 
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stable lncRNA-deficient mouse lines with slightly varying genomic compositions. Remarkably, 
deletion of the targeted genomic regions resulted in almost complete ablation of target lncRNA 
expression, but did not impact on fertility or elicit noticeable alterations in behaviour or 
development. In light of this, we conclude that the generated mouse models represent powerful 
model systems for in vivo characterisations of lncRNA-mediated signaling networks in hepatic 
metabolism. 
5.4. Genetic lincIRS2 deficiency results in hyperglycemia and impacts on 
expression of key metabolic enzymes 
To identify systemic metabolic consequences of genetic lncIRS2 deficiency, we compared 
metabolic parameters between cohorts of lincIRS2∆/∆ mice with C57BL/6 mice. While we could not 
detect differences in body weight progression until 18 weeks of age, we found significantly 
increased blood glucose levels in male and female 11 weeks-old lincIRS2∆/∆ mice.  
When performing intraperitoneal insulin and glucose tolerance tests at 11 and 12 weeks of age, 
respectively, we found that the previously observed defects in glycemic control of lincIRS2∆/∆ mice 
sustained after insulin and glucose challenges. Remarkably, 60 mins after insulin administration 
and 120 mins after glucose administration, we monitored similar blood glucose levels between 
C57BL/6 and lincIRS2∆/∆ mice, indicating that hyperglycemia of lincIRS2∆/∆ mice can temporarily 
abate to wildtype levels. 
We next surveyed indirect calorimetric parameters between wildtype and homozygous lincIRS2∆/∆ 
mice, which could explain the hyperglycemia in lincIRS2∆/∆ mice. Three-day measurements of 16 
weeks-old mice of the respective cohorts did not detect significant changes in energy expenditure 
or lipid versus carbohydrate substrate mobilisation. Yet, we observed a tendency towards higher 
rates of oxygen consumption and carbon dioxide production, and thus a tendency towards higher 
overall energy expenditure, in lincIRS2∆/∆ mice, which was not associated with increased nutrition 
or activity. However, owing to high biological variance among individuals in our study, further 
studies are necessary to examine possible increases in energy expenditure of lincIRS2∆/∆ mice.  
In order to assess putative transcriptional alterations, which could account for the observed 
hyperglycemia in lincIRS2∆/∆ mice, we evaluated the expression of key metabolic genes in livers of 
18 weeks-old C57BL/6 and heterozygous as well as homozygous lincIRS2∆ mice. Although 
lincIRS2 deficiency did not result in significantly altered expression levels of metabolic genes 
encoding for glucose transporters or enzymes regulating fatty acid synthesis, we detected 
genotype-dependent changes in expression levels of genes controlling fatty acid beta-oxidation, 
insulin signaling and hepatic gluconeogenesis. Fatty acid beta-oxidation rate-limiting enzymes 
ACOX1 and CPT1A as well as insulin signaling proteins IRS-1, IRS-2 and FOXO1 displayed 
tendencies to elevated expression levels in both heterozygous lincIRS2wt/∆ and homozygous 
lincIRS2∆/∆ mice. Strikingly, we also detected strong genotype-dependent elevations of 
gluconeogenesis regulatory enzymes G6PC and PCK1 upon heterozygous and homozygous 
deletion of lincIRS2, which could explain hyperglycemia of lincIRS2∆/∆ mice due to increased rates 
of hepatic glucose production.  
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Collectively, the metabolic characterisation of lincIRS2∆/∆ mice demonstrated that genetic lincIRS2 
deficiency results in the development of significant hyperglycemia, including strong trends towards 
impaired insulin and glucose resistance and no significant differences in energy expenditure or lipid 
versus carbohydrate substrate mobilisation. Furthermore, genetic lincIRS2 deficiency impacted on 
the regulation of key metabolic genes controlling hepatic gluconeogenesis and fatty acid beta-
oxidation, which could constitute alterations in metaboregulatory networks that ultimately lead to 
the observed hyperglecemia in lincIRS2∆/∆ mice. As heterozygous and homozygous lincIRS2 
deficiency resulted in derepressed gluconeogenic G6pc, Pck1 and Foxo1 as well as lipogenic 
Acox1 and Cpt1a gene expression, we concluded that lincIRS2 is essential for the physiological 
control of hepatic glucose and lipid homeostasis in vivo. 
5.5. Reduction of lincIRS2 levels affects gluconeogenic and lipogenic gene 
expression and reduces insulin-mediated AKT phosphorylation 
As genetic lincIRS2-deficiency does not unequivocally prove that the lincIRS2 transcript accounts 
for the observed alterations in metabolic signaling pathways, we monitored the transcriptional 
regulations of the previously examined set of key metabolic genes upon conditions of reduced 
lincIRS2 expression levels and in response to 6 hrs metabolic stimulations. We isolated primary 
hepatocytes from 14-18 weeks-old C57BL/6 mice and could significantly reduce lincIRS2 transcript 
levels using anti-lincIRS2 LNAs. When analysing primary hepatocytes grown in control medium, 
we did not detect changes in expression of key metabolic genes upon lncIRS2 knockdown. 
However, we observed alterations in transcriptional regulations of metabolic genes when LNA-
treated primary hepatocytes were stimulated with insulin, glucagon or fasting mimicking 
metabolites forskolin and dexamethasone. Whereas genes encoding for glucose transporters 
displayed no significant changes in gene expression upon lincIRS2 knockdown in stimulated 
primary hepatocytes, we detected significantly elevated expression levels of fatty acid synthesis-
controlling enzymes ACACA and SREBP1 in LNA-treated primary hepatocytes upon glucagon 
stimulation, suggesting that lincIRS2 mediates glucagon-triggered increases of lipogenesis. In line 
with the previous gene expression analysis of lincIRS2∆/∆ mice, we also found transcriptional 
alterations of metabolic genes controlling fatty acid beta-oxidation, insulin signaling and 
gluconeogenesis upon lincIRS2 reduction in primary hepatocytes. This included significant 
changes in expression of lipolytic enzyme CPT1A upon insulin stimulation as well as significantly 
increased levels of insulin signaling proteins IRS-1 and IRS-2 when LNA-treated primary 
hepatocytes were stimulated with glucagon. Most interestingly, lincIRS2 knockdown in primary 
hepatocytes resulted in significantly altered expression levels of gluconeogenesis regulatory 
enzymes G6PC and PCK1, including reduced insulin-evoked gene repressions and lowered 
fasting-induced elevations in gene expression. We interpret these findings as additional evidence 
that lincIRS2 interacts with multiple metabolic signaling pathways, as already observed in 
lincIRS2∆/∆ mice. These experiments furthermore indicate that lincIRS2 impacts on transcriptional 
alterations of gluconeogenic, lipolytic and lipogenic genes in response to anabolic and catabolic 
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metabolic stimuli, which could explain the impaired glucose homeostasis upon genetic lincIRS2 
deletion. 
To investigate the systemic metabolic consequences of lincIRS2 knockdown in vivo, we biweekly 
injected C57BL/6 mice with control or anti-lincIRS2 LNAs and compared the same metabolic 
parameters between the respective cohorts of mice, as previously done with lincIRS2wt/wt and 
lincIRS2∆/∆ mice. In anti-lincIRS2 LNA-treated mice, we observed no significant changes in body 
weight gain and could not detect elevations in blood glucose levels, as found in hyperglycemic 
lincIRS2∆/∆ mice, which indicates that reducing lincIRS2 transcript levels is not sufficient to cause 
systemic hyperglycemia in vivo. When performing intraperitoneal insulin and glucose tolerance 
tests at 11 and 12 weeks of age, respectively, we observed no differences in glucose clearance 
between mice treated with control or anti-lincIRS2 LNAs, but a strong tendency towards insulin 
resistance upon lincIRS2 reduction, as seen in lincIRS2∆/∆ mice. In line with the genetic loss of 
lincIRS2, these results corroborate the conclusion that lincIRS2 is essential for physiological 
glucose homeostasis and demonstrate that both genomic lincIRS2 deletion and transient lincIRS2 
knockdown lead to impaired glucose metabolism in vivo. 
Before sacrifice at 18 weeks of age, we intraperitoneally injected LNA-treated mice with insulin or 
NaCl solutions to examine lincIRS2-mediated differences in insulin-induced phosphorylation of 
protein kinase AKT, the major signaling protein controlling liver energy homeostasis. As expected, 
we observed strong elevations of AKT phosphorylation at serine residue 473 (pAKTS473) upon 
acute insulin stimulation in both groups of LNA-treated mice. However, when we compared AKT 
phosphorylation between control LNA and anti-lincIRS2 LNA treated mice, we detected significant 
reductions in insulin-evoked AKT phosphorylation in anti-lincIRS2 LNA-treated mice, without 
changes in total AKT abundance. Since pAKTS473 represents a direct upstream effector regulating 
expression of gluconeogenic genes G6pc and Pck1, this finding suggests that lincIRS2 deficiency 
causes dampened insulin-induced AKT phosphorylation and in turn results in increased expression 
of G6pc and Pck1, as observed in anti-lincIRS2 LNA-treated primary hepatocytes and lincIRS2-
deficient mice. 
In conclusion, these results demonstrate that reductions of lincIRS2 transcripts cause differences 
in transcriptional regulations of key metabolic genes in response to anabolic and catabolic 
metabolic signaling and lead to impaired glucose metabolism in vivo. Furthermore, lowered AKT 
phosphorylation upon lincIRS2 transcript reduction indicates that lincIRS2 is not only essential for 
proper glucose homeostasis, but also for insulin-evoked suppression of hepatic glucose production 
in vivo, which conforms with hyperglycemia development in lincIRS2∆/∆ mice. 
Collectively, we propose the concept that nutrient-sensitive lncRNA lincIRS2 is transcriptionally 
coupled to alterations of systemic nutrient states and controls liver energy homeostasis by 
impacting on insulin-induced phosphorylation of AKT and on transcriptional regulations of 
gluconeogenic, lipolytic and lipogenic genes in response to anabolic or catabolic metabolic 
signaling. 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5.6. Future Perspectives 
Our extensive RNA-Seq analyses demonstrated global regulations of hepatic lncRNAs in response 
to chronic and acute nutrient challenges as well as pronounced anticorrelative transcriptional 
regulations of lncRNAs and protein-coding mRNAs. As all of these findings indicate global 
transcriptional regulations of lncRNAs, which appear to be independent of protein-coding mRNA 
regulation, the role of lncRNA-specific upstream effector pathways needs to be addressed in future 
studies to identify transcription factors that facilitate adaptations of lncRNA expression. However, a 
simultaneous regulation of hundreds or thousands of lncRNA transcripts relies on the presence of 
common regulatory genomic elements within the respective lncRNA genes, and thus also the 
global genomic architecture of lncRNA loci, including transcription factor binding sites, proximal 
and long-range enhancers as well as accumulations of epigenetic marks and the overall chromatin 
state, should be investigated in more detail. Our RNA-Seq studies provide a rich source of global 
transcriptome data across different metabolic states and hence could be used to assess lncRNA-
specific regulatory genomic elements. 
When applying our selection criteria to the obtained transcriptome data, we identified 15 lncRNAs 
that are differentially regulated upon chronic obesity. Yet, we only selected two transcripts for 
further investigations and the remaining transcripts could also constitute metabolically-relevant 
mediators, as demonstrated in case of lncRNA candidate C730036E19Rik [165]. In addition, more 
lncRNA regulators of metabolism can be identified by our RNA-Seq studies, as our initial candidate 
selection procedure was only based on the chronic obesity RNA-Seq data, but not on the RNA-Seq 
data from differentially-fed mice. As shown by previous reports [172, 173], numerous lncRNAs are 
transcriptionally induced by fasting and thus hitherto undiscovered lncRNAs partaking in the 
regulation of cellular energy homeostasis can also be found in further analyses of our RNA-Seq 
data sets from differentially-fed mice.  
 
The Gm15441∆ mouse model system 
During the course of this study, we generated an in vivo mouse model lacking exon 1 of lncRNA 
Gm15441 and demonstrated that this genomic deletion resulted in significant reductions in 
Gm15441 expression, without affecting expression of the adjacent protein-coding Txnip locus. 
However, we were not able to further characterise the systemic metabolic characteristics of 
Gm15441∆/∆ mice and further studies need to be conducted to evaluate putative consequences of 
genetic Gm15441 deletion on liver energy homeostasis, including gene expression analysis of key 
metabolic genes as well as monitoring systemic metabolic parameters of Gm15441∆/∆ mice. 
Importantly, although Gm15441∆/∆ mice did not display alterations in Txnip expression, the 
consequences of Gm15441 deficiency on TXNIP protein levels should be assessed by western 
blotting analysis, as recent studies reported that lncRNAs can control mRNA translation of 
overlapping protein-coding genes at the post-transcriptional level [233, 234]. Of note, the 
transcriptional units of Gm15441 contain the required functional RNA sequences, which have been 
shown to trigger increased mRNA translation of overlapping protein-coding genes, and a previous 
study also predicted that translation of Txnip would be affected by Gm15441 transcripts [235]. 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The lincIRS2∆ mouse model system 
We successfully generated an in vivo mouse model devoid of lincIRS2 expression and showed that 
genetic loss of exon 1 of lincIRS2 results in impaired glucose homeostasis and insulin-evoked 
suppression of hepatic glucose production in vivo. Yet, the genomic deletion also abrogated 
expression of overlapping lncRNA Gm2814, although transcriptional units of Gm2814 were not 
affected by our genomic deletion. For this reason, we can not exclude the possibility that removal 
of Gm2814 expression partly contributes to the observed hyperglycemic and insulin-intolerant 
phenotype of lincIRS2∆/∆ mice. Hence, further studies are needed to validate that the observed 
physiological effects can be solely attributed to the genetic loss of lincIRS2 expression, such as 
gene expression analysis of metabolic gene expression in primary hepatocytes upon LNA-
mediated knockdown of Gm2814 or metabolic characterisations of anti-Gm2814 LNA-treated mice. 
In our in vivo studies, we observed reductions in insulin-evoked AKT phosphorylation upon 
lincIRS2 knockdown and linked this phenomena to altered expression levels of gluconeogenic, 
lipolytic and lipogenic genes. Yet, phosphorylated AKT also directly impacts on several other 
metabolically-relevant downstream targets, such as GSK-3, which regulates glycogen synthesis 
[116], and TSC-2, which controls cell growth and protein synthesis via mTORC1 [117]. Thus, 
lincIRS2∆/∆ mice or lincIRS2∆/∆ primary hepatocytes can be used to identify the impact of lincIRS2 
deficiency on glycogen metabolism, proliferation markers and protein homeostasis. As 
phosphorylation of AKT at serine residue 473 is mediated by mTORC2, which itself is regulated by 
insulin and nutrient availability [115], possible consequences of lincIRS2 deficiency on mTORC2 
expression, abundance or function can also be addressed using our lincIRS2∆/∆ mouse model. In 
addition to mTORC1 and mTORC2, lincIRS2∆/∆ primary hepatocytes can be analysed with regard 
to alterations in abundance or phosphorylation of other major metabolic signaling proteins, such as 
FOXO1, IRS-1 and IRS-2. Due to its close genomic positioning to lincIRS2 and a common 
transcriptional regulation across mouse models of obesity and differential feeding, Irs2 in particular 
represents a possible interaction partner of lincIRS2 and can be investigated in western blotting 
analysis of lincIRS2∆/∆ primary hepatocytes or livers of lincIRS2∆/∆ mice. 
We detected alterations in gene expression of lipolytic and lipogenic genes upon lincIRS2 
deficiency as well as reductions in insulin-evoked AKT phosphorylation, which besides to 
gluconeogenesis also controls lipogenesis [117]. Thus, lincIRS2∆/∆ mice can also be used to further 
elucidate the impact of lincIRS2 on lipid homeostasis, for instance by monitoring lipid production 
and systemic levels of circulating fatty acids in vivo. Ultimately, lincIRS2∆/∆ mice can be exposed to 
high-fat diet feeding and examined in regard to ameliorated or aggravated phenotypes of systemic 
glucose and lipid homeostasis. 
Considerations to detect molecular interaction partners of Gm15441 and lincIRS2 
To further explore global consequences of Gm15441 and lincIRS2 deficiency, livers from the 
respective in vivo mouse models can be utilised for protein mass spectrometry [236], RNA-Seq or 
ChIP-Seq studies, which could display potential differences in protein abundance, gene expression 
or chromatin modifications, respectively. Of note, primary hepatocytes of the respective mouse 
models can not only be used in studies examining differences in protein abundance and 
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phosphorylation or transcriptional alterations of metabolic genes upon metabolic stimulations, but 
also to identify putative global differences in chromatin architecture using chromosome 
conformation capture techniques [237]. Furthermore, possible genomic binding sites and RNA or 
protein interactions partners of the respective lncRNAs can be identified using lncRNA-specific 
RNA immunoprecipation approaches, such as ligation of interacting RNA followed by high-
throughput sequencing (LIGR-Seq) [238] or capture hybridization of RNA targets (CHART) 
technologies [221]. 
 
Taken together, the Gm15441- and lincIRS2-deficient mouse lines represent powerful in vivo model 
systems to study lncRNA-mediated cellular adaptations to acute and chronic metabolic cues and 
can be utilised in further studies to identify lncRNA-specific genomic or proteomic interaction 
partners. 
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Chapter 6 - Appendix 
6.1. Summary 
Due to the current worldwide prevalence of overweight and obesity, an increasing number of 
individuals is affected by concomitant deregulations of glucose and lipid metabolism, which foster 
the development of obesity-associated diseases, such as cardiovascular pathologies, Alzheimer’s 
disease, certain cancer subtypes, and type 2 diabetes mellitus. As central hub of energy 
metabolism, the liver orchestrates the production and storage of carbohydrates and lipids in 
response to nutrient availability and other metabolic stimuli. Yet, although a multitude of regulatory 
proteins and signaling pathways controlling liver metabolism have been identified in recent years, 
the molecular mechanisms by which the liver perceives the abundance or lack of nutrients and 
facilitates adaptions to the metabolic status remain poorly understood.  
Long noncoding RNAs represent a hitherto insufficiently described class of RNA molecules, some 
of which have been attributed to vital developmental processes. However, just a few studies have 
identified long noncoding RNAs governing liver energy homeostasis and a multitude of long 
noncoding RNA genes have not yet been ascribed to specific molecular functions. In light of this, 
we monitored the expression levels of long noncoding RNAs in livers of mouse model systems for 
chronic obesity and short-term alterations of nutrient availability as well as in human liver biopsies, 
and detected that the global expression of long noncoding RNAs inversely correlates with the 
global expression of protein-coding mRNAs. In order to elucidate if the global anticorrelative 
regulation of long noncoding RNAs impacts on murine energy metabolism, we performed 
additional experiments in cell culture systems and identified two long noncoding RNA transcripts, 
which are significantly regulated upon chronic obesity, dynamically expressed in response to short-
term nutritional changes and transcriptionally influenced by metabolic stimuli. Using CRISPR/Cas9-
mediated genome engineering technology, we generated deleted alleles of the selected long 
noncoding RNA genes Gm15441 and lincIRS2, both of which result in ablated expression of the 
respective RNA molecule in in vivo mouse models. Finally, we demonstrate that lincIRS2 
deficiency in in vivo mouse models leads to systemic hyperglycemia and impaired insulin 
tolerance, and provide evidence that lincIRS2 is essential for proper glucose and lipid homeostasis 
by influencing insulin-induced phosphorylation of key metabolic enzyme AKT and by regulating the 
expression of key gluconeogenic, lipolytic and lipogenic genes. 
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6.2. Zusammenfassung 
Durch die globale Ausbreitung von Übergewicht und Fettleibigkeit ist der Stoffwechsel von einer 
stetig wachsenden Gruppe von betroffenen Personen vor große Herausforderungen gestellt, 
insbesondere durch pathologische Veränderungen des Glukose- und Fettstoffwechsels, welche die 
Entwicklung von Übergewichts-assoziierten Krankheiten wie Herz-Kreislauferkrankungen, 
Alzheimer, Krebs oder Typ 2 Diabetes fördern. Als zentrale Schaltstelle des Stoffwechsel 
koordiniert die Leber in Abhängigkeit zum jeweiligen Ernährungszustand die Aufnahme sowie die 
Produktion von Kohlenhydraten und Fetten. Doch obwohl bereits zahlreiche regulierende Proteine 
und Signalwege im Leberstoffwechsel identifiziert worden sind, bleiben viele Fragen über die 
Mechanismen, wie die Leber die Verfügbarkeit oder den Mangel an Nährstoffen erkennt und in 
entsprechende Anpassungen des Stoffwechsel anpasst, unbeantwortet. 
Lange, nichtkodierende RNAs sind eine bislang unzureichend beschriebene Klasse von 
Molekülen, die zwar mit überlebenswichtigen Entwicklungsprozessen, jedoch noch nicht mit 
leberspezifischen Stoffwechselprozessen assoziiert worden sind. Wir haben daher die 
Expressionslevel von langen, nichtkodierenden RNAs in Lebern von verschiedenen Mausmodellen 
für chronisches Übergewicht und für kurzzeitig veränderten Ernährungszustand sowie in 
menschlichen Leberbiopsien überprüft und dabei herausgefunden, dass die globale Expression 
von langen, nichtkodierenden RNAs stets gegensätzlich zur globalen Expression von 
proteinkodierenden mRNAs reguliert wird. Um zu überprüfen, ob diese reziproke Regulation 
konkrete Auswirkungen auf den systematischen Stoffwechsel in der Maus hat, haben wir weitere 
Untersuchungen im Zellkulturmodell unternommen und letztlich zwei, besonders regulierte, lange, 
nichtkodierenden RNAs identifiziert. Durch Nutzung der CRISPR/Cas9 Technologie zur Editierung 
von Genomsequenzen haben wir deletierte Allele der beiden selektierten RNA Gene Gm15441 und 
lincIRS2 erzeugt, welche im Mausmodell zur nahezu vollständigen Ablation der Expression der 
jeweiligen RNA Moleküle führen. Abschließend demonstrieren wir, dass die vollständige 
Abwesenheit des lincIRS2 Transkriptes in erhöhten Blutzuckerwerten und verminderter 
Insulintoleranz im Mausmodell resultiert, und zeigen Resultate, welche nahelegen, dass das 
lincIRS2 RNA Molekül entscheidend in der Regulation des leberspezifischen Glukose- und 
Fettstoffwechsel mitwirkt, indem es Veränderungen des Ernährungszustandes mit der 
Genexpression von Glukose- und Fettstoffwechselproteinen koppelt und die Insulin-induzierte 
Phosphorylierung vom metabolischen Schlüsselenzym AKT beeinflusst. 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6.3. Supplemental figures 
Supplemental Figure 1: Summarised read information for RNA-Seq analyses. 
Summarised read information for RNA-Seq analyses of liver RNA derived from obesity mouse models, differentially-fed 
mouse models and human liver biopsies. 
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 Supplemental Figure 2: Hepatic expression of lincIRS2 and IRS-2 in the mouse models of chronic obesity and 
differential feeding. 
Liver RNA-Seq tracks showing the genomic locus of lncRNA candidate 4833411C07Rik (lincIRS2) and neighboring gene 
insulin receptor substrate 2 (IRS-2) as well as their hepatic expression levels in the mouse models of chronic obesity 
(Dock7m/m [orange], LepRdb/db [red], NCD [light blue] and HFD [dark blue]) and differential feeding (Ad libitum [light green], 
Fasting [azure], Refeeding [dark green]). Indicated chromosomal coordinates relate to the respective light blue regions. 
The distance between 4833411C07Rik and IRS-2 is approximately 82 kb. 
 
Supplemental Figure 3: Overview of the lincIRS2 locus, including both transcript isoforms.  
Liver RNA-Seq tracks showing the genomic locus of lncRNA candidate 4833411C07Rik (lincIRS2) as well as its hepatic 
expression levels in the mouse models of chronic obesity (Dock7m/m [orange], LepRdb/db [red], NCD [light blue] and HFD 
[dark blue]) and differential feeding (Ad libitum [light green], Fasting [azure], Refeeding [dark green]). Blue boxes indicate 
annotated exons of transcript isoforms 4833411C07Rik-201 and 4833411C07Rik-202. Blue arrows indicate PCR primers 
P1 and P2 used for qPCR gene expression analysis. 
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 Supplemental Figure 4: Outcome of PNI targeting lincIRS2 exon 1.  
Outcome of PNI using CRISPR/Cas9 components to target exon 1 of lncRNA candidate lincIRS2, depicting average lysis 
rate of zygotes, number of transferred 2-cell stage embryos and born founder animals. 
Supplemental Figure 5: Outcome of PNI targeting Gm15441 exon 1.  
Outcome of PNI using CRISPR/Cas9 components to target exon 1 of lncRNA candidate Gm15441, depicting average 
lysis rate of zygotes, number of transferred 2-cell stage embryos and born founder animals. 
Supplemental Figure 6: Comparison of generated Gm15441∆/∆ mouse lines.  
Overview of Ensemble genome browser tracks depicting generated Gm15441∆ alleles. Error-prone NHEJ repair of Cas9-
induced DSBs resulted in minor variations of truncated Gm15441∆ alleles in the four stable Gm15441∆ mouse lines (Line 
837, Line 842, Line 847 and Line 849). The deletion size for the respective mouse lines is as follows: Line 837, 420 bp; 
Line 842, 422 bp; Line 847, 433 bp; Line 849, 411 bp. The Gm15441∆ mouse line described in this work is Line 837. 
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